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Preface 
Procreation is a fact of life; the ability to have offspring may be considered to be the 
feature that defines 'life' itself, as it is a necessary condition for survival of the 
species. For individuals, this is not so self-evident. People may choose to remain 
childless, and the ones who wish to have children will not always succeed. For such an 
essential biological treat, the natural variation in fertility between individuals is huge: 
the monthly chance to become pregnant and have a child is around 0.2 on average, but 
it varies between couples from values as high as 0.5 to very low values, and for some 
couples the chance is effectively zero. While in previous times this just had to be 
accepted, modern Reproductive Medicine has developed treatment methods for 
couples that have an unresolved child wish. This doesn't mean that all of these couples 
will become pregnant: chance also plays a role in the success of treatment. This thesis 
is devoted to chances in fertility. It treats two subjects that are of interest to clinical 
Reproductive Medicine: in Part I, natural fertility chances in a population and in Part 
II, chances on outcome of treatment of one particular group of infertility patients. 
Part I analyses a 19th century population. Two research questions are investigated 
with the aim to learn something from the past: one concerns the variation in the age at 
which female fertility comes to an end, and seeks evidence whether this variation 
might be related to the biological process of ovarian ageing. The second question 
concerns the pregnancy chances after a period of unsuccessful trying. This is of 
interest to clinicians who have to decide to start treatment in patients without an 
obvious diagnosis. 
The research subject of Part II is the prediction of pregnancy chances after treatment 
of patients who have fertility problems due to cycle disturbances. The aim is to 
construct statistical models that may be used to predict -for individual patients- the 
pregnancy chances with the standard treatment protocol. These prediction models are 
then used in an analysis in which the efficiency of the treatment protocol is compared 
with several alternative protocols. 
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Part I 
Population studies on natural fertility 

1 
Introduction part I: 
Lessons from a historical natural fertility population 
for modern reproductive medicine 
BACKGROUND 
In most western societies, reproductive behavior is nowadays controlled to a high 
degree: observed fertility patterns in a population -how many children do couples get 
and when do they get them- are the result of choices made by individuals rather than 
biological factors. This is in marked contrast with previous times, in which it was the 
biological destiny of women to have children - or to remain childless involuntarily. 
The driving force behind the change that has occurred is undoubtedly the availability 
of reliable contraception (Leridon, 1998), which has gone hand in hand with changes 
in social attitudes with respect to reproduction (e.g. secularization, emancipation of 
women (Blossfeld, 1995)). In many Western European societies, the number of 
children per woman has dropped below the natural replacement level (Von Cube, 
1986), and everywhere couples who want to have children carefully plan when to have 
them. In many countries women delay childbearing to later age, the most pronounced 
example being the Netherlands in which the mean age at first childbirth has risen from 
24.6 years in 1970 to 29.2 years in 2001. Since pregnancy chances decrease with age 
of the women (Schwartz and Mayaux, 1982) (van Noord-Zaadstra et al., 1991), 
postponement of the first child has led to an increase in incidence of subfertility (te 
Velde, 1991). 
Reproductive medicine has developed out of the need of couples that have an 
unresolved child wish. When this condition lasts for more than one year, couples are 
diagnosed as "infertile" and in most cases some form of treatment is started within 1 or 
2 years following diagnosis unless the couple becomes pregnant spontaneously. 
Knowledge on natural fertility may help reproductive medicine both in the clinical 
question of deciding whether to treat or to wait and in research questions on the 
biology of human reproduction. A number of these questions cannot be answered in a 
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modem society because a) fertility is expressed in a highly controlled fashion and b) 
the natural course of "disease" is disturbed by treatment. Instead, data of natural 
populations could be used. Up till now, studies on fertility in natural populations have 
been mainly demographically or biometrically oriented (Wood, 1994) and studies with 
a clinical perspective have been rare (Potter and Parker, 1964) (Schwartz, 1981) 
(Menken et al., 1986). In Part I of this thesis, a unique database on a large historical 
natural population from Quebec, Canada, is used to study two research questions from 
clinical reproductive medicine. 
THE BALSAC DATABASE ON A HISTORICAL NATURAL FERTILITY 
POPULATION FROM QUEBEC, CANADA 
Description of the population and the BALSAC database 
The studies in this thesis use data on the population of the Saguenay Lac St-Jean 
(SLSJ) region in Quebec, Canada. The SLSJ region became populated by colonists 
from the nearby Charlevoix region from 1838 onwards. For a long time it was 
geographically isolated from the rest of Quebec (The highway to Quebec City was 
established only in 1951) (Bouchard, 1996). Due to their tradition of short lactation, 
the total number of children per woman was high in comparison with other natural 
populations (Lalou, 1990), which makes them ideally suited to study human fertility 
under natural conditions. The demographic fertility transition occurred relatively late 
in this region, in 1946-1955 among farmers and in 1931-1935 in others (Bouchard and 
Roy, 1991). The main reasons for this late transition lie in the fact that the population 
was predominantly rural and agricultural, little educated and culturally dominated by 
the Roman Catholic Church, leading to a paternalistic society (Bouchard, 2000). The 
really big change in fertility in the whole of Quebec occurred during the 'Quiet 
revolution' in the 1960's: Between 1959 and 1971, Quebec moved from the position 
of having the highest birth rate in Canada to that of the lowest (Belanger, 2000). 
Data of the population of the SLSJ region from church registers (Roman-Catholic) 
on baptism, marriage and death are contained in the 'BALSAC' demographic database 
at the Interuniversitary Institute for Population Research (IREP) in Chicoutirni, 
Quebec, Canada (Bouchard et al., 1989). The database comprises the entire population 
of the region from the beginning of the colonisation in 1838 until 1970. We selected 
all children from N = 2,683 grandmothers who had their last child before 1900: 10,216 
sons and 9,317 daughters, together with their (grand)children. The analyses described 
in Part I of this thesis are based on the data of the daughters. 
Level of natural fertility 
Demographic definitions 
In demography, a clear distinction is made between the physiological capacity to get 
children, and the actual result of this capacity (Wood, 1994). The physiological 
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capacity of a woman, man, couple, group, or population to produce live children is 
called fecundity. The lack of that capacity is called infecundity or sterility. The 
probability to conceive during a month of unprotected intercourse is called 
fecundability (Gini, 1924). The actual reproductive performance is called fertility, and 
is used to denote the number of live born children during a certain period. Infertility 
refers to the absence of live births. Much demographic research has been focused on 
describing and explaining the variation in fertility both between populations and 
between individuals within a population. The main tool of understanding the variation 
has been to try to distinguish the various factors that determine fertility, and seek for 
factors that are constant across populations or individuals. Most importantly, the 
process of producing a live birth has been broken down into three components that 
depend on the age of a woman: the monthly probability of conceiving, the probability 
of fetal loss and the probability of being definitively sterile. However, many 
difficulties arise in such an approach and rather advanced computational problems 
have to be solved (Trussell and Wilson, 1985) (Barrett, 1986). In the literature on 
clinical reproductive medicine, a growing awareness is emerging that the fmal goal to 
achieve is a live birth (Collins eta!., 1995) (Snick eta!., 1997) (Vail and Gardener, 
2003) (Barlow, 2003). Therefore, data on live births are well suited for our research 
questions that are inspired by clinical considerations. 
When do we speak of natural fertility? 
The classical defmition of natural fertility was given by the French demographer Louis 
Henry (Henry, 1961): "By natural fertility we mean fertility which exists or has 
existed in the absence of deliberate birth control. ... Control may be said to exist when 
the behavior of the couple is bound to the number of children already born and is 
modified when this number reaches the maximum which the couple does not want to 
exceed.". This defmition emphasizes two separate aspects of birth control: it should be 
deliberate and parity-dependent. Social factors such as taboos on pre-marital 
intercourse, sexual taboos during lactation or a prescribed period of lactation, limit the 
number of children, but without the couple intending to do so. Nor do they depend on 
the number of children already born. Therefore, natural fertility is not determined 
solely by physiological factors. Since our main interest is in physiological fertility we 
will have to devote some attention to behavioral factors, most notable the period of 
post-partum amenorrhea caused by breastfeeding. 
Female age at marriage 
Female age at first marriage was very young in this population: the mean was 21.3 
years (SD = 5.1), the median was 20 years. In older pre-industrialization European 
populations, the mean ages at marriage ranged from 24.6 to 26.7 years (Dixon, 1971). 
The distribution is skewed to the right, as seen in Figure 1. 
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Figure 1 Distribution offema1e age at first marriage of 4,508 women born in the SLSJ region between 1840 
and 1900. 
The level of fertility 
The level of fertility in this young marrying population is well expressed by the total 
number of children that women have. This number may be calculated for all married 
women, and for the subgroup of women who remain married at least until the age of 
50. In a demographic sense, these are the women who have been able to complete their 
reproductive career. The distribution of number of children per woman is depicted in 
Figure 2. The mean number of children per woman was 7.9 (SD 4.8) and 9.1 (SD 4. 7) 
respectively. The maximum number of children born to a woman was 22. This woman 
was born in 1890, married at age 16, had her last child at age 43 and died at age 68. 
Demographic indicators for a limitation of fertility 
We speak of natural fertility when no attempt is made to limit the family size by using 
birth control measures. The religious nature of the population (Roman Catholic) and 
the ongoing tradition of high fertility in the whole of Quebec must have put social 
pressure on couples to get children: the total fertility rate for the whole population of 
Quebec was 5.6 children per woman in 1891 (Henripin, 1968). According to Henry 
(Henry, 1976), the absence of birth control could be verified by comparing the age-
specific number of children per married woman per year (or age-specific marital 
fertility rate) for different groups of age-at marriage. If couples used birth control to 
limit their family size, a difference in number of children per year would be noticed 
between women who married young and women who married at a later age. We have 
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Figure 2 Distribution of number of children per women, for all women (left panel) and for the selection 
of women who were married until at least age 50 (right panel). Data from the SLSJ population. 
performed such an analysis; the results are depicted in Figure 3. It is clear from this 
figure that there is no indication of limitation of family size in this population. 
The high level of fertility had a severe negative impact on the life expectancy of 
women, as in pre-modem times maternal mortality was a major killer. This is clearly 
illustrated in Table 1 where we look at the expected total duration of life at various 
ages. While the difference in expected total duration of life between birth and age 20 is 
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Figure 3 Marital fertility rate in 5-years classes of age of the woman for 6 groups of age at marriage. Data 
from the SLSJ population 
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Table 1. Expected total duration oflife (years) at birth, and when reaching ages 20 and 50. Men and women 
from the SLSJ population, born in 1840-1899, and from the Netherlands in 1998 for comparison. 
SLSJ, Quebec Netherlands 1998 
Men Women Men Women 
At birth 42.9 40.8 74.8 80.5 
At age 20 65.0 60.3 75.2 80.6 
At a e 50 73.2 73.0 76.7 81.7 
a reflection of childhood mortality, the difference between men and women at ages 
before 50 is an illustration of the impact of maternal mortality. 
How representative are the data in a demographic database? 
A demographic database based on Church records does not give a full account of the 
life history of all individuals contained in the database. Emigration and missing dates 
are the two main reasons for this. We will explore to what extent these factors pose a 
problem for the analyses and the interpretation of the results. 
Moving out of the region: emigration 
With the prospering of the industries in New England in the United States of America, 
an emigration wave occurred from the whole of rural Quebec (Lavoie, 1979). The 
Church records only contain registrations of children of emigrating married women 
from before the date of emigration and we do not know about eventual later born 
children or about the end of marriage. Therefore, we had to restrict our selection of 
subjects to married women who did not emigrate, i.e. their marriage ended (by death 
of themselves or their partner) in the SLSJ region (86% of the married women). In our 
analyses, we assumed that the women who stayed in the region did not form a 
selection with respect to fertility. 
It may be that being childless made emigration easier or more attractive. On the 
other hand, it may just as well be that the economic necessity to emigrate was larger 
for couples with many children. These presumptions are hard to verify: the mere fact 
that the woman emigrated limits the amount of time she spent in the region to produce 
children. Therefore, emigrating women will have fewer children in the Church 
registers than women who stayed in the region and more of them will be without child. 
Indeed, the average number of registered births was 5.0 for emigrating women and 7.8 
for women who stayed in the region and the proportion childlessness was 18% and 8% 
respectively. We cannot tell from these figures whether emigration was related to 
fertility. However, we can compare the time between marriage and birth of the first 
child, for women who had at least one child, assuming that less fertile women take 
longer time to become pregnant. The medians and 25th to 75th percentiles were 11.5 
(9.8- 15.5) months and 11.5 (9.8- 15.2) months respectively for emigrating women 
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and for women who stayed in the region (P = 0.6, Mann-Whitney test). This tells us 
that the time to pregnancy of emigrating women who had a child before they left the 
region, was not different from women who stayed in the region. The emigrating 
women who did not have a child before they left the region, may have had a child 
(shortly) after that time. It then depends on whether they left the region soon after 
marriage or after a long period of time: in the former case they are likely to be as 
fertile as women who stayed in the region, whereas in the latter case they are likely 
less fertile, since their time to first pregnancy was longer than average. We conclude 
that: women who emigrated and had children at that time were as fertile as women 
with children who stayed in the region. Women who emigrated without children may 
have been less fertile, but this depends on how soon after marriage they emigrated. 
Missing birth dates of children 
For some women, the Church registers mention one or more children without a birth 
date. We cannot establish with certainty the ages of these women at first and last 
childbirth and they are therefore excluded from analyses. However, this exclusion 
biases the estimation of the probability to be childless, because the women with 
children are underrepresented. To deal with this problem we used 'sampling weights' 
that down-weigh the women without children. To give an example: in a group of N 
women, 4% remained childless and 96% had children, but in 10% ofthese women the 
birth date of one or more of their children was missing, and they are left out of the 
analysis. The number of women in the analysis is then: 0.04*N women without 
children, and (1-0.10)*0.96*N women with children. The estimate of childlessness is 
0.04*N I (0.04*N + (l-0.10)*0.96*N) = 4.4%, instead of 4%. We compensate for this 
bias by assigning a sampling weight of (1-0.10) to the women without children. The 
corrected estimate of becomes (l-0.10)*0.04*N I ((1-0.10)*0.04*N + (1-
0.10)*0.96*N) = 4%. 
Two remarks should be made here: 
1. We chose to down-weight the women without a child, where we might just as 
well have 'up-weighted' the women with children. However, we are going to use 
life-table methods to estimate childlessness, in which the women who remained 
childless are censored at the date of end of marriage. The statistical information in 
that type of analysis is solely determined by the number of women with children, 
and 'up-weighting' of these women would create more information than is present 
in the data, leading to too narrow confidence intervals. 
2. We will also investigate differences in fertility within the group of women with 
children. The exclusion of women with missing childbirth dates should then be 
non-differential with respect to fertility. It seems unlikely that this requirement is 
fulfilled, for women with many children will have a higher chance that at least 
one of the birth dates is missing than women with few children. A logistic 
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regression analysis revealed that the chance of having children with missing birth 
dates indeed increased with higher number of children, from 7.4% for women 
with only one child to 12.7% for women with 20 children (P = 0.015). However, 
no such association was found in the subgroup of women who remained married 
until at least age 50, which is the group that will be used in these analyses (see 
below). 
RESEARCH QUESTIONS 
As said before, we will try to answer research questions from reproductive medicine in 
a historical natural population. 
The first question, inspired by the observation that some women can get children up 
till late ages where others experience their end of fertility at a very young age is: 
1. What is the variation in female reproductive life span? Is the reproductive 
life span correlated to fertility at young age and if so, how strong is this 
correlation? 
Women in modem western societies are postponing reproduction to an age that is 
compatible with their lifestyle and personal circumstances. An issue of progressive 
concern is how long women can wait before their chances of becoming pregnant and 
having a child deteriorate. It has been argued that both the age-related decline and the 
end of female fertility are determined by the same biological process. If this holds, we 
expect that fertility at young age is positively related to the female reproductive life 
span. The aim of this study is first to evaluate in the BALSAC database the degree of 
variability of the reproductive female life span. Second, to evaluate whether fertility at 
young age is correlated to the reproductive life span and thereby explains some of this 
variation. 
The second question is inspired by the clinical decision problem of when to start 
treatment in women who are diagnosed as infertile. 
2. Are fertility chances after 12 months trying to conceive small, as implied by 
the current standard of calling a couple infertile after 12 months? 
Several studies have published models for the prediction of spontaneous pregnancy 
chances among infertile patients, based on follow-up of actual patients. In all these 
studies, the follow-up was limited because many patients started treatment soon after 
inclusion. Instead, data on a historical population without treatment or contraception 
may be used to estimate the spontaneous pregnancy prognosis of infertile couples. The 
aim of this study is to assess the spontaneous pregnancy prognosis of infertile couples, 
depending on the woman's age, the duration of infertility and parity. 
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Selection of subjects 
For our studies on natural fertility, the subjects should be married and their date of end 
of marriage should be known in the database, as stated above. In some cases we 
restricted the sample further to women whose marriage lasted at least until their 50th 
birthday. The selection is depicted in detail in Figure 4. 
Unknown 
438 
Died< 15 yr 
3,106 
No date of 
end marriage 
735 
Childless 
211 
Mothers 
2,683 
Died>= 15 yr 
5,893 
Figure 4 Selection of subjects from the SLSJ population. 
Birth date 
unlmown 
318 
Not married 
650 
End Marriage 
<50 
1,737 
Sons 
10,216 
20 
OUTLINE OF PART I 
In chapter 2, research question 1 is answered by analyzing the variability of age at last 
childbirth and the association between two measures of fertility at young age and age 
at last childbirth, on the BALSAC database. 
In chapter 3 we give an answer to research question 2 by analyzing the time from 
marriage to first childbirth and the time between first and second childbirth in the 
BALSAC database. 
In chapter 4, the shortest chapter, the importance of the time-to-pregnancy concept is 
stressed, and its relation to the monthly pregnancy chances is explained. 
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The end of female fertility is highly variable 
and related to fertility at young age 
ABSTRACT 
Introduction: Women in modem western societies are postponing reproduction. An 
issue of progressive concern is until which age women can still have a child. The first 
aim of this study was therefore to evaluate the degree of variability in female 
reproductive life span. The second aim, motivated by the theory of ovarian ageing, 
was to evaluate whether the reproductive life span is correlated to fertility at young 
age. We investigated these research questions in a group of women from a 19th 
century natural fertility population in Quebec, Canada. 
Materials and methods: We included 2,488 women born between 1840 and 1899, 
whose marriage lasted at least until age 50. The Kaplan-Meier method on age at last 
childbirth was used to determine the age-specific chance of being effectively infertile, 
i.e. no further become pregnant leading to live birth. We used two measures of fertility 
at young age: the birth rate between ages 18 and 30 and the maximum number of 
children born within a five-year period. Spearman's correlation coefficients of the 
measures of fertility at young age with age at last childbirth were determined and 
corrected for the potentially confounding variables: year of birth, age at marriage and 
occupation of the husband as an indicator for socio-economic status. 
Results: The chance that a woman no longer conceives a pregnancy leading to live 
birth was 10% at age 29 years. It increased to 25%, 40%, 50%, 60%, 75% and 90% at 
ages 37, 39, 40.5, 41, 42.5 and 44 years respectively. The birth rate between ages 18 
and 30 and the maximum number of children born within a five-year period were 
positively correlated with age at last childbirth (r = 0.15 and 0.14 respectively, P < 
0.001). The correlation was absent in women of above average fertility, but stronger 
for women of below average fertility (r = 0.22 and 0.28 respectively). Correction for 
confounders had no major influence on results. 
Conclusions: The end of effective fertility shows a large variation. There is evidence 
that part of this variation is explained by fertility at young age. 
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INTRODUCTION 
Since the introduction of effective birth control at the end of the sixties, extraordinary 
changes in reproductive behaviour have taken place, such as voluntary childlessness, 
rapid decrease in the number of children per couple and delays in childbearing (van de 
Kaa, 1987). Having children became no longer the unavoidable destiny of a woman, 
but an issue for careful consideration and planning. Many couples nowadays delay 
childbearing to a period in life that is compatible with their lifestyles and personal 
circumstances. 
However, an issue of progressive concern is how long women can wait before their 
chances of having a child deteriorate. Because of the wide-scale use of contraceptive 
measures in modem western populations, this problem can only be studied in so-called 
natural fertility populations in which birth control was not or hardly practiced and 
religious convictions urged couples to produce as many children as long as possible. 
Under such circumstances, age at last childbirth can be considered as the best proxy 
for the age at which effective female fertility, i.e. the ability of a woman to conceive a 
pregnancy that will end in a live birth, comes to an end (Bongaarts, 1982). Studies in 
natural fertility populations have shown that fertility declines with age in a manner that 
is universal throughout the human species (Leridon, 1977) (Bongaarts, 1982) (Spira, 
1988) (Wood, 1989). Although decreasing coital frequency also plays part, the female 
age-related contribution to this decline appears to be of paramount importance 
(Weinstein et al., 1993). 
It has been argued that the decline -from birth onwards- of both the quantity and the 
quality of the oocyte/follicle pool determines the age-dependent loss of female fertility 
(Faddy et al., 1992) (te Velde et al., 1998). If this concept holds, we expect that 
women with a slow rate of decline have a higher fertility at young age and also a later 
onset of sterility compared to women with a faster decline. As a consequence, fertility 
at young age would be positively related to the onset of female sterility. The aim of 
this study was first to evaluate the degree of variability in reproductive female life 
span. Second, to evaluate whether fertility at young age is correlated with the 
reproductive life span. 
MATERIALS AND METHODS 
Subjects 
The study used data from women born between 1840 and 1899 in the Saguenay-Lac-
St-Jean (SLSJ) region in Quebec Canada, who married and died in the region. The 
SLSJ region became populated by colonists from the nearby Charlevoix region around 
the middle of the 19th century and their data from church registers (Roman-Catholic) 
on birth, baptism, marriage and death are contained in the BALSAC demographic 
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database (Bouchard et al., 1989). Due to their tradition of short lactation, the total 
number of children per woman was high in comparison with other natural populations 
(Lalou, 1990), which makes them ideally suited to study human fertility under natural 
conditions. The demographic fertility transition occurred relatively late in this region, 
in 1946-1955 among farmers and in 1931-1935 for all other professions (Bouchard 
and Roy, 1991). For this reason, the birth cohorts chosen were restricted to those 
between 1840 to 1899, to limit the effect of the use of contraceptives on the apparent 
fertility of the women. 
In natural populations, age at last childbirth is a marker of the end of effective 
fertility when a woman remains married long enough. Therefore, only women whose 
marriage lasted at least until the age of 50 were considered (in demography, this is the 
age at which a woman's reproductive career is considered to be completed). We 
assumed that marriages ended with the death of the woman or of her husband, since 
divorce was extremely rare in this Church-dominated population (Bouchard, 2000). 
Fertility at young age 
Evidence from artificial insemination programs in which the women did not have an 
apparent impairment of fertility showed that pregnancy chances are optimal from the 
age of 18 years onwards, and start to decline only after the age of 30 (Schwartz and 
Mayaux, 1982) (van Noord-Zaadstra et al., 1991). This motivated us to measure 
fertility at young age for an individual woman by her birth rate during the age period 
18 to 30. We defmed the birth rate as the number of childbirths between ages 18 and 
30, divided by the number of married years in that age interval. For women who 
married after the age of 18, only the years between marriage and the 30th birthday 
contributed to the married years. A woman should have at least one childbirth between 
ages 18 and 30. This measure of individual fertility is similar to the age-specific 
fertility rate, a population measure commonly used by demographers (Newell, 1988). 
As a second measure of fertility at young age we used the maximal number of births 
in five successive years (NMAX) (Le Bourget al., 1993). This parameter measures the 
peak reproductive performance of a woman, which not necessarily occurs at young age 
for all women, but will do so for most of them. 
Data analysis 
The age at which effective fertility ended was estimated using both the age at last 
childbirth for the women who had children and the age at marriage of the women who 
remained childless. These latter women might have had a childbirth (and consequently 
also a last childbirth), if they had married at a younger age. Therefore, we included 
them in the analysis by assuming that their chances of having a last childbirth at the 
ages before their marriage were equal to the chances of the women who were married 
at those ages. Technically, this analysis was performed using the Kaplan-Meier 
method, with time running backwards from age 55 onwards (the last age at which a 
woman gave birth to a child was 54). The (55 minus) age at last childbirth was the 
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time of event and (55 minus) age at marriage was the censoring time for the women 
who remained childless. The resulting Kaplan-Meier estimates were plotted against the 
original age-axis (subtracting 9 months to account for the gestational period between 
conception and live birth) to give the curve of the age at which effective fertility came 
to an end. We tested whether the results depended on the age at which the woman 
married, as has been suggested in the literature (Trussell and Wilson, 1985), by using 
the log-rank statistic on age at marriage in 5-year groups. 
There were women who had one or more children mentioned in the database, 
without their birth date. Consequently, we didn't know which child was the lastbom 
and so these women had to be excluded (11% of the women with children). Because of 
this exclusion, women with a child are under-represented in the analysis, which made 
a correction of the Kaplan-Meier estimates afterwards necessary. 
The associations between the two measures of fertility at young age and age at last 
childbirth were quantified by Spearman's rank correlation. In order to have at least 5 
married years available between ages 18 and 30, the data were restricted to women 
who were married before age 25. Further, we excluded women who had their last 
childbirth before the age of30, because in these women the birth rate between ages 18 
and 30 would (by defmition) be reduced and therefore correlated 'by construction' 
with age at last childbirth. 
Literature shows that the occupation of the husband, the woman's year of birth 
(Bouchard and Roy, 1991) (Lycett et al., 2000) and her age at marriage (Trussell and 
Wilson, 1985) are associated both with fertility at young age and age at last childbirth. 
Therefore, we considered these factors as potential confounders, and we corrected our 
analysis using the following categories: occupation of the spouse in three classes 
('farmer', 'blue collar' and 'white collar'), year of birth from before 1860 and until 
1890-1899 in five 10-year intervals, and age at marriage in five classes ('under 17', 
four two-year intervals from 17 to 25). To quantify the strength of association between 
the measures of fertility at young age and age at last childbirth after adjustment for 
confounders, Spearman's rank correlation was calculated between the measures of 
fertility at young age and the residuals from an ANOV A for age at last childbirth on 
the confounding factors. 
The parameters of fertility measure the overall effect of biological potential and 
behaviour. Particularly breastfeeding may be an important behavioural factor 
determining apparent fertility, by lengthening the interval between births. We 
estimated the period of breastfeeding for each woman by taking the difference 
between the interval from first to second birth and the interval from marriage to first 
birth (Sheps, 1965). 
A p value below 0.05 was considered to denote statistical significance. 
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RESULTS 
Initially, we selected 4,508 married women born between 1840 and 1899 from the 
database, but 1,737 of them had to be excluded because their marriage ended before 
their 50th birthday. Of the selected 2,771 women, 211 (7.6%) remained childless. For 
283 of the 2,560 women with child (11 %), the age at last childbirth was unknown, 
which excluded them from analysis, but which was corrected for afterwards. The 
analysis determining the age at which the effective fertility ended was therefore based 
on 2,488 women(= 2,277 with child+ 211 childless). 
In this selection, the median age at last childbirth was 41.4 years, with a range from 
17 to 54 years. The Kaplan-Meier curve for the age at which the effective fertility 
ended is shown in Figure 1. The curve shows a moderate increase that starts to 
accelerate at age 30 and becomes more profound from age 35 onwards. The chance 
that a woman no longer conceives a pregnancy leading to live birth was 10% at age 29 
years. It increased to 25%, 40%, 50%, 60%, 75% and 90% at ages 37, 39, 40.5, 41, 
42.5 and 44 years respectively. The Kaplan-Meier curve did not depend on the age at 
which the woman married (P = 0.2). 
The second analysis, about the relationship between fertility at young age and age at 
last childbirth required a further selection of women: of the previously selected 2, 771 
women (see above), 2,239 were married before age 25, 109 of whom were childless 
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Figure 1 Cumulative age at the end of effective fertility. Kaplan-Meier estimates for 2,488 women, with 
95% confidence interval. 
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Table 1 Age at last childbirth, total number of births, birth rate between age 18 and 30, number of births, 
five-year interval of maximal fertility and estimated duration of breastfeeding for 1,755 women from the 
SLSJ region (Quebec, Canada). 
(a) Descripive statistics 
Mean (Std. Median (P10-P90)* 
Dev) 
Age at last childbirth (years) 41.0 (3.6) 41.6 (35.9-45.0) 
Total number of births 11.0 (3.1) 11 (7-15) 
Birth rate between age 18 and 30 (per year) 0.58 (0.14) 0.58 (0.42-0.75) 
Maximal number of births in five successive years 3.7 (0.7) 4 (3-5) 
Five year interval of maximal fertility (midpoint) 25.4 (4.2) 24.5 (20.9-31.6) 
Estimated period ofbreastfeeding (months) 6.8 (13.6) 6.3 (-3.0-15.2) 
*P 10 and P90 represent the 1Oth and 90th percentiles. 
(b) Spearman's rank correlation coefficients 
ALAS BR 18-30 NMAX 
Age at last childbirth (ALAS) .15 .14 
Birth rate between age 18 and 30 (BR 18-30) .15 .66 
Maximal number of births in five successive years (NMAX) .14 .66 
Estimated period ofbreastfeeding -.o7 -.21 -.27 
Note: Correlations coefficients larger in size than 0.05 are statistically significant 
and in 252 women the age at last childbirth was unknown. Of the remaining 1,878 
women, 109 had their last childbirth before age 30 and another 14 women did not have 
a childbirth before the age of 30. Since we wanted to correlate fertility at young age 
with the end of effective fertility these women (109 + 252 + 109 + 14) had to be 
deleted, and therefore this analysis is based on 1,755 women. 
The characteristics of these women are shown in Table l(a), and their pairwise 
correlations in Table l(b). Both the birth rate between ages 18 and 30 and the 
maximum number of births within a five year period showed a positive association 
with age at last childbirth (r = .15 and r = .14 respectively, both P < 0.001). The 
correlation with the estimated duration of breastfeeding was negative, as to be 
expected (r = -.21 and -.27 respectively). 
The nature of the association between age at last childbirth and the birth rate 
between ages 18 and 30 is illustrated in Figure 2. A steady increase in age at last 
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childbirth with increasing birth rate per year is seen, from 37 years at a birth rate of 0.2 
to a maximum of 41 years for birth rates of 0.5 and higher. The distribution of age at 
last childbirth, depicted on the vertical axis, is skewed, with some women having their 
last childbirth already at a very young age. The distribution of the birth rate between 
18 and 30 is shown on the horizontal axis and is more symmetrical, with most women 
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Figure 2 Correlation between age at last childbirth and birth rate between ages 18 and 30. On the axis, the 
distribution of the data is depicted. N = 1,755. 
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having a birth rate between 0.4 and 0.8 births per year. 
The association between the maximal number of births in five successive years and 
age at last childbirth is depicted in Figure 3. The same levelling off in trend is 
observed as in Figure 2. The trend is present until a maximum of 4 children per 5 
years_ For the highest group (>= 5 births) a minor further increase in age at last 
childbirth is seen, whereas in Figure 2 the curve seems to go down a little. 
The distribution of the confounding factors and their relationship with age at last 
childbirth and fertility at young age are shown in Table 2. Occupation of the husband 
was significantly associated with age at last childbirth, which was one year later for 
the wives of farmers compared to the 'blue collar' and 'white collar' groups. No 
significant association was present with fertility at young age. A more recent year of 
birth was significantly associated with earlier age at last childbirth, but at the same 
time with an elevated level of the maximal number of births in five years. Finally, 
younger age at marriage was associated with a lower birth rate between ages 18 and 
30, with a slightly higher maximal number of births in five years, but not with age at 
last childbirth_ Adjustment for the confounding factors hardly changed the association 
between age at last childbirth and the measures of fertility at young age (adjusted r = 
0.15 and 0.15 for the birth rate between ages 18 and 30 and the maximum number of 
birth in five years respectively, both P < 0.001). 
DISCUSSION 
Female fertility and the age at which it comes to an end can best be studied in so-
called natural fertility populations, in which birth control is not (or hardly) practiced 
(Menken et al., 1986). The mean age for the birth of the last child are surprisingly 
similar in most natural fertility populations all over the world, including contemporary 
ones (Wood, 1994). Age at last childbirth can be regarded as the age when the 
effective fertile period of a woman comes to an end. Many demographers regard the 
theoretical age at sterility as the end of fertility (the capacity of a woman to conceive 
irrespective of the result of pregnancy) (Leridon, 1977) (Trussell and Wilson, 1985) 
(Wilson et al., 1988) (Larsen and Menken, 1989). However, for the aim of counseling 
women about how long they can postpone childbearing, age at last child birth is of 
greater importance than the age at sterility, because couples want to have an estimate 
of the period of time they still can have children. 
Our data demonstrate that the end of the effective fertile period of women is extremely 
variable, with a median age of 41.4 years ranging from 17 to 54 years_ In most women, 
the effective fertile period ends between 35 and 45 years. But still in about 19% of the 
women this period ends before 35 years and in 5% it ends after age 45 (Figure 1). A 
similar study has been performed by Trussell and Wilson using the sterility definition 
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Table 2 Age at last childbirth, birth rate between ages 18 and 30 and maximal number of births in five 
successive years, by the husband's occupation, year of birth and age at marriage, for 1,755 women from the 
SLSJ region (Quebec, Canada). 
Age (yr) at last Birth rate/year Maximal number of 
childbirth ages 18-30 births in 5 years 
Number Mean(SD) Mean(SD) Mean(SD) 
Husband's 
P-valuea < 0.001 0.07 0.6 
occupation 
Farmer 1098 41.4 (3.5) .59 (.13) 3.7 (.7) 
Blue collar 562 40.4 (3.7) .57 (.14) 3.7 (.7) 
White collar 77 40.4 (4.0) .57 (.17) 3.7(.9) 
Year ofbirth P-valueb < 0.001 0.2 < 0.001 
<1860 168 41.9 (3.4) .57 (.13) 3.6(.7) 
1860-69 296 41.4 (3.1) .58 (.12) 3.7 (.7) 
1870-79 487 41.0 (3.4) .58(.14) 3.7 (.7) 
1880-89 567 40.9 (3.8) .58(.14) 3.8(.7) 
1890-99 237 40.1 (4.2) .58(.16) 3.8 (.8) 
Age at marriage P-valueb 0.8 < 0.001 0.02 
<=16 138 41.1 (3.4) .54 (.12) 3.9(.7) 
17-18 428 41.1 (3.6) .55(.12) 3.7 (.7) 
19-20 562 41.0 (3.6) .58 (.13) 3.7 (.7) 
21-22 370 40.8 (3.6) .60 (.14) 3.7(.8) 
23-24 257 40.9 (3.8) .61 (.16) 3.6 (.7) 
Total 1755 41.0 (3.6) .58 (.14) 3.7 (.7) 
o.bP-values from analysis ofvariance(ANOVA), F-test" or test for trendb. 
(Trussell and Wilson, 1985). For ages below 35, their estimates were remarkably 
similar to ours. However, at higher ages their estimates of sterility chances were 
considerably lower, after they corrected their data for age at marriage. Since older 
female age is associated with an increased risk of pregnancy loss, it makes sense that 
our estimates of effective infertility are higher than the demographic estimates of 
sterility. A remarkable finding in the report by Trussell and Wilson was that women 
who married at a young age appeared to have an earlier onset of permanent sterility. 
They speculate that this phenomenon is caused by infections, occurring during or after 
childbirth, that resulted in sterility due to tubal disease. A consequence of early 
marriage is then that a woman is exposed to these risks from an early age onwards. We 
could not see such an effect in our data: earlier age at marriage was not related with a 
reduction of effective fertility. The data most commonly used by demographers are 
usually older than ours -mostly pre-industrial (Menken eta!., 1986) (Wood, 1994)-
and it may well be that the risk of infections during childbirth was higher in those 
times than in our population living at the end of the 19th and beginning of the 20th 
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century, where the knowledge of modem health care practices, such as better hygiene, 
were possibly already (partly) implemented (Loudon, 1986). Therefore, we regard our 
data as more representative for modem times than the pre-industrial populations used 
by Trussell and Wilson. 
We excluded many women because their marriage ended before their 50th birthday, 
since in these women age at last childbirth cannot be observed. In 65% of cases, 
marriages ended before age 50 because the woman had died. One may wonder 
whether the selected women did not form a healthy sub-group that is not representative 
in fertility for the total population. However, the two measures of fertility at young age 
in women who were excluded were very similar to the values in the selected women: 
the birth rate between ages 18 and 30 was on average 0.58 (SD = 0.13) and the 
maximal number of children in five successive years 3.7 (SD = 0.8), comparable with 
the values in Table 1. Therefore, we conclude that the selection of women that we used 
in our analysis was representative for the population. 
What does this "lesson from the past" teach us? First, in the present era of 
postponing the time to have children, women should be aware of these facts. 
Unfortunately, there are no early signs of premature reproductive failure. In a previous 
study we demonstrated (van Zonneveld et al., 2003) that before the period of irregular 
menstrual cycles and climacteric complaints, there is a long period of infertility during 
which women still have normal ovulatory cycles and normal hormone levels. This 
period is likely to be preceded by many years of progressively declining pregnancy 
chances. Even the most advanced assisted reproductive technique comes too late in 
such a situation and the only way still to become pregnant and have a child -allbeit 
genetically different- is to resort to oocyte donation. Second, that the end of the female 
reproductive period is extremely variable. The chances to have the end of the effective 
fertile period before age 35 are relatively low, about 17%. Would that be a too 
pessimistic estimate for the present time? In a previous study we compared the age 
distributions of age at menopause in a contemporary population and age at last 
childbirth in the SLSJ population (te Velde and Pearson, 2002). The almost equal 
distributions of both populations, including the skewness to younger ages, not only 
suggest that mean ages differ by about ten years, but that individual women also 
experience a ten year difference between the age of becoming infertile and age at 
menopause. The striking similarity not only suggests that premature ovarian failure 
probably did occur in this 19th century population, but also that the end of female 
fertility and age at menopause are part of the same process. 
Recently, we have summarized other arguments suggesting that the age-dependant loss 
of female fertility is dictated by the decline of both the quantity and quality of the 
oocyte pool (te Velde and Pearson, 2002). During early fetal life the ovaries are 
packed with the entire stock of follicles (oocytes surrounded by ovarian granulose 
cells), but already before birth, numbers of follicles decline in an exponential fashion. 
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From the millions present before birth, some 100.000 are left at the beginning of 
puberty and when the menopause is reached at a mean age of 51 years, the supply is 
reduced to less than thousand, a number insufficient to sustain the hormonal changes 
necessary for menstruation (Faddy eta!., 1992). The essence of this so-called ovarian 
concept is that after a period of optimal fertility from age 18-30 years, oocyte quality 
decreases in parallel to the progressive loss of follicle numbers and that menopause is 
the fmal reproductive event, marking the defmite exhaustion of the follicle pool. It is 
the only event in the cascade of changes involved in the ageing process that can be 
noticed unambiguously by individual women. Determination of the ages and periods 
of the preceding events, such as the beginning of subfertility and infertility is much 
more difficult to establish. The mean age of menopause is 50-51 years in all western 
countries, with a huge variation from 40-60 years (Treloar, 1981). According to the 
ovarian concept, we would expect that fertility at young age would positively correlate 
with the end of the fertile period. Indeed, we found a positive relation between fertility 
at young age and age at last childbirth as a proxy for the end of effective female 
fertility, confirming this concept. 
We used two different measures of fertility at young age, the birth rate between ages 
18 and 30 and the maximal number of children within a five-year period. While the 
first parameter measures -by definition- fertility at young age, the second one 
measures the peak fertility of a woman (Le Bourg et al., 1993 ), which not necessarily 
occurs at young age for all women, but usually does: the two measures showed a 
positive correlation (r = 0.66, Table lb). The relation between the first measure and 
age at last childbirth was obvious until a fertility level of about 1 birth in every two 
years between ages 18 and 30. Given that the period ofbreast-feeding was estimated to 
be on average six months (Table la), this probably is the maximum achievable in 
highly fertile women. Because we found that higher fertility at young age was 
associated with shorter periods ofbreastfeeding (see Table lb), we conclude that the 
women who showed higher levels of fertility at young age probably accomplished this 
by breastfeeding their children for a shorter period. The second measure, the maximal 
number ofbirths during 5 years, confinned this pattern (Figure 3). In the subgroup of 
women who have a birth rate of less than 0.6 per year, the correlation coefficients with 
age at last childbirth became 0.22 and 0.27 instead of the correlations of0.15 and 0.14 
presented in Table l(b). Given the fact that many other variables including coital 
frequency and fertility of the male partner, but also unknown factors originating from 
life style and environment, must have influenced the age at which the female 
reproductive period ended, we consider these correlations as surprisingly high. 
In summary, we conclude that the end of effective female fertility is extremely 
variable and that part of this variation is explained by fertility at young age. 
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Primary and secondary infertility before the era of birth control: 
lessons from the past 
ABSTRACT 
Objective: To assess the spontaneous pregnancy prognosis of infertile couples, 
depending on the woman's age, the duration of infertility and parity. 
Design: Analysis of demographic data. 
Setting: The Saguenay-Lac-St-Jean region in Quebec Canada. 
Patients: 4,125 married women, born between 1844 and 1900. 
Interventions: Women who did not conceive their first child within 1 to 4 years after 
marriage or their second child within 1 to 4 years after the first childbirth were labelled 
as primary or secondary infertile. Age, duration and parity-dependent prognosis was 
estimated using Cox regression. 
Main outcome measure: Pregnancy resulting in live birth. 
Results: Of the women with 'primary' infertility of one year duration, 44% were 
predicted to conceive a child within the next year in the age group 20-24, and 39%, 
32% and 22% respectively in the age groups 25-29, 30-34 and 35-39. At 2 years 
durations the age specific predictions were 26%, 21%, 17% and 12%. Predictions for 
'secondary' infertility at one year duration were 63%, 56%, 48% and 36%, and at 2 
years duration 38%, 33%, 28% and 19% respectively in the age groups 20-24, 25-29, 
30-34 and 35-39. 
Conclusions: In women under 35, after one year of primary infertility and 1-2 years of 
secondary infertility, prospects are good. If nothing is found diagnostically, prognosis 
may be better and therapy could be withheld for the next 1 or 2 years. 
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INTRODUCTION 
In this era of assisted reproductive technology (ART), there is little attention for the 
chances of a couple to conceive spontaneously. Yet, in order to judge whether 
treatment is indicated, such knowledge is mandatory. 
Studies on prognostic factors in patients with subfertility have shown that increased 
female age, longer duration of infertility and primary infertility have an adverse effect 
on the chance of spontaneous conception leading to live birth (Collins et al., 1995 
Eimers et al., 1994 Snick et al., 1997). In these studies, couples with a fertility 
problem were followed until pregnancy or start of treatment. The estimates of the 
effects of the prognostic factors on the probability of pregnancy appear to be 
consistent between these studies. However, since patients who got treated may be a 
selected part of the total group of couples with a fertility problem, the absolute level of 
the cumulative pregnancy curve ("how many couples will eventually become pregnant 
spontaneously?") and its shape ("how fast do they become pregnant?") may be biased. 
Only long-term follow-up of untreated couples can give truly reliable information on 
the chance to conceive spontaneously. In modem western populations such a study is 
unlikely to be performed, because treatment nowadays cannot be withheld for long. 
Data from populations where there is no evidence of birth control (which we will call 
natural populations), either non-western or historical, do not suffer from this problem, 
and therefore may reveal useful information for clinical practice. 
We studied the spontaneous pregnancy prognosis for primary and secondary 
infertility, dependent on age and duration of infertility, in a historical natural 
population. The aim of our study was to present data on the chance to become 
pregnant spontaneously from a population without contraception or fertility treatment. 
MATERIALS AND METHODS 
Subjects and definitions 
We selected 4,508 women, born between 1844 and 1900 in the Saguenay-Lac-St-Jean 
region in Quebec Canada, who had a registration of the date of marriage and the date 
of death of herself or of her husband. The Saguenay-Lac-St-Jean region became 
populated by immigrants from the nearby Charlevoix region around the middle of the 
19th century and the data from church registers on birth, baptism, marriage and death 
are contained in the BALSAC demographic database (Bouchard et al., 1989). We used 
the data concerning year and age at marriage, and the dates of birth of the first and 
second child. The birth cohort 1844 to 1899 was chosen to exclude as much as 
possible any disturbing effect of the use of contraceptive measures (Lalou, 1990). Of 
these 4,508 married women, 364 (8.1 %) remained childless. 
The following definitions were used: Infertility was used in the context of not 
having a child within a certain period. Primary infertility referred to not having a first 
child within a certain period following marriage, secondary infertility referred to not 
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having a second child within a certain period following the first childbirth. 
Childlessness denoted that a couple never had a child, but in practice the proportion 
childlessness was estimated at 10 years after marriage. We avoided the word 'sterility' 
since it suggests that childlessness was involuntary, which we can never know for 
certain in any population. 
Missing birth dates 
For 383 women, one or more children were registered in the database without their 
birth date. Consequently, we don't know for sure which child is the firstborn. We 
decided to exclude these women, leaving 4,125 for analysis. However, because of this 
exclusion the women with a child are under-represented in the analysis, which made a 
correction afterwards necessary. Missing birth dates of children occurred just as often 
in women who had a second child as in women who had only one child. Therefore the 
analysis of the time from first to second childbirth was based on the women without 
missing birth dates of their children, and no correction was needed here. 
Data analysis 
Kaplan-Meier analysis, stratified by age at marriage, was used to estimate the 
cumulative chance of first childbirth. The time between the date of marriage and the 
birth of the first child was the time variable. In case no first childbirth was registered, 
the observation was censored: the time variable was set equal to the end of marriage 
(defmed by either death of the woman or of her husband, whichever occurred first). In 
a similar fashion the proportion of women who had a frrst child, but who remained 
without a second child was estimated with starting time set at date of first childbirth, 
and stratification by age at first childbirth. Cox regression with a flexible spline 
function was used to obtain a smoothed estimate of childlessness by age at marriage. 
In order to extrapolate the fmdings of the present study to modem times, we made 
the assumption that a modem woman who starts trying to become pregnant for the first 
time at a certain age is comparable to a 191h century woman who married at that age. A 
fictitious diagnosis of primary infertility was established for women who did not have 
a frrst child conceived at 1, 2, 3 and 4 years after marriage (i.e. no child birth at 1, 2, 3 
and 4 years after marriage, with a 9 months average gestational period added). The 
same was done for secondary infertility, starting from the time of frrst childbirth. In 
that case, the 'diagnosis' was established at 1 - 4 years duration since the frrst 
childbirth, with 9 months added for gestation. The average length of the period of 
post-partum amenorrhea due to breastfeeding was also added; it was estimated as the 
average difference between the time from frrst to second child and the time from 
marriage to the first child, for the women who had a second childbirth; the result was 6 
months. 
The data of these women formed a cohort that was used in a Cox regression analysis 
to estimate the age, duration of infertility and parity specific prognosis from the time 
of diagnosis of infertility, as it would have been established in a modem clinical 
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setting. The results were presented as fecundability ratios for five-year categories of 
age and 1-year categories of duration of infertility. The fecundability ratio (or hazard 
ratio in survival analysis) has the interpretation of relative risk of becoming pregnant 
(per cycle) in a certain category compared to the risk in a reference category. 
Since the same woman could be included several times in this analysis (e.g. if she 
conceived her first child at 3.5 years after marriage she was included 3 times: with 
duration of infertility 1, 2 and 3 years), the data are not statistically independent. 
Therefore, the confidence intervals were corrected using Huber's method (Huber, 
1967). 
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Figure 1 Cumulative probability of childbirth (Kaplan-Meier estimates for women from the Saguenay 
region, born between 1844 and 1899) 
a) first childbirth, by age at marriage (n = 4,125) 
b) second childbirth, by age at first childbirth (n = 3,761) 
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The percentage childlessness in this historical population (8.1% as a raw percentage, 
7.4% estimated by the Kaplan-Meier method) is about twice as high as expected in a 
modem population (Greenhall and Vessey, 1990). Therefore, we adjusted the results 
for primary infertility by reducing childlessness by half, or, in formula form, by 
applying an extra fecundability ratio of 1.27 (= log(0.037) I log(0.074)) to the results 
of the Cox regression for primary infertility. 
RESULTS 
The Kaplan-Meier estimate of childlessness -corrected for under-representation of 
women with missing birth dates of children- was 7.4% after 10 years of marriage. This 
was 6.2%, 7.7%, 14.3% and 20.9% for women who were married at age 20-24, 25-29, 
30-34 and 35-39 respectively (Figure la). The analysis was repeated for second 
childbirth (Figure 1 b). 
Ten years after the frrst childbirth, 3.2% of the primiparous women were estimated not 
to have experienced a second childbirth. This was 1.8%, 4.3%, 7.0% and 21.7% for 
women who had their frrst child at age 20-24, 25-29, 30-34 and 35-39 respectively. 
The relation between age at marriage and the percentage childlessness is depicted in 
more detail in Figure 2. 
The results of the Cox regression analysis for the cohort, obtained by establishing a 
diagnosis of infertility are depicted in Table 1. A consistent downward trend in 
fecundability ratio is observed with increasing age and increasing duration of 
infertility. 
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Figure 2 Percentage childlessness by age at marriage for 4,125 women from the Saguenay region, born 
between 1844 and 1899. Estimates of a Cox regression model using a flexible spline function, with 95% 
Confidence limits. 
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Table 1 Fecundability ratio's of the Cox regression model for categories of age, duration of infertility and 
type of infertility. Estimated on data from a natural population. 
Age 
20-24 years a 
25-29 years 
30-34 years 
35-39 years 
Duration 
12 months" 
24 months 
36 months 
48 months 
Primary versus secondary 
infertility a 
a Reference category 
Fecundability ratio 
0.83 
0.67 
0.45 
0.49 
0.37 
0.26 
0.55b 
95% Confidence interval 
0.70-1.00 
0.51-0.87 
0.31-0.64 
0.45-0.54 
0.33-0.42 
0.22-0.31 
0.46-0.66 
b The fecundability ratio of primary versus secondary infertility is adjusted upwards, corresponding with a 
reduction of the proportion childlessness in this population by half. 
The 12 months prognosis calculated from this analysis is depicted in Table 2, for 
primary infertility (first column) and for secondary infertility (second column). 
DISCUSSION 
This study found a strong dependency of the chance of spontaneous pregnancy leading 
to live birth on female age, duration of infertility and parity, in a population that is 
likely to have experienced conditions of natural fertility, i.e. with negligible use of 
contraceptive practices. 
Because clinical diagnosis of infertility is concerned with pregnancy and not with 
live birth, the cumulative Kaplan-Meier estimates for live birth were shifted back in 
time over a period of 9 months, giving the time of conception resulting in live birth. 
Still, this does not account for spontaneous abortions and miscarriages. Age-specific 
probabilities of foetal loss have been estimated to be 14%, 16%, 19% and 24% per 
recognised pregnancy at ages 25, 30, 35 and 40 respectively (Wood and Weinstein, 
1988). In principle, these figures could be used to calculate back from first live birth to 
first pregnancy. However, this calculation is complicated because more than one 
pregnancy followed by foetal loss may have occurred before the pregnancy leading to 
live birth was realised. Back-calculation will result in higher cumulative pregnancy 
curves that are shifted back in time (Bongaarts, 1975). In the literature on fertility 
prognosis, an increasing awareness is emerging that the aim of infertility treatment is 
to achieve a live birth (Collins et al., 1995 Snick et al., 1997) and not just pregnancy. 
When clinicians adopt this point of view, we consider our results relevant for clinical 
practice. 
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Table 2 Cumulative probability of conception leading to childbirth(%) at 12 months after establishment of 
infertility, predicted by a Cox regression model with female age, duration and type (primary/secondary) of 
infertility. 
Age at establishment 
of infertility " 
20-24 years 
25-29 years 
30-34 years 
35-39 years 
Duration 
of infertility 
12 months 
24months 
36 months 
48 months 
12 months 
24months 
36 months 
48 months 
12months 
24 months 
36 months 
48 months 
12 months 
24months 
36 months 
48 months 
Cumulative probability of conception leading to 
childbirth(% with 95% CI) at 12 months 
Primary infertility Secondary infertility b 
44% (40-50) 63% (58-68) 
26% (22-28) 38% (34-43) 
20% (17-23) 31% (26-36) 
15% (12-17) 23% (19-28) 
39% (33-44) 56% (51-62) 
21% (17-25) 33% (29-38) 
16% (14-20) 26% (23-31) 
12% (10-15) 20% (16-23) 
32% (26-40) 48% (40-57) 
17% (14-22) 28% (22-34) 
14% (10-17) 22% (17-27) 
10% (8-12) 16% (12-20) 
22% (16-32) 36% (27-47) 
12% (9-16) 19% (14-27) 
9% (6-12) 15% (11-21) 
6% (5-10) 11% (8-16) 
"Means that the woman was aged, e.g., 20-24 years when her duration of infertility reached 12 months (or 
24 months etc.) 
b The start of the second child wish is assumed to be on average 6 months after the first childbirth. This was 
the average period of breastfeeding. 
We defmed secondary infertility as not having conceived a second child within a 
certain period following the first childbirth. The clinical defmition of secondary 
infertility is different: it concerns also third, fourth and higher order conceptions, not 
just the second one. We note however that two-thirds of the births after the first child 
concerned second children in the year 2001 in the Netherlands (Centraal Bureau voor 
de Statistiek, 2002), so our defmition covers a vast majority of secondary infertility in 
the modern clinical sense. Further, it seems plausible that the prognosis to conceive a 
following child is at least as good for women who already have more than one child as 
it is for women who have just one child. Therefore our results may be regarded as a 
lower limit of the prognosis of patients with secondary infertility. 
The overall incidence of childlessness in this population was 7.4%, which is 
comparable to figures found in other historical natural populations (Leridon, 1977) 
(Menken et al., 1986), but which is high in comparison with data on modern 
populations. A figure of 3-4% seems nowadays more appropriate (Greenhall and 
Vessey, 1990). Therefore we reduced the proportion childlessness by half in our 
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analysis of prognosis in primary infertility. Previously (te Velde et al., 2000), we used 
a theoretical model for the heterogeneous distribution of monthly pregnancy chances 
in natural populations (Bongaarts, 1975), together with a 4% sterility rate. The 
resulting probability of conceiving within the next year was 49% after 1 year and 14% 
after 3 years. These figures are comparable to the results from the present study for 
women with primary infertility who are younger than 30 years (Table 2). Furthermore, 
the theoretical model predicts that 84% of women conceives their first child within one 
year after marriage (i.e. at duration zero), almost equal to the estimate of 86% for 
women aged 20-24 in our sample (Figure la). In the study by Snick on subfertile 
couples in a primary care setting (Snick et al., 1997) patients were followed until 
spontaneous pregnancy or start of treatment. The 12 months prediction of pregnancy 
leading to live birth of patients with primary unexplained infertility ranged from 48% 
for women under 30 with duration of infertility ::::: 2 years to 27% for women over 30 
and duration longer than 2 years. For secondary unexplained infertility the figures 
ranged from 63% to 42% respectively. The corresponding predictions for couples with 
a diagnosis of semen defect were 32% to 17% (primary) and 44% to 27% (secondary) 
respectively. The fmdings of the present study, in which no diagnosis is known, are in 
between these values. 
The high proportion of childlessness in this historical population raises several 
questions about the validity of the extrapolation to modem times. Was this really a 
natural fertility population in the sense that no use was made of contraception, either to 
avoid getting any children (voluntary childlessness) or to limit family size? Was the 
incidence of infertility in the 19th century comparable to the present incidence? And 
finally, were women who married late in this on average very young marrying 
population comparable to women in modem times who voluntarily choose to start 
getting children late? 
No data are available on voluntary childlessness, but the religious nature of the 
population (Roman Catholic) and the ongoing tradition of high fertility must have put 
social pressure on all couples to get children: the total fertility rate for the whole 
population of Quebec was 5.6 children per woman in 1891 (Henripin, 1968). One 
indication of the near absence of contraceptive use comes from an analysis of the age-
specific average number of children per married woman per year. This was 0.5 
child/year at ages between age 20 and 29 and steadily declined at older ages. If 
couples had wanted to limit their family size, women who were married at age 20 
would have completed their family well before they were 40. They would have had a 
lower average number of children per year at 35-39 years than women who only 
married at age 35. However, the age specific average number of children per woman 
did not depend on the age of marriage of the woman (data not shown). Absence of 
methods to limit family size is further illustrated by the 'completed fertility' (i.e. the 
mean number of children at age 50 for women still married at this age) classified by 
age at marriage. It was 10.8 and 6.8 for women married before age 20 and at age 25-29 
respectively. The high average number of children in the women who married at 
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young age is not compatible with a widespread use of methods to limit family size. Of 
course, this still doesn't exclude the possibility that a small and select group of couples 
remained voluntarily childless. 
We have no data on the incidence of true sterility in this population, but we do have 
data on mortality that give some indications about the general health of men and 
women. The life expectancy at birth was 43 years for males and 41 years for females, 
while at age 20 the expected total duration of life was 65 and 60 years respectively. 
The low life expectancy at birth was due to childhood mortality: 32% of men and 30% 
of women died before the age of 10 years. The lower life expectancy of women 
compared to men was largely due to maternal mortality: overall 6.6% of women died 
during or within a month after the birth of a child. Indeed, the expected total duration 
of life for men and women who had reached age 50 was comparable: about 73 years 
for both. These figures suggest that the general health of this population wasn't that 
much poorer than that of a modem western society, but rather that infant mortality was 
high and obstetrical care was largely lacking. Infections associated with complications 
during childbearing are probably the main cause of maternal mortality. Even if a 
woman survived such an infection, her health status may have been compromised and 
her fertility hampered, e.g. through tubal occlusion caused by the infection. This may 
have influenced our results for secondary infertility, but it does not explain why so 
many women remained childless. Consanguineous marriages occurred, but not in a 
high proportion, as special dispensation was required from the Church. No differences 
in time to first or second childbirth were observed between consanguineous and non-
consanguineous marriages (fecundability ratio consanguineous versus non-
consanguineous: 1.09, 95% CI (0.91 to 1.31)). 
The age at first childbirth in this historic population was considerably younger than 
it is at present in western societies. Nevertheless we extrapolated our fmdings to 
modem times. One may wonder whether a 19th century woman from Quebec Canada, 
who married at the late age of 30, really had the same pregnancy prospects as a woman 
in a modem western society such as the Netherlands, for whom 29.2 years is the 
average age on which the first child is born. However, we note that women who 
married at age 40, still had a 43% chance (95% CI 33% to 53%) of eventually getting 
a child (Figure 2). In this same population, the median age at last childbirth of women 
who married before the age of 25 was 41.4 years, i.e. 50% of the young-married 
women was able to get children after the age of 41. Thus the fertility of women who 
married at the late age of 40 was comparable to the fertility of young-married women 
at about that age. 
Which lessons for modem clinical practice can be deduced from these historic data? 
In this population nothing is known about possible diagnoses of infertility. Therefore, 
the predicted prognosis for a certain age and duration of infertility applies only to the 
average of a group of patients with these characteristics. Our results indicate that after 
1 year of primary infertility in patients under 35, and 1-2 years of secondary infertility 
irrespective of age, prospects are on average still good, since 3 0% or more of patients 
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will become pregnant within the next year. If diagnostics are started at these durations 
of infertility (earlier on indication) and nothing is found, we may conclude that 
prognosis is better than the population average, and therapy could be withheld for the 
next 1 or 2 years. For young women (age< 30) with secondary infertility prospects are 
still considerable even after 3 years of infertility. 
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Variation in couple fecundity and time to pregnancy, 
an essential concept in human reproduction 
In clinical practice infertility is usually defined as a failure to become pregnant during 
a 12-month period of regular, unprotected intercourse. Hence fertility is assumed to be 
normal when a pregnancy occurs within this period. This definition has led to a 
dichotomous concept -of fertility or infertility-, which not only ignores the essence of 
reproduction, but also gives rise to misinterpretations. For example, couples are 
inclined to think that, if a pregnancy has not occurred within a year, they are sterile 
and require immediate infertility treatment. 
In fact, reproduction is a matter of chance depending on the subtle balance between 
success or failure of complex, mostly poorly understood, sequential processes that may 
lead to a pregnancy and eventually to the birth of a healthy child. These processes 
include spermatogenesis and oogenesis, sexual intercourse and transport of gametes, 
fertilisation, migration of the embryo to the uterus and its subsequent implantation, 
and finally intrauterine development of the fetus. Failure can occur at any link of this 
delicate chain, but most commonly does so at the early stages. With regular 
intercourse a new chance of pregnancy arises every menstrual cycle. Demographic 
studies show that the distribution of monthly fertility of couples trying to conceive is 
heterogeneous and fits a beta-distribution (Bongaarts, 1975), (Leridon and Spira, 
1984). Each couple has a more or less constant monthly probability of conceiving, but 
between couples the probabilities vary widely, from 0% to an upper limit of about 
60%. A monthly fertility of zero corresponds to true infertility in the sense of sterility, 
which occurs in 3-5% of all couples (Greenhall and Vessey, 1990). 
With a high monthly fertility the average time to pregnancy is short, and vice versa 
(Baird eta!., 1986). Survival analysis is the appropriate method for assessing time-to-
pregnancy data. Since the more-fertile couples tend to conceive first, as time goes by 
progressively less-fertile couples selectively remain in the population of couples who 
have not achieved a pregnancy (Leridon, 1977). Hence how long couples have been 
unsuccessful at conceiving is an essential estimate of the degree of subfertility. The 
figure, which is derived from data collected by Bongaarts in natural, non-
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contraception-practising populations (Bongaarts, 1975) and based on a sterility rate of 
4%, shows that, as the duration of inability to achieve a pregnancy increases, the 
probability of success during the subsequent year sharply decreases. However, the data 
also show that, if the unproductive period is short ( eg, 12 months), the probability of 
success is still considerable -half the couples will conceive during the following year. 
These reasonable pregnancy prospects illustrate that the defmition of infertility as a 
failure to conceive within a year contains an oversimplification that may result in 
premature resort to assisted-reproduction techniques, with their associated risks. 
Time to pregnancy has also been used in reproductive epidemiology for assessing 
exposures related to lifestyle, environment, or occupation in case-control studies 
(Baird et al., 1986), (de Cock et al., 1994). If time to pregnancy is significantly longer 
in the exposed couples than in the controls, the conclusion that the exposure negatively 
affects fertility is justified. In several studies time to pregnancy seems to be a sensitive 
outcome measure for overall couple fertility. It does not enable conclusions as to 
which link of the reproduction chain is affected. Other disadvantages are that time to 
pregnancy in this type of studies is susceptible to bias and confounding, and that it 
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evaluates only exposures in couples who sooner or later achieve a pregnancy; it cannot 
assess the effect on the proportion of truly infertile couples (Baird et al., 1986) 
Determinants of sperm quality such as sperm concentration are other measures used 
in reproductive epidemiology (Bonde and Giwercman, 1995). Several studies have 
shown a secular trend of decline in these variables since the fifties (Carlsen et al., 
1992), (Auger et al., 1995). Because this fmding may be a reflection of the effect of 
environmental pollution, it has raised serious concern (Sharpe and Skakkebaek, 1993). 
In a paper in today's Lancet, Michael Joffe started with the hypothesis that a decline in 
male fertility, with an increase in time to pregnancy, is to be expected as a 
consequence of declining sperm quality (Joffe, 2000). 
Instead, he reports a significant decrease in time to pregnancy over the past 40 years. 
He concludes that, if a decline in male fertility has occurred, it has been fully 
compensated by other factors related to couple fertility. Another conclusion should be 
that at present the near panic sometimes expressed in the lay press about the effects of 
environmental pollution on sperm quality and male fertility is not justified. 
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Introduction Part II: 
Prediction of ovulation induction outcome in 
normogonadotropic anovulatory infertility 
BACKGROUND 
In the Netherlands, each year about 13,000 couples visit a fertility clinic for the first 
time because of an unresolved child wish. In 30% of cases the diagnosis is "cycle 
disturbances" (i.e. about 4,000 women) (Rowe et al., 1993). There are many causes of 
anovulation that result in cycle disturbances. The usual clinical classification, 
recommended by the World Health Organization (Rowe et al., 1993), is based on 
serum levels of hormones. Low gonadotrophins together with low oestrogen levels are 
suggestive of a central cause of disease at the hypothalamic-pituitary level (category 
World Health Organisation I (WHO I)), while low oestrogen levels together with 
elevated gonadotrophins are indicative of a disease at the ovarian level (WHO III). 
The most prevalent form however (80%, which amounts to 3,200 new patients per 
year in the Netherlands) is characterised by normal gonadotrophins together with 
normal oestrogen levels (WHO II). For this form of cycle disturbances several 
treatment options are available. Modem treatment options include laser ovarian 
surgery (Cohen, 1996) (Farquhar et al., 2001) insulin sensitizing agents (Heard et al., 
2002) (Nestler et al., 2002) (Glueck et al., 2002) and aromatase inhibitors (Mitwally 
and Casper, 2001 ). However, most patients receive the classical treatment algorithm, 
consisting of three main treatment options. The treatments have different burden, risks, 
costs and chances of ongoing pregnancy. There are also huge differences between 
individual patients in response to these treatments. The current sequence of treatment 
is from the least burdensome and cheapest to the most burdensome and most costly 
treatment. 
Almost all patients with WHO II anovulatory infertility receive, according to the 
conventional treatment algortihm, the anti-estrogen Clomiphene Citrate CCC) as first 
line treatment. CC is relatively cheap and has few side effects. The standard schedule 
is to administer CC during 5 days, in doses increasing from 50 mg during the first 
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cycle, v1a 100 mg to a maximum of 150 mg, depending on the occurrence of 
ovulation. About 25% of patients show no ovulation, even after the maximal dose: 
they have Clomiphene Resistant Anovulation (CRA). Of the women who do ovulate 
with CC, about 40% are still not pregnant after 6 - 9 months (Clomiphene Failures). 
Therefore, CC fails in 55%(= 25% + 0,4 x 75%) of patients, in spite of having been 
treated during half a year (Gorlitsky et al., 1978) (Hammond et al., 1983). 
The women that do not become pregnant with CC are subsequently treated with 
Gonadotrophins. This is a more burdensome and also more expensive treatment than 
CC. The percentage ovulation per cycle of Gonadotrophin Ovulation Induction (GOI) 
is about 70% and the cumulative pregnancy rate after 7 cycles of treatment is at least 
55% (van Santbrink et al., 1995) (White et al., 1996). The amount of follicle 
stimulating hormone (FSH) administered should, considering the individual ovarian 
response, be adjusted per patient. In doing this, one easily gives too much or too little 
because the therapeutical bandwidth of this medication is tight. Sometimes a GOI-
cycle results in hyper response of the ovaries, with a large number of follicles growing 
at the same time. When treatment is continued in such a cycle, there is a risk of a large 
multiple pregnancy and/or of the potentially life threatening ovarian hyper stimulation 
syndrome (OHSS) (Fauser and Van Heusden, 1997). For these reasons, treatment in a 
cycle with hyper response should be cancelled. Despite intensive control during 
treatment, complications can never be ruled out, and some patients seem -in 
retrospect- to be more prone than others to get complications. 
The last step in the treatment sequence for ovulation disorders is In Vitro 
Fertilisation (IVF). This is the most burdensome and most costly treatment. The risk of 
serious complications is however less than with GO I. There is a chance of a multiple 
pregnancy, but this chance is strongly determined by the number of embryos that is 
transferred to the uterus. The success rate of treatment is dependent on the pregnancy 
rate per cycle and the number of cycles that is performed. Recent figures for the 
Netherlands are: 19% per cycle with an average of 2.1 cycles, giving in total 40% 
ongoing pregnancies (Kremer et al., 2002). 
It seems obvious to deploy the least burdensome and cheapest treatment in the first 
line, and only after this turn to the more burdensome and more expensive treatments. 
Indeed, this is the current practice (N ederlandse V ereniging voor Obstetrie en 
Gynaecologie (NVOG) guidelines "Anovulatie en kinderwens", June 1996, composed 
by Fauser et al.). 
However, it cannot be excluded that some patients could benefit from different 
treatment regimens than the standard. To fmd out which patients this concerns and 
what the alternative treatment regimens are, we need to know the chances of success 
for individual patients on each of these treatments, based on the standardised initial 
examination. For example, if we can predict beforehand that a patient has a very small 
chance to become pregnant with CC (=high chance of being CRA or Clomiphene 
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Failure), it might be more efficient to start immediately with GOI. In women of more 
advanced age this means that precious time - with fast declining pregnancy chances -
is won. In case CC is the first line treatment, but doesn't lead to pregnancy, the GOI 
treatment -particularly the starting doses - may be geared to the CC response. This 
might diminish the chance of complications. Next, the decision to proceed to IVF 
might be partly based on the response during the CC and/or GOI cycles. It may be that 
for some patient groups, both CC and GOI could be skipped, based on the fmdings in 
the initial examination of the patient. Finally, there might be patient groups (e.g. with 
very mild cycle disturbances), whose chance on a spontaneous pregnancy is so high 
that treatment is not yet indicated. 
RESEARCH QUESTIONS 
In our quest for individualising treatment regimens for patients with WHO II 
anovulatory infertilily, we will address the following research questions. 
1. Which patient characteristics are predictive of pregnancy chances following 
ovulation induction with Clomiphene Citrate (CC)? What is -in this respect-
the relation between the intermediate endpoint 'ovulation' and the final 
endpoint pregnancy? 
The prediction of pregnancy chances with CC treatment is methodologically 
challenging: patients who do not reach the intermediate endpoint 'ovulation' will stop 
CC-treatment, because their chances of becoming pregnant with it are zero. These 
patients cannot be analysed on the same level as the patients who do ovulate. 
Therefore, special attention will be devoted to the role of this intermediate (time-
dependent) endpoint in the prediction of pregnancy chances with CC. 
2. Which patient characteristics are predictive of pregnancy chances of classical 
ovulation induction with Clomiphene Citrate (CC) followed by 
Gonadotrophin ovulation induction (GOI)? 
Part of the comparison of different treatment strategies is to be able to predict the 
pregnancy chances of the combined strategy of Clomiphene Citrate (CC) followed by 
Gonadotrophin ovulation induction (GOI) in of case absent pregnancy. Therefore, an 
overall analysis of the time to pregnancy with the combined strategy will be 
performed. 
After these two, we are ready to address the final question: 
3. What is the optimal treatment sequence for WHO H patients based on their 
individual characteristics and on the response in previous treatment steps? 
The previously developed prediction models are used to perform a cost-effectiveness 
analysis for subgroups defmed by individual patient characteristics that were found to 
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be predictive of outcome. For each subgroup, the cost-effectiveness of the standard 
treatment sequence CC -> GOI -> IVF will be compared to alternative treatment 
strategies in which one or more of the treatment steps are skipped. 
OUTLINE OF PART II 
In chapter 6, the methodology that is used to answer research question 1 is described, 
and the reasons are explained why the analysis was split into three parts. 
The results described in chapter 7 concern the prediction of the intermediate (time-
dependent) endpoint Clomiphene Resistant Anovulation (CRA, i.e the defmitive 
assessment that ovulation cannot be induced by CC in this patient). It forms the first 
step in answering research question 1. 
The second step in answering research question 1 consists of the prediction of 
pregnancy chances in patients who are not CRA, and is presented in chapter 8. 
Chapter 9 describes the third and fmal step in answering research question 1: the 
integration of the prediction model for the chance to be CRA with the prediction 
model for pregnancy chances in patients who are not CRA. 
In chapter I 0 the analysis is presented that will answer research question 2, prediction 
of outcome after the combined sequence of CC followed by GOL 
In chapter II: a cost-effectiveness analysis is performed to optimize the treatment 
strategy for anovulatory infertility (WHO II), based on individual patient 
characteristics. This chapter presents the fmal analysis, answering research question 3. 
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Characteristics of the best prognostic evidence: 
An example on prediction of outcome after 
Clomiphene Citrate induction of ovulation in normogonadotropic 
oligoamenorrheic infertility 
ABSTRACT 
The standard first-line treatment for normogonadotropic anovulatory infertile patients 
[referred to as World Health Organization group 2 (WHO 2)] is ovulation induction 
using clomiphene citrate (CC) in incremental doses. Twenty to 25% of women show 
clomiphene-resistant anovulation (CRA), that is, they remain anovulatory even after 
multiple attempts with increased doses ofCC. About 50% ofthe ovulatory CC patients 
conceive within six CC-induced cycles. Given the heterogeneous nature of the group, 
the individual prognosis (i.e., the chance of success) will vary considerably between 
patients. In the event an individual prognosis of each patient would be available before 
the start of the treatment, the overall efficiency of ovulation induction could be 
improved. 
Prognostic evidence at an individual level should use multiple patient variables, 
including results from previous treatments (if any). When variables are interdependent, 
a statistical model can be used to relate individual characteristics with the predicted 
outcome. Such a model will provide estimates of prognosis for individualized patient 
profiles, allowing new patients to profit from the experience of the cohort of previous 
patients used to build the modeL This paper discusses the prediction of time to 
pregnancy following induction of ovulation with CC. This prediction was broken 
down in two steps, leading to two separate prognostic models. The first model predicts 
an intermediate outcome, the chance that the patient will be CRA (i.e., no ovulation in 
response to CC medication); the second model predicts the fmal outcome (time until 
pregnancy) in women who do ovulate. 
The CRA model was based on a prospective cohort study of 201 patients with 
normogonadotropic oligoamenorrheic infertility, 45 of whom were CRA (22%). It 
contained four predictor variables all related to the diagnosis of PCOS within the 
57 
58 
group of WHO 2: Increased free androgen index (FAI; hyperandrogenemia), elevated 
body mass index (BMI; obesity), greater mean ovarian volume (as an ultrasound 
feature of polycystic ovaries), and amenorrhea were all predictive for CRA. The 
second model was based on the non-CRA patients and contained two prognostic 
variables: increased age and oligomenorrhea were predictive for longer time to 
pregnancy after first ovulation with CC. Using the example of the prediction of time to 
pregnancy following induction of ovulation with CC, we present and discuss 
characteristics of good prognostic evidence for clinical use, focusing on study design, 
statistical analysis, evaluation, and presentation of results. 
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INTRODUCTION 
Anovulation is a frequent cause of infertility. These women usually present with oligo-
or amenorrhea. In the great majority of infertile women presenting with cycle 
abnormalities, serum follicle-stimulating hormone (FSH) and estradiol (E2) levels are 
within normal limits. The group of patients presenting with normal FSH and E2 are 
referred to as World Health Organization group 2 (WHO 2) indicating a "pituitary-
ovarian disbalance." Women within this heterogeneous group may (in addition to 
anovulation) present with obesity and hirsutism. Various endocrine abnormalities such 
as elevated luteinizing hormone (LH) levels, hyperandrogenernia, and insulin 
resistance, along with abnormalities in the insulin like growth factor system, have been 
observed. Moreover, polycystic ovaries may be found. Among many others, our group 
has focused on pathophysiology (Pache eta!., 1991) (van Dessel eta!., 1996) (Laven 
et al., 2001), endocrine abnormalities (Fauser eta!., 1991), and ultrasound features 
(Pache eta!., 1992) involved in the polycystic ovary syndrome (PCOS). Depending on 
inclusion criteria used, between 40 and 70% of WHO 2 patients can be diagnosed as 
PCOS (van Santbrink et a!., 1995). This poorly defined syndrome is believed to be 
quite frequent among the female population (incidence around 5%) but little is known 
regarding underlying pathophysiological mechanisms. 
The standard treatment for WHO 2 patients is ovulation induction, including 
clomiphene citrate (CC) in incremental doses as first-line therapy, followed by 
exogenous FSH in case of failure to ovulate or conceive. Twenty to 25% of women 
show clomiphene-resistant anovulation (CRA), that is, they remain anovulatory even 
after multiple attempts with increased doses of CC. About 50% of the ovulatory CC 
patients conceives within six CC-induced cycles. Of the women who fail to conceive 
with CC treatment, approximately 90% will ovulate and 50% will conceive 
subsequently following FSH ovulation induction. However, ovarian hyperstimulation 
and multiple pregnancies are frequent complications (Fauser and Van Heusden, 1997). 
The above-mentioned figures apply to the group of WHO 2 patients as a whole. For 
an individual patient the outcome will be either success or failure. Given the 
heterogeneous nature of the group, the individual prognosis (i.e., the chance of 
success) will vary considerably between patients. If an individual prognosis of each 
patient were available before the start of the treatment, the overall efficiency of 
ovulation induction might be improved. A more patient-tailored treatment strategy 
could be designed, such as altered dose regimens, skipping first-line treatment with 
CC, or going directly in selected patients to alternative treatment modalities such as 
metforrnin or laser surgery of ovaries. 
For subgroups defined by a single characteristic (e.g., amenorrhea or age > 30), 
prognostic evidence may come from experience in large groups of patients with this 
characteristic. Prognostic evidence at an individual level, however, should use multiple 
patient variables, including results from previous treatments (if any). When variables 
are interdependent, a statistical model can be used to relate individual characteristics 
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with a predicted outcome. Such a model will provide estimates of prognosis for 
individualized patient profiles, allowing new patients to profit from the experience of 
the cohort of previous patients used to build the model. 
Throughout this paper we will discuss the prediction of time to pregnancy following 
induction of ovulation with CC. This prediction was broken down into two steps, 
leading to two separate prognostic models. The first model predicts an intermediate 
outcome, the chance that the patient will be CRA (i.e., no ovulation in response to CC 
medication) (Imani et al., 1998); the second model predicts the final outcome (time 
until pregnancy) in women who do ovulate (Imani et al., 1999). The CRA model was 
based on a prospective cohort study of 201 patients with normogonadotropic 
oligoamenorrheic infertility, 45 of whom were CRA (22%). It contained four predictor 
variables all related to the diagnosis of PCOS within the group of WHO 2: increased 
free androgen index (FAI; hyperandrogenemia), elevated body mass index (BMI; 
obesity), greater mean ovarian volume (as an ultrasound feature of polycystic ovaries), 
and amenorrhea were all predictive for CRA. The second model was based on the non-
CRA patients and contained two prognostic variables: increased age and 
oligomenorrhea were predictive for longer time to pregnancy after first ovulation with 
cc. 
Although the prognostic evidence contained in a statistical model will provide a 
better quantification of the relationship between predictors and outcome compared 
with informal clinical reasoning, it may perform disappointingly in clinical practice 
because of possible unreliability of the model predictions. Therefore, a study aimed at 
obtaining prognostic evidence should also assess the reliability of the evidence, 
through proper evaluation of the statistical model. 
We will present and discuss characteristics of good prognostic evidence for clinical 
use, focusing on study design, statistical analysis, and evaluation and presentation of 
results. 
STUDY DESIGN 
The essence of prognosis is to relate patient and disease characteristics known at 
present to outcome in the future. Therefore, longitudinal data from a cohort study are 
required to construct such a prognostic model. The cohort study may be either 
prospective or retrospective. From a methodological point of view the prospective 
design is to be preferred, as it allows investigators to standardize treatment, guarantees 
that variables of interest are registered, minimizes missing data, and maximizes 
completeness of follow-up. In the design phase of the study decisions have to be made 
on the outcome measure(s) and on the potential predictive variables, based on prior 
information from literature and pathophysiological knowledge. 
The CC study was a prospective longitudinal follow- up study, initiated in 1993. 
Consecutive patients who were referred by their general practitioner and diagnosed as 
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WHO 2 were included. The study was set up with several endpoints in mind, because 
it was aimed at longitudinally following patients throughout the various treatment 
steps (Imani et al., 1998) (Imani et al., 1999) (Jmani et al., 2000) (Imani et al., 2002b) 
(Imani et al., 2002a). The final outcome measure was time to first ongoing pregnancy. 
An important intermediate outcome in CC treatment was CRA. For the CC study, 
follow-up ended with the definitive assessment of CRA, with first pregnancy 
following CC, or with no pregnancy following at least one CC-induced ovulatory 
cycle. Initial screening characteristics together with anamnestic variables, such as age 
of the woman, duration of infertility, and prior pregnancies, were recorded in a 
database because they were potentially predictive of outcome. The screening 
characteristics were chosen with the presumed etiology of PCOS in mind, including 
cycle history, body weight, serum LH, androgen and insulin levels, and ultrasound 
features of polycystic ovaries. 
ANALYSIS 
Data Considerations 
The outcome that is to be predicted can be continuous (e.g., FSH response dose in 
gonadotropin induction of ovulation (Imani et al., 2002a)), dichotomous (e.g., CRA 
[yes/no] following clomiphene citrate medication (Imani et al., 1998) (Imani et al., 
2000), pregnancy [yes/no] in an in vitro fertilization [IVF] cycle (Templeton et al., 
1996)), or "censored time to event" (e.g., time to pregnancy after first ovulation with 
CC (lmani et al., 1999), time to spontaneous pregnancy or live birth (Eimers et al., 
1994) (Collins et al., 1995) (Snick et al., 1997), and cumulative pregnancy rates in 
IVF (Stolwijk et al., 1996)). An observation on time to pregnancy is called "censored" 
if follow-up ended before pregnancy occurred. Preferably, coding of predictor 
variables is as detailed as possible (i.e., continuous if the underlying phenomenon is 
measured on a continuous scale). Categorizing ofvariables leads to loss of information 
and should be performed, if at all, in the analysis phase only. 
Choice of Model 
Several types of statistical techniques may be applied to relate predictor variables to an 
outcome. Among others we may mention regression models, neural networks (Cross et 
al., 1995) (Baxt, 1995), classification and regression trees (Breiman et al., 1984), and 
probabilistic networks (Pearl, 1988) (Heckerman et al., 1992) (Shwe et al., 1991). We 
will focus on regression models, because they are most frequently used in medical 
applications. 
A regression model relates an outcome variable (Y) to one (univariable) or to the 
weighted sum of several (multivariable) predictor variables (X= {X1 •.• ~} ). The 
weights by which the variables are multiplied are called "regression coefficients" (/3;, i 
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= 1 ... p) and represent the strength of the association between a predictor and the . 
outcome. The weighted sum is called the prognostic index (PI). In formula: 
PI= fJIXI + ... + fJ7P 
Three main types of regression models should be distinguished, dependent on the 
type of outcome data (Table 1): (1) ordinary linear regression for continuous 
outcomes, (2) logistic regression for dichotomous (or binary) outcomes, and (3) Cox 
proportional hazards regression for censored time to event data (also known as 
survival data). 
The CRA prediction model was of type (2) logistic. The outcome CRA (yes or no) 
was known for all patients, because they were followed until first ovulation or 
definitive assessment of CRA. In contrast, the outcome for the time to pregnancy in 
women who ovulated following CC was not known for all patients: many patients had 
censored observations because their follow-up ended without pregnancy having 
occurred. But they could have become pregnant after their end of follow-up. The 
appropriate prediction model in women who ovulated following CC was of type (3), 
Cox proportional hazards regression. 
In a univariable model, the magnitude of a regression coefficient may or may not be 
explained by the presence of one or more predicting variables that are not in the 
Table 1: Three types of outcome data, with corresponding regression technique and interpretation of 
regression coefficients 
Type of outcome 
y 
Regression 
techni ue 
Relationship between outcome (Y) and 
prognostic index (PI) 
Continuous YIX = ~0 + PI a.b 
linear 
Dichotomous 
Logistic 
Censored time to 
event 
Cox proportional 
hazards 
l a,b.c 
Pr{Y =II X}=-------
l+Exp[-(,80 +PI)] 
Pr{free of event at Y = T I X}= 
S(Y = T I X)= S(Y = T I O)Exp(PI) b,d 
a fJ0 is the intercept of the regression formula 
b PI=fJIXI + ... +fJpXp 
Interpretation of regression 
coefficient fJ; 
{J;: change in average outcome 
per unit change of the variable 
Exp(fJ;) = Odds Ratio (OR): 
change in Odds on outcome 
per unit change of the variable 
Exp(fJ;) = Hazard ratio (HR): 
change in hazard on outcome per 
unit change of the variable 
c Pr{Y=liX} is the probability that the dichotomous outcome Ywill take the value l, for a patient with 
predictor variables X. 
d Pr{free of event at Y=IlX} = S(Y = TIX) is the probability that the event has not yet occurred at 
follow-up time Y = T, for a patient with predictor variables X (this is also known as the Survival 
probability, referring to the origins of this method that lie in analysis of mortality). S(Y = TIO) is the 
'baseline' survival probability, corresponding to a patient with all predictor variables equal to 0. Note 
that for each follow-up time T the survival probability can be calculated, giving a survival curve. When 
the event of interest is pregnancy instead of mortality the 'one minus survival' curve is usually 
preferred. 
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modeL In multivariable models, regression coefficients are corrected for the 
prognostic contribution of the other variables in the modeL In the analysis for CRA, a 
total of 9 of 16 potential predictor variables were significant in univariable analysis, 
but only four were left in the multivariable modeL The prognostic contribution of the 
other five univariably significant variables became negligible and statistically 
nonsignificant after correction for the four variables in the fmal modeL For instance, 
hyperandrogenemia was univariably significant but made no prognostic contribution to 
the multi variable model with F AI in it. 
Informative Censoring 
Cox regression makes the assumption that censoring is uninformative. In our time to 
pregnancy analysis this means that the fact that the follow-up of the patient ended 
before the patient had become pregnant (censoring) is not related to her pregnancy 
chances. Our initial objective was to construct a single prognostic model for pregnancy 
following CC-medication, using Cox regression. However, we realized that patients 
who dropped out because they became CRA violated the assumption of uninformative 
censoring. Because these patients didn't ovulate, they had a very low, if not zero, 
probability of conceiving. Assuming that these patients had the same probability of 
conceiving as patients who did not drop out is wrong. For this reason Cox regression 
could not be applied directly. This was the reason for the approach taken, in which 
separate analyses were performed for the chance to reach ovulation (i.e., predicting 
who will become CRA (Imani et al., 1998)) and for the time until pregnancy, given 
that ovulation had occurred (Imani et al., 1999). Logistic regression was used to 
predict who became CRA. For the analysis of time to pregnancy in case of ovulation, 
Cox regression was used in the non-CRA patients, with possible censoring at the end 
of their follow-up. Reasons for censoring could be dropout because the patient moved 
to another residence or because the couple had marital problems. We assumed that 
dropout for these reasons was not related to pregnancy chances and therefore this 
censoring was uninformative. Some patients were censored because they started CC 
treatment just a few months before the end date of the study (December 1997). 
Patients who were not pregnant at this time were also censored. In general, censoring 
because of study design or protocol is uninformative, because no prognosis-related 
selection of patients occurs. 
Model Development 
Determining which predictor variables will be part of the model is a major challenge. 
Already in the design phase of the study choices have been made on which variables to 
register. Usually a wide scope of variables is included so as to not miss factors that 
could later appear to be important. Especially in anovulation (a medical field in which 
the pathophysiology of disease is not completely resolved and many new factors are 
reported continuously) it is tempting to include many variables. For prognostic 
modeling this is usually not sensible. Including all registered variables as predictors in 
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the prognostic model may lead to serious overfitting and also to redundancy in case of 
mutually strongly correlated predictors. Furthermore, it is impractical to use a model 
with many predictors. Often, a reduction in the number of predictor variables is 
required. 
Preferably, a conservative approach should be used in model reduction: start with a 
limited set of variables that have been established as having prognostic value in the 
literature. It is generally advised to use no more than one potential predictor on every 
10 cases (i.e., patients in ordinary linear regression or events in logistic and Cox 
regression) (Harrell et al., 1985). Experience in large simulation studies shows that a 
model with this approach will perform well in a new, independent data set (Steyerberg 
et al., 2000). Often, further reduction of the number of predictors is achieved by 
applying statistical criteria such as backward or forward stepwise selection. These 
methods delete or include variables in a stepwise fashion according to repeated 
statistical significance testing. In this way noninformative variables are excluded from 
the model, but the danger is that some informative variables are also excluded. 
Furthermore, it involves statistical testing and fitting on the same data, known to lead 
to biased estimates of the coefficients for the variables that are included (Miller, 1990) 
(Hurvitch and Tsai, 1990). Simulation studies have shown that stepwise selection with 
the usual significance level of P = 0.05 may lead to poor model performance in new 
data. It is better to apply a less strict P value: P values of 0.1 0, 0.20, and even 0.50 
have been proposed (Steyerberg et al., 1999). In our case study P = 0.10 was used. For 
the CRA model we started with six plausible predictor variables that were significant 
in univariable analysis (amenorrhea, bleeding interval in case of oligomenorrhea, BMI, 
hyperandrogenemia, F AI, and mean ovarian volume) plus two variables that have 
appeared in literature as potential predictors (LH levels and mean follicle number). 
Using a stepwise backward elimination method four variables were retained in the 
fmal model: F AI, BMI, amenorrhea, and mean ovarian volume (Table 2). 
Missing Data 
Missing data may form a serious problem in multivariable modeling for several 
reasons. When the outcome variable is missing, bias may occur if values are missing 
selectively. For instance, women who become pregnant may be more willing to 
respond to a questionnaire on the outcome of treatment than women who don't get 
pregnant. As a result, the chance of pregnancy will be overestimated when only the 
women who responded are used for analysis. Care should be taken to avoid this as 
much as possible. When a predictor variable is missing, usually no bias is introduced 
when the couple is dropped from the analysis. However, it is a waste of data to drop a 
couple in which the outcome and many predictor variables have been measured, just 
because one of the predictor variables is missing. Imputation techniques may be used 
to keep these cases in the analysis (Little, 1992). Although imputation doesn't produce 
new independent information, it prevents existing information from being dropped. 
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Table 2: Univariable and multivariable (stepwise selected) Odds ratios in logistic regression 
predicting CRA. 
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Odds ratios (OR)4 for CRA Multivariable 
Predictor variable 
Clinical 
Amenorrhea vs oligomenorrhea 
Bleeding interval in case of 
oligomenorrhea (days) 
BMI (kg/m2) 
Endocrine 
Hyperandrogenemia 
(elevated T and/or AD) 
FAib 
LH (IU/L) 
Ultrasound 
Mean ovarian volume (mL) 
Mean follicle number 
* P<0.05 
** p < 0.01 
Range 
0 - 1 
35 - 150 
14-44 
0 - 1 
.5 -24.2 
1.2 -22.6 
2.7 -22.1 
3.0 -25.0 
Univariable Multivariable 
3.7** 5.0** 
1.02* 
1.12** 1.10** 
3.24** 
1.25** 1.16** 
1.02 
1.16** 1.11* 
1.06 
with 
Shrinkage 
correction c 
3.8 
1.08 
1.13 
1.09 
a The interpretation of Odds ratios in univariable analysis is as follows: Amenorrheic women are almost 4 
times as likely (OR= 3.7) to be CRA as oligomenorrheic women. With each I point increase in BMI, the 
likelihood of being CRA increases (relatively) by 12% (OR= 1.12). 
b Free androgen index= T x 100 I SHBG 
c The multivariab1e odds ratios with shrinkage correction are calculated as Exp(s x j3;), with s = 0.82, the 
shrinkage factor and jJ; the regression coefficient for variable X; from logistic regression. 
In very special circumstances the predictor variable is missing for a reason that is 
connected to selective values of the outcome variable. An example in our case study is 
formed by sperm parameters in predicting time to pregnancy. Some men didn't show 
up at the appointment for semen sampling because their wife became pregnant soon 
after start of medication. Probably the semen was of good quality in these cases, and 
the fact that the semen variables were missing was related both to the outcome 
variable (short time to pregnancy) and to the value of the semen variables. This is 
called "informative missingness" for which a correction should be applied. This has 
been done in our analysis (Imani et al., 1999). Using the imputation for missing semen 
data, the Cox regression model for time to pregnancy in patients who were non-CRA 
was build in a stepwise fashion, starting with the seven variables that had P _ 0.20 in 
univariable analysis (age of the woman, amenorrhea, bleeding interval in case of 
oligomenorrhea, LH, F AI, androstenedione, and estradiol). In the fmal model only two 
variables (age and amenorrhea) were retained. Both forward and backward variable 
selection produced the same final model. 
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EVALUATION: GENERALIZABILITY/ VALIDATION 
The purpose of developing a prognostic model is to provide valid predictions in future 
patients, and it is the task of the developers of the model to assess its validity. Validity 
refers to a number of concepts that all relate to whether the model predictions can be 
trusted: 
• Random or prediction error: How precise are the predictions? 
• Systematic error or reliability: Do the predictions agree with observations? Has to 
do with model misspecification, or omitted predictor variables. 
• Discrimination: To what extent are the model predictions able to separate between 
outcome categories? 
When validity is assessed on exactly the same patients that were used to develop the 
model, we speak of "apparent validity." Validity in new but similar patients from the 
same setting is called "internal validity," and "external validity" refers to patients from 
another time or place. For assessment of external validity a new study should be set 
up. Preferably, this should be a prospective longitudinal cohort study, just like the 
study that was used to develop the modeL 
Usually, we can only assess apparent and internal validity. For apparent validity we 
simply apply the model to the same data that were used to develop the modeL For 
internal validity we use the same data, but model development and assessment of 
validity are performed on different parts of the data. Cross-validation is a method in 
which the data set is randomly split in a number of parts of equal size. In turn, each 
part is used to evaluate a model that has been developed on the complementary parts. 
Well-known examples are the split-quarter and split-half methods. In the most extreme 
variant a single patient is left out to evaluate a model build on all other patients. This is 
then repeated for each patient (leave-one-out method). 
The major drawback of cross-validation is that it is inefficient because only part of 
the data is used for model development or evaluation. A method that uses all available 
data is the bootstrap method. In this method the model-building process (selection of 
variables in the model and parameter estimation) is repeated a pre-specified number of 
times (e.g., 200 times). Each repetition consists of creating a new data set (bootstrap 
sample) by drawing cases with replacement from the original data. The resulting 
model from each bootstrap sample is evaluated on the original data. This procedure 
mimics what would happen if new data were collected repeatedly in the same setting 
(Efron and Tibshirani, 1993) and therefore assesses internal validity. 
Random or Prediction Error 
Uncertainty about the predictions of the model will always exist because of the 
statistical imprecision of the regression coefficients. For a given patient profile, the 
model produces a predicted outcome, with an associated 95% confidence intervaL The 
prediction is to be interpreted as a mean value for this patient profile, and the 
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confidence interval refers to the uncertainty about this mean value. For dichotomous 
outcomes, such as in logistic regression predicting CRA, the prediction is to be 
interpreted as the proportion of patients with this profile that is expected (by the 
model) to be CRA. 
Systematic Error or Reliability 
Predictions of the model may also show systematic error when compared with actual 
observations. Reliability (or calibration) refers to how well predictions agree with 
observations. For example, if the model predicts that a patient has a 70% probability of 
being CRA, is the probability really 70%? Of course the real probability cannot be 
observed in an individual patient, because she either is CRA or not, but one could 
imagine a group of identical patients and determine their frequency of CRA. Assessing 
apparent reliability is equivalent to verifying that the model fits well to the data, by 
performing a goodness of fit test such as the Hosmer-Lemeshow for logistic regression 
(Hosmer and Lemeshow, 1989). Lack of fit may occur with improper modeling ofthe 
"dose-response" relationship between a continuous predictor and the outcome (e.g., 
the usual linear form is chosen where the data follow a nonlinear "bathtub" kind of 
curve), or because important interactions between predictors are omitted from the 
model. To resolve lack of fit, subject knowledge from pathophysiology may be of 
greater help than statistical "data dredging," because ofthe risk of chance findings and 
overfitting. This is particularly so when you are already asking much of the data (by 
considering too many variables, stepwise selection). 
When there is no (more) lack of fit, the agreement between predictions and 
observations will be good in the data that were used to develop the model. However, 
statistical theory (Copas, 1983) (Van Houwelingen and Le Cessie, 1990) and recent 
simulation studies (Steyerberg et al., 2000) have shown that in new patients the model 
predictions will be overoptimistic: higher than average predictions are too high and 
lower than average predictions are too low, a phenomenon related to "regression to the 
mean." It becomes worse when the number of candidate predictor variables is higher 
relative to the number of patients with the outcome. It has been shown that reliability 
in new patients will improve if all regression coefficients are corrected by a shrinkage 
factor (Van Houwelingen and Le Cessie, 1990). The bootstrap method is well suited to 
estimate the shrinkage factor that is required. Using the bootstrap method with 200 
replications, we found a shrinkage factor of 0.82 for the CRA prediction model. This 
means that the fmal multivariable model, on average, will give the best fitting 
predictions in new data when all regression coefficients are 18% smaller in absolute 
SIZe. 
Discriminative Ability 
Discrimination refers to the ability of the model to discriminate between good and 
poor prognosis patients, and it is a quantification of the degree to which predicted 
probabilities are lower for patients with poorer outcome. For logistic models it may be 
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measured by the area under the ROC curve (AUC), for Cox models by the c-statistic 
(Harrell et al., 1984). They have a similar interpretation: given two randomly selected 
patients with different outcomes (e.g., one CRA, the other non-CRA or the time to 
conception of one patient is shorter than for the other one), AUC or c-statistic gives 
the probability that the model prediction is worse in the patient with the worst 
outcome. For sensible models it should be higher than 0.5, which is the AUC of a 
noninformative "flip of a coin" model. 
Apparent discriminative ability is always optimistic. Internal validation techniques 
such as the bootstrap method will result in lower and more appropriate values for AUC 
or c-statistic than the apparent value. For the final CRA prediction model, the apparent 
AUC was 0.84, and the "optimism corrected" value, as determined by bootstrapping, 
was 0.82. Discrimination is an intrinsic quality of the model: two different models 
applied to one data set may have different discrimination. But it also depends on the 
range of outcome and predictor variables in the population. 
In Figure 1, the distribution of predicted probability to be CRA is plotted for the 
ovulatory and CRA patients separately. The figure shows the amount of spread in 
prognosis the model has accomplished. The less overlap the two groups show, the 
easier it will be to distinguish ovulatory patients from CRA patients on the basis of the 
predicted probability, and the better the discrimination will be. 
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Figure 1: Box and whisker plot of the distribution of predicted probability to be CRA in ovulatory and 
in CRA patients respectively. Boxes represent median and 25th and 75th percentiles. Whiskers represent 
the I Oth and 90th percentiles. 
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PRESENTATION 
Finally, the results of model development and (internal) validation have to be 
presented. This may be done in the form of the regression formula, with the estimated 
coefficients, corrected by a shrinkage factor, obtained from the statistical software. 
Although the calculation of the prognostic index may be done with pen and paper, for 
logistic regression and the Cox model the transformation from prognostic index to 
predicted outcome variable (the "link function") is too complicated to perform by hand 
(Table 1), and users will have to implement the formula in computer software such as 
a spreadsheet. Alternatively, a score chart may be constructed. This consists of a score 
table, in which, for each value of the predictors, a score is assigned corresponding to 
the "shrunken" regression coefficient from the modeL For this purpose, continuous 
predictors are divided into categories. The clinician has to look up the scores 
corresponding to the values of the predictor variables and add them, giving a sum 
score. Finally, the probability corresponding to the sum score can be read from a graph 
or table that also has to be provided. 
Alternatively, a fully graphical presentation form, such as a nomogram, may be 
chosen. For the CRA prediction model, a special score chart was devised, containing 
the four predictors in the model (Imani et al., 1998). To obtain an over all prediction of 
pregnancy chances, prior to start of CC medication (and thus prior to knowledge about 
CRA), the models for CRA and for prediction of pregnancy in case of ovulation were 
combined in a nomogram (Imani et al., 2002b). 
RECOMMENDATIONS 
1. Choose the outcome parameter( s) carefully and pay due attention to the design 
of the study. In fertility medicine, a prospective cohort study is in almost all 
cases the most appropriate design. 
2. Decide carefully which variables to include as potential predictors. This means 
in terms of anovulation which biologically plausible factors may be involved in 
the etiology of ovarian dysfunction and may predict outcomes of ovarian 
stimulation. Find the right balance between completeness (you don't want to 
miss important predictors) and parsimony (too many predictors will result in 
complex and badly performing models). 
3. Choose the proper type of statistical analysis. Beware of violation of model 
assumptions, particularly when censored time to event such as time to 
pregnancy is the outcome parameter. 
4. Perform internal validation by cross-validation or bootstrapping. This will 
result in a shrinkage factor for the prognostic index, as well as better 
assessment of model performance measures such as the AUC. 
70 
References 
Baxt WG. (1995) Application of artificial neural networks to clinical medicine. Lancet. 346, 1135-8. 
Breiman L, Friedmand L, Olshen R, Stone CJ. (1984) Classification and regression trees, 
Wadsworth,Belmont, CA. 
Collins JA, Burrows EA, Wilan AR. (1995) The prognosis for live birth among untreated infertile couples. 
Fertil Steril. 64, 22-8. 
Copas JB. (1983) Regression, prediction and shrinkage (with discussion). Journal of the Royal Statistical 
Society Series B. 45, 311-354. 
Cross SS, Harrison RF, Kennedy RL. (1995) Introduction to neural networks. Lancet. 346, 1075-9. 
Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993. 
Eimers JM, te Velde ER, Gerritse R, Vogelzang ET, Looman CW, Habbema JD. (1994) The prediction of 
the chance to conceive in subfertile couples. Fertil Steril. 61,44-52. 
Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD. (1991) Serum bioactive and 
immunoreactive luteinizing hormone and follicle- stimulating hormone levels in women with cycle 
abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Meta b. 73, 811-7. 
Fauser BC, Van Heusden AM. (1997) Manipulation of human ovarian function: physiological concepts and 
clinical consequences. Endocr Rev. 18, 71-106. 
Harrell FE, Jr., Lee KL, Califf RM, Pryor DB, Rosati RA. (1984) Regression modelling strategies for 
improved prognostic prediction. Stat Med. 3, 143-52. 
Harrell FE, Jr., Lee KL, Matchar DB, Reichert TA. (1985) Regression models for prognostic prediction: 
advantages, problems, and suggested solutions. Cancer Treat Rep. 69, 1071-77. 
Heckerman DE, Horvitz EJ, Nathwani BN. (1992) Toward normative expert systems: Part I. The Pathfinder 
project. Methods Inf Med. 31, 90-105. 
HosmerDW, Lemeshow S. Applied logistic regression. New York, NY: John Wiley & Sons Inc, 1989:140-
145. 
Hurvitch CM, Tsai CL. (1990) The impact of model selection on inference in linear regression. Am Statist. 
44,214-217. 
Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. (1998) Predictors of patients remaining 
anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic 
infertility. J Clin Endocrinol Metab. 83,2361-5. 
Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. (1999) Predictors of chances to conceive in 
ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic 
oligoamenorrheic infertility. J Clin Endocrinol Metab. 84, 1617-22. 
Imani B, Eijkemans MJ, de Jong FH, Payne NN, Bouchard P, Giudice LC, eta!. (2000) Free androgen index 
and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate 
induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 85, 
676-82. 
Imani B, Eijkemans MJ, Faessen GH, Bouchard P, Giudice LC, Fauser BC. (2002a) Prediction of the 
individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in 
normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril. 
77, 83-90. 
Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. (2002b) A nomogram to predict the 
probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic 
oligoamenorrheic infertility. Fertil Steril. 77,91-7. 
Laven JS, Imani B, Eijkemans MJ, de Jong FH, Fauser BC. (2001) Absent biologically relevant associations 
between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in 
normogonadotrophic anovulatory infertility. Hum Reprod. 16, 1359-64. 
Little RJA. (1992) Regression with missing X's: a review. JAm Stat Assoc. 87, 1227-1237. 
Miller AJ. (1990) Subset selection in regression, Chapman & Hali,London. 
Pache TD, Chadha S, Gooren LJ, Hop WC, Jaarsma KW, Domrnerholt HB, et a!. (1991) Ovarian 
morphology in long-term androgen-treated female to male transsexuals. A human model for the study of 
polycystic ovarian syndrome? Histopathology. 19,445-52. 
Chapter 6: Characteristics of prognostic evidence 71 
Pache TD, Wladimiroff JW, Hop WC, Fauser BC. (1992) How to discriminate between normal and 
polycystic ovaries: transvaginal US study. Radiology. 183,421-3. 
Pearl J. (1988) Probabilistic reasoning in intelligent systems: networks of plausible inference, Morgan 
Kaufmann Publishers,Palo Alto CA. 
Shwe MA, Middleton B, Beckerman DE, Henrion M, Horvitz EJ, Lehmann HP, eta!. (1991) Probabilistic 
diagnosis using a reformulation of the INTERNIST-1/QMR knowledge base. I. The probabilistic model 
and inference algorithms. Methods InfMed. 30,241-55. 
Snick HK, Snick TS, Evers JL, Collins JA. (1997) The spontaneous pregnancy prognosis in untreated 
subfertile couples: the Walcheren primary care study. Hum Reprod. 12, 1582-8. 
Steyerberg EW, Eijkemans MJ, Habbema JD. (1999) Stepwise selection in small data sets: a simulation 
study of bias in logistic regression analysis. J Clin Epidemiol. 52, 935-42. 
Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. (2000) Prognostic modelling with logistic 
regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 19, 
1059-1079. 
Stolwijk AM, Hamilton CJ, Hollanders JM, Bastiaans LA, Zielhuis GA. (1996) A more realistic approach to 
the cumulative pregnancy rate after in- vitro fertilization. Hum Rep rod. 11, 660-3. 
Templeton A, Morris JK, Parslow W. (1996) Factors that affect outcome of in-vitro fertilisation treatment. 
Lancet. 348, 1402-6. 
van Dessel HJ, Schipper I, Pache TD, van Geldorp H, de Jong FH, Fauser BC. (1996) Normal human 
follicle development: an evaluation of correlations with oestradiol, androstenedione. and progesterone 
levels in individual follicles. Clin Endocrinol (Oxj). 44, 191-8. 
van Houwelingen JC, Le Cessie S. (1990) Predictive value of statistical models. Stat Med. 9, 1303-25. 
van Santbrink EJ, Hop WC, van Dessel TJ, de Jong FH, Fauser BC. (1995) Decremental follicle-stimulating 
hormone and dominant follicle development during the normal menstrual cycle. Perfil Steril. 64, 37-43. 

Predictors of Patients Remaining Anovulatory during 
Clomiphene Citrate Induction of Ovulation in 
Normogonadotropic Oligoamenorrheic Infertility 
ABSTRACT 
The diagnostic criteria used to identify patients suffering from polycystic ovary 
syndrome remain controversial. The present prospective longitudinal follow-up study 
was designed to identify whether certain criteria assessed during standardized initial 
screening could predict the response to ovulation induction with clomiphene citrate 
(CC) in 201 patients presenting with oligomenorrhea or amenorrhea and infertility. 
Serum FSH levels were within the normal range (1-10 lUlL), and all patients 
underwent spontaneous or progestin-induced withdrawal bleeding. Initial CC doses 
were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, 
doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation 
with CC was used as the end point. After a complete follow-up (in the case of a 
nonresponse, at least 3 treatment cycles with daily CC doses up to 150 mg), 156 
patients (78%) ovulated. The free androgen index (FAI =testosterone/sex hormone-
binding globulin ratio), body mass index (BMI), cycle history (oligomenorrhea vs. 
amenorrhea), serum androgen (testosterone and/or androstenedione) levels, and mean 
ovarian volume assessed by transvaginal sonography were all significantly different (P 
< 0.01) in responders from those in nonresponders. FAI was chosen to be the best 
predictor in univariate analysis. The area under the receiver operating characteristics 
curve in a multivariate prediction model including F AI, BMI, cycle history, and mean 
ovarian volume was 0.82. 
Patients whose ovaries are less likely to respond to stimulation by FSH due to CC 
treatment can be predicted on the basis of initial screening characteristics, such as F AI, 
BMI, cycle history (oligomenorrhea or amenorrhea), and mean ovarian volume. These 
observations may add to ongoing discussion regarding etiological factors involved in 
ovarian dysfunction in these patients and classification of normogonadotropic 
anovulatory infertile women. 
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INTRODUCTION 
Chronic anovulation is a frequent cause of infertility, and approximately 80% of these 
patients present with serum FSH and estradiol levels within the normal range (WHO 
group 2) (Rowe et al., 1993) The antiestrogen clomiphene citrate (CC) is considered to 
be a successful treatment strategy in these patients. It has been documented that 
approximately 70-80% of these women will become ovulatory (Macgregor et al., 
1968) (Gorlitsky et al., 1978) (Shepard et al., 1979) (Hammond et al., 1983) (Polson 
et al., 1989) (Opsahl et al., 1996), whereas 40-50% of ovulatory women will conceive 
(Gorlitsky et al., 1978) (Hammond et al., 1983). 
Polycystic ovary syndrome (PCOS), usually referred to as chronic hyperandrogenic 
anovulation, represents a distinct proportion of WHO group 2 anovulatory patients. It 
is uncertain to what extent PCOS patients are particularly prone to remain resistant to 
CC medication (Lobo et al., 1982) (Adashi, 1996). Discussion continues regarding the 
validity of criteria used to diagnose PCOS (Franks, 1995) as well as its relevance for 
clinical practice. We have previously demonstrated that a distinct overlap exists 
between endocrine and ultrasound features used by various researchers (van Santbrink 
et al., 1997). If strict criteria are used for PCOS diagnosis, a large heterogeneous 
group ofnormoestrogenic patients will remain unclassified. 
Thirty-five years after its first clinical introduction (Greenblatt et al., 1961), CC still 
remains the first line treatment strategy in normogonadotropic anovulatory patients. 
Although rising serum FSH levels due to CC interference with estrogen negative 
feedback may be held responsible for stimulating follicle growth (Jacobson et al., 
1968) (Miyake et al., 1983) (Kerin et al., 1985), other mechanisms of action have also 
been proposed (Adashi, 1996) (Butzow et al., 1995). A significant proportion of 
treated women, however, do not respond. The aim of this study was to investigate 
whether clinical, endocrine, and sonographic characteristics during initial screening of 
normogonadotropic anovulatory infertile women may predict the ovarian response to 
CC medication. This approach may help to defme conditions that prevent the ovary 
from responding to stimulation by increased FSH levels and to further classify WHO 
group 2 anovulatory patients. 
SUBJECTS AND METHODS 
Subjects and study design 
Approval for this study was obtained from the human subject committee of the 
Dijkzigt Hospital/Erasmus University. Between February 1993 and September 1996, 
201 patients presenting with oligomenorrhea (interval between vaginal bleeding >35 
days and <6 months) or amenorrhea (bleeding interval >6 months) and infertility were 
recruited. Informed consent was obtained from all participants. All subjects were 
referred directly by their general practitioner to our infertility unit. None had received 
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previous ovulation induction medication. Additional inclusion criteria were serum 
FSH levels within normal limits (1-10 IU/L) (Rowe et al., 1993) (van Santbrink et al., 
1995), spontaneous menses or a positive bleeding response to progestagen withdrawal, 
normal serum PRL and THS levels, body mass index (BMI; weight divided by the 
square of the patients height) more than 18, and age less than 40 yr. 
Clinical, endocrine, and sonographic screening was carried out before initiation of 
CC therapy. Clinical screening included infertility and cycle history, BMI, previous 
medication, and/or surgery. Endocrine screening included serum assays of FSH, PRL, 
TSH, LH, estradiol, androstenedione (AD), testosterone (T), sex hormone-binding 
globulin (SHBG), cortisol, and dehydroepiandrosterone sulfate. Fasting blood samples 
were taken randomly between 0800-1000 h before the initiation of therapy. Venous 
blood samples were centrifuged within 2 h after withdrawal and were stored at -20 C 
until assayed. Transvaginal sonographic screening included assessment of the ovarian 
stroma echogenicity (arbitrarily classified from 1-3), ovarian volume (milliliters), and 
total number of follicles (both ovaries), as described previously (van Santbrink et al., 
1997) (Pache et al., 1992b). Serum LH and FSH levels were measured by 
immunoradiometric assay (Medgenix, Fleurus, Belgium), and T, AD, SHBG, and 
dehydroepiandrosterone sulfate were determined using RIA kits (Diagnostic Products 
Corp., Los Angeles, CA), as described previously (Fauser et al., 1991) (van Dessel et 
al., 1996). 
The treatment schedule and assessment of ovarian response were as follows. CC 
medication was initiated on day 3 after spontaneous or progestagen-induced 
withdrawal bleeding. The starting dose was 50 mg/day, orally, for 5 subsequent days. 
In the case of an absent response, daily doses were increased by 50 mg in the next 
cycle to a maximum dose of 150 mg/day in the following cycle. If ovulation occurred, 
the dose remained unaltered during subsequent cycles. First ovulation was used as the 
end point. The duration of follow-up for all patients included in the study was at least 
three treatment cycles. Ovulation was assessed by midluteal serum progesterone 
measurement (levels >25 nmol/L indicating ovulation) combined with transvaginal 
sonographic monitoring of follicle growth until the appearance of a preovulatory 
follicle (mean diameter, 18 mm) and subsequent follicle rupture, or by biphasic basal 
body temperature charts. Responders were defmed as patients who ovulated during CC 
therapy, independent of the dose administered. The number of treatment cycles and the 
CC dose in which first ovulation occurred were recorded. Clomiphene-resistant 
anovulation (CRA) was defined as patients who do not ovulate despite receiving 
maximum treatment doses of 150 mg/day. 
Data analysis 
Distribution of characteristics in patient groups is presented as the mean ± SD. We 
used the Mann-Whitney U test and the Wilcoxon rank sum W test for exploratory 
comparison of initial parameters between responders and nonresponders. The 
univariate and multivariate relation with response to CC was assessed using logistic 
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regression analysis. The following parameters were used in the analysis: BMI, free 
androgen index (FAI; T x 100/SHBG), serum T and/or AD concentrations, serum LH 
levels, cycle history (oligomenorrhea or amenorrhea), cycle duration in case of 
oligomenorrhea, mean ovarian volume, and follicle number. Backward stepwise 
elimination was used for the multivariate logistic analysis of prediction of patients 
being CRA, and P 0.10 was used as a cut-off level for elimination of nonsignificant 
predictors from the prognostic model. The area under the receiver operating 
characteristics (ROC) curve (AU C) was used to assess the discriminative ability of the 
logistic models. The AUC gives the proportion of all pairs of patients (each pair 
consisting of one patient without and the other patient with a response to CC) in which 
the model predicts a higher probability of no response for the patient without response. 
The Statistical Analysis System program (SAS Institute, Cary, NC) was employed for 
data analysis. 
Because selection and estimation were performed for 8 potential predictors on a 
dataset with only 45 events (CRAs), correction for overfitting was performed (Harrell 
et al., 1996). The internal validity of the prognostic model was tested by a 
bootstrapping method in which the selection and estimation process was repeated 200 
times. Each of these repetitions consisted of creating a new dataset (bootstrap sample) 
by drawing cases with replacement from the original data. The backward stepwise 
elimination process was performed on this dataset, yielding a set of selected predictors 
and parameter estimates (Harrell et al., 1996). Resulting model estimates of each 
bootstrap sample were evaluated on the original data, and a shrinkage factor was 
estimated to correct for statistical overoptimism (Van Houwelingen and Le Cessie, 
1990). The Hosmer-Lemeshow goodness of fit test (Hosmer and Lemeshow, 1989) has 
been used to check for lack of fit of the fmal model. The logistic coefficients that were 
corrected by the shrinkage factor have been translated into an easy to use score chart. 
The scores were calculated by multiplying the shrunk coefficients by 10 and rounding 
them off to the nearest whole number. 
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RESULTS 
The number of patients who did or did not ovulate after CC medication in increasing 
doses of 50, 100, and 150 mg daily are depicted in Figure 1. Forty-five patients 
(22.5% of the overall study group) remaining anovulatory were considered having 
CRA. A total of 432 cycles were analyzed. 
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Figure 1: Distribution ofnormogonadotropic oligomenorrheic or amenorrheic infertile women who do or do 
not ovulate after CC induction of ovulation in incremental daily doses of 50, 100, or 150 mg for 5 
subsequent days. A total of 45 women (22.5% of the overall study group) remain anovulatory. 
From the total study group of 201 women, 91 (46%) were considered obese (BMI 
>26), 101 patients (50%) presented with an elevated FAl (>4.5), 85 patients (42%) 
presented with hyperandrogenemia (T 3.2 nmol/L and/or AD 16.3 nmol/L) (van 
Santbrink et a!., 1997) (Fauser et a!., 1991), and in 125 patients (66%) polycystic 
ovaries (mean ovarian volume 10.8 mL and/or mean follicle number per ovary 1 0) 
(van Santbrink et al., 1997) (Pache eta!., 1992b) were diagnosed. Finally, 105 patients 
(54%) presented with elevated LH (7.0 IU/L) serum levels (van Santbrink et al., 1997) 
(Fauser eta!., 1991). 
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Table 1: Clinical, endocrine, and ultrasound characteristics (mean± SD) during initial screening of201 
normogonadotropic oligomenorrheic or amenorrheic infertile women, and separated for patients who do 
(responders) or do not ovulate (CRA) after CC induction of ovulation. 
Screening parameters Overall group CC responder CRA P value" (n = 201) (n = 156; 77.5%) (n = 45; 22.5%) 
Clinical 
Age (yr) 28 ± 4.4 28 ±4.5 27.5 ±4.5 NS 
Primary infertility (n) 145 (72%) 110(71%) 35 (78%) NS 
Amenorrhea (n) 39 (19%) 22 (14%) 17 (38%) 0.0004 
Bleeding interval (days, in 79 ± 62 70±56 113 ±72 <0.0001 
case of oligomenorrhea) 
BMI (kg/m2) 26.6 ± 6.2 25.5 ± 5.8 30.0 ± 6.6 0.0001 
Endocrine 
T (nmol/L) 2.3 ± 0.9 2.1 ± 0.9 2.7 ± 1.0 0.001 
AD (nmol/L) 16.5 ± 7.8 15.3 ± 6.5 20.5 ± 10.2 0.001 
SHBG (nmol!L) 53± 31.7 57± 32.5 38.3 ±23.8 <0.0001 
F Al (T X 1 00/SHBG) 5.9 ± 4.3 4.9 ± 3.4 9.3 ± 5.3 <0.0001 
LH (IU/L) 7.8 ± 4.3 7.8 ± 4.3 8.2 ±4.6 NS 
FSH (IU/L) 4.4 ± 1.4 4.5 ± 1.4 4.2 ± 1.4 NS 
E2 (pmol/L) 282 ± 233 296 ± 195 234±78 NS 
DHEAS (f.Lmol/L) 7.9 ± 3.8 7.9±3.7 7.9±4 NS 
TVS 
Total stroma scoreb 3.0 ± 1.0 2.8 ± 1.3 3.3 ± 1.1 0.006 
Mean ovarian vol (mL) 10.0 ± 4.4 9.2±5.7 12.2 ± 5.8 0.0007 
Mean follicle no. 11.5 ± 5 11 ± 6 12± 5 NS 
a Comparison of cc responders VS. CRA (by Mann-Whitney u test). 
h Arbitrarily defmed as one to three per ovary (both ovaries added). 
In Table 1, clinical, endocrine, and ultrasound characteristics are presented for the 
overall study group and separately for patients who did or did not ovulate after CC 
medication. Forty-four percent of patients presenting with amenorrhea (17 of 39) were 
considered to have CRA, whereas only 17% (28 of 162) of patients with 
oligomenorrhea showed no response. 
Statistical significance in univariate analysis with logistic regression analyses and 
ROC AUC of the initial parameters are depicted in Table 2. The AUCs for F AI and 
BMI were the highest (0.76 and 0.70, respectively). The ROC curve with the best 
performance (F AI) and that with the poorest performance (serum LH) are shown in 
Figure 2. 
Chapter 7: Prediction of CRA 79 
Table 2: Univariate and multivariate logistic regression analyses with score test and area under the ROC 
curve (AUC) of initial clinical, endocrine, and sonographic screening parameters in 20 I normogonadotropic 
oligomenorrheic or amenorrheic infertile women for the prediction of patients remaining anovulatory after 
CC induction of ovulation. 
Parameters Pvalue AUCa 
Univariate analyses 
FAI (T X 100/SHBG) <0.0001 0.76 
BMI (kg/m2) <0.0001 0.70 
Mean ovarian vol 0.0001 0.67 
Hyperandrogenemia (elevated T and/or AD) 0.0007 0.64 
Oligomenorrhea or amenorrhea 0.0005 0.62 
Mean follicle no. 0.1 0.58 
Bleeding interval in case of oligomenorrhea 0.42 0.53 
LH (IUIL) 0.5 0.52 
Multivariate analysis 
Prediction model for CRAb 0.82 
a Area under the ROC curve. 
b Combination of four initial screening parameters: FAI, BMI, cycle history (oligomenorrhea or 
amenorrhea), and mean ovarian volume. 
Of the 201 patients, 187 had complete data on the variables used in the multivariate 
analysis. Using the backward elimination procedure, 4 variables were selected in the 
final model: 1) FAI, 2) BMI, 3) cycle history (oligomenorrhea or amenorrhea), and 4) 
mean ovarian volume. By using the combined information of these 4 variables, the 
AUC further improved to 0.82 (Table 2 and Figure 2). 
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Figure 2: ROC curve of serum LH concentration, F AI, or the prediction model (F AI, BMI, cycle history, 
and mean ovarian volume combined) for predicting CRA in a total group of 20 I normogonadotropic 
oligomenorrheic or amenorrheic infertile women. 
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The bootstrap procedure revealed that these 4 predictors were selected in over two 
thirds of the bootstrap samples, whereas all other candidate variables were selected in 
less than half of the samples, which illustrates the stability of the final modeL The 
shrinkage factor was estimated from the bootstrap procedure to be 0.82, indicating that 
when this study is replicated many times, the resulting coefficients of the fmal 
multivariate model are, on the average, 18% smaller. This was incorporated in the 
calculation of the scores. 
The scores for different parameters are depicted in Table 3, and resulting 
probability scores for patients remaining anovulatory after CC medication are shown 
Table 3 Score chart with the four initial screening parameters of the final model for prediction of patients 
remaining anovulatory after CC induction of ovulation in normogonadotropic oligomenorrheic or 
amenorrheic infertile women (total scores, 0-53) 
Initial screening parameters 
F AI (T X 1 00/SHBG) 
<2 
2-3 
3-4 
4--5 
5-6 
6-8 
8-11 
>11 
BMI (kg/m2) 
<20 
20-21.5 
21.5-23 
23-25 
25-27 
27-31 
31-35 
>35 
Mean ovarian vol (rnL) 
<6 
6-7 
7-8 
8-9 
9-11 
11-13 
13-16 
>16 
Cycle history 
Oligomenorrhea 
Amenorrhea 
Score a 
0 
1 
2 
3 
5 
6 
10 
14 
0 
2 
3 
4 
6 
8 
12 
15 
0 
2 
2 
3 
5 
6 
9 
11 
0 
13 
Total score 
a Encircle the scores related to each category of the screening parameters and add them together. Correspond 
the total score to the score chart (Fig. 3). As an example, a new amenorrheic patient had the following 
fmdings: F AI= 8.7, BMI = 29.4, and mean ovarian volume= 13 rnl. Scores are 10 for FAI, 8 for BMI, 9 for 
mean ovarian volume, and 13 for having amenorrhea. The total score is 40, and the corresponding 
probability to be CRA is 65%. 
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in Figure 3. The Hosmer-Lemeshow goodness of fit test showed no lack of fit of the 
fmal model to the data (P = 0.3). 
DISCUSSION 
It may be helpful for further classification of normogonadotropic anovulatory 
infertility and for evaluating pathophysiological factors involved in ovarian 
abnormalities in these patients to study in a longitudinal fashion whether initial 
screening parameters may predict success, failure, or complications of induction of 
ovulation. The present study was designed to investigate as a first step whether ovarian 
response after CC medication could be predicted. It is established in the literature that 
approximately 75% of patients will ovulate, and less than 50% of the total population 
will conceive after CC as first line medication. If patients remaining anovulatory 
despite CC therapy could be identified beforehand, ineffective and time-consuming 
CC treatment could be prevented. This may be helpful, particularly for women of 
advanced reproductive age. Further studies, however, are required to investigate 
whether alternative primary treatment options are cost effective. Moreover, etiological 
factors involved in ovarian dysfunction could be identified in this heterogeneous 
patient group, as subjects whose ovaries will or will not respond to increased FSH 
stimulation may be differentiated. 
For this first analysis of response to CC medication we decided to focus on 
ovulation rather than conception. Ovulation is biologically relevant and most closely 
connected to the desired effects of CC medication. Analysis of conception as the end 
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Figure 3 Total score from the score chart and the corresponding probability for a given woman to remain 
anovulatory after CC induction of ovulation. 
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point requires a comprehensive study of other potential confounders, such as tubal 
factor, sperm factor, and endometrial function. Four initial screening parameters (FAI, 
BMI, mean ovarian volume, and cycle history) could be identified, predicting patients 
remaining anovulatory after CC medication. A combination of these parameters 
showed good predictive power, with a ROC AUC of 0.82. Several studies have been 
published recently regarding the use of a similar multivariate model for predicting 
chances for conception in infertile patients with regular cycles (Eimers eta!., 1994) 
(Collins eta!., 1995) (Snick et a!., 1997). Various researchers have investigated the 
predictive value of clinical and endocrine screening parameters for the response to CC. 
Only a positive correlation between body weight and the dose of CC required to 
induce ovulation has been established (Lobo et a!., 1982) (Shoham et a!., 1990). A 
recent study has indicated that increased BMI is the only initial parameter that is 
significantly different between responders and nonresponders (Kousta eta!., 1997). To 
our knowledge this is the first time a multivariate prediction model has been applied in 
the treatment of anovulatory infertility. We could demonstrate that patients suffering 
from amenorrhea, obesity, increased ovarian volume, and elevated androgen levels (a 
complex of signs, symptoms, and ultrasound and endocrine fmdings frequently 
referred to as PCOS) are most likely to remain anovulatory after CC induction of 
ovulation. A model can be used to predict chances for an individual patient to remain 
anovulatory by calculating a total score on the basis of these initial screening 
characteristics. Further studies should validate the prediction model in a new group of 
patients. The present study also suggests that LH concentrations do not predict ovarian 
response after CC medication in accordance with recent observations by others 
(Kousta eta!., 1997). These data oppose the concept that elevated LH is implemented 
in ovarian dysfunction in these patients (Yen, 1980). However, the assessment of LH 
levels in anovulatory patients is problematic due to effects of timing, the 
immunoassays used, and the pulsatile nature of LH release (Fauser and De Jong, 
1993). 
Together, these observations suggest that obese hyperandrogenic women are less 
likely to respond to increased stimulation by FSH, suggesting that these factors are 
instrumental in follicle maturation arrest (Franks eta!., 1998) and an increased FSH 
threshold (Polson et a!., 1989). The correlation between BMI and ovarian response 
after CC treatment suggests that much emphasis should be focused on weight 
reduction. However, it should be realized that scientific proof for this approach is 
lacking, and that weight reduction may not necessarily result in normal response. 
Previous work from our group demonstrated indeed that long term androgen 
medication in female to male transsexuals induces polycystic ovary morphology, 
characterized by increased ovarian size, augmented follicle number, and stroma 
hyperplasia (Pache eta!., 1991). Assessment of steroid levels in follicle fluid obtained 
from polycystic ovaries suggested that disturbed dominant follicle selection in 
hyperandrogenic patients may result from disrupted enhancement of FSH-induced 
aromatase activity (Pache et a!., 1992a). This could be due to intraovarian 
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dysregulation of FSH action, which precludes a normal response (i.e. follicle growth 
and ovulation) after incremental FSH levels elicited by CC medication. Factors 
involved may include locally produced growth factors or insulin resistance (Giudice, 
1992) (Nestler, 1997). Alternative explanations for a nonresponse after CC may 
include 1) an abnormal hypothalamic/pituitary response to steroid feedback resulting 
in an insufficient rise in FSH after CC, 2) individual differences in the FSH 
isohormone profile resulting in discrepancies in bioactive FSH concentrations despite 
similar immunoreactive FSH levels, 3) additional, as yet unidentified, mechanisms 
responsible for at least part of CC actions. Recently reported CC-induced changes in 
the insulin-like growth factor system (Butzow et al., 1995) may be relevant in this 
regard. It may be speculated that improved insight into any of these factors 
(intraovarian dysregulation (Fauser and Van Heusden, 1997), hypothalamic/pituitary 
dysfunction (Berga and Daniels, 1997), FSH heterogeneity (Ulloa-Aguirre et al., 
1995), or the insulin-like growth factor system (Giudice, 1992)) may eventually result 
in additional predictors of the CC response. Further studies focusing on insulin 
resistance may also be of interest, as recent reports suggest that ovarian dysfunction 
may improve after the use of insulin-sensitizing agents (Sattar et al., 1998). 
Preliminary observations (Imani, B. and Fauser, B. C. J. M., unpublished observations) 
suggest that fasting insulin levels are increased in CRA patients. It requires further 
study to clarifY whether insulin resistance is a determining factor in an abnormal 
response to FSH independent from androgen concentrations, as the majority of studies 
propose that insulin resistance is associated with PCOS through increased thecal cell 
androgen production (Nestler, 1997). 
In conclusion, this study demonstrates that it is possible to predict patients 
remaining anovulatory during CC induction of ovulation using criteria that are directly 
associated with PCOS, predominantly obesity and hyperandrogenemia. Further studies 
should establish whether the occurrence of pregnancies after CC medication can also 
be predicted and whether similar factors are involved. The identification of initial 
characteristics that predict the ovarian response to ovulation induction therapy may 
help to further classifY the heterogeneous group of normogonadotropic anovulatory 
infertile women. The present study suggests that hyperandrogenemia and obesity are 
crucial in inducing ovarian abnormalities that are less likely to respond to increased 
stimulation by FSH. 
Footnote 
1 This work was supported by the Stichting V oortplantingsgeneeskunde Rotterdam 
and a research grant from F erring Nederland. 
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Predictors of chances to conceive in ovulatory patients during 
clomiphene citrate induction of ovulation in normogonadotropic 
oligoamenorrheic infertility 
ABSTRACT 
The present prospective follow-up study was designed to identifY whether clinical, 
endocrine, or ultrasound characteristics assessed by standardized initial screening of 
normogonadotropic oligo/amenorrheic infertile patients could predict conception in 
160 women who reached ovulation after clomiphene citrate (CC) medication. 
Additional inclusion criteria were total motile sperm count of the partner above 1 
million and a negative history for any tubal disease. Daily CC doses of 50 mg 
(increasing up to 150 mg in case of absent ovarian response) from cycle days 3-7 were 
used. First conception (defmed as a positive urinary pregnancy test) was the end point 
for this study. A cumulative conception rate of73% was reached within 9 CC-induced 
ovulatory cycles. Patients who did conceive presented more frequently with lower age 
(P < 0.0001) and amenorrhea (P < 0.05) upon initial screening. In a univariate 
analysis, patients with elevated initial serum LH concentrations (>7.0 lUlL) had a 
higher probability of conceiving (P < 0.01). In a multivariate analysis, age and cycle 
history (oligomenorrhea vs. amenorrhea) were identified as the only significant 
parameters for prediction of conception. 
These observations suggest that there is more to be gained from CC ovulation 
induction in younger women presenting with profound oligomenorrhea or amenorrhea. 
Screening characteristics involved in the prediction of ovulation after CC medication 
in normogonadotropic oligo/amenorrheic patients (body weight and 
hyperandrogenernia, as shown previously) are distinctly different from predictors of 
conception in ovulatory CC patients (age and the severity of cycle abnormality). This 
disparity suggests that the FSH threshold (magnitude of FSH required for stimulation 
of ongoing follicle growth and ovulation) and oocyte quality (chances for conception 
in ovulatory cycles) may be differentially regulated. 
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INTRODUCTION 
The synthetic antiestrogen clomiphene citrate (CC) represents an easy to use, 
convenient, inexpensive, and safe first choice medication in normogonadotropic 
oligo/amenorrheic infertility (WHO group 2) (Rowe et al., 1993). Life-table analysis 
of pregnancy rates after CC medication and prediction of treatment outcome have been 
the subject of extensive investigation (Macgregor eta!., 1968) (Gorlitsky eta!., 1978) 
(Shepard eta!., 1979) (Lobo eta!., 1982) (Hammond eta!., 1983) (Polson eta!., 1989) 
(Shoham et al., 1990) (Opsahl et a!., 1996) (Kousta et a!., 1997). Cumulative 
pregnancy rates after CC treatment between 37-97% have been reported (Gorlitsky et 
a!., 1978) (Shepard eta!., 1979) (Hammond eta!., 1983). A positive correlation was 
established between body weight and the CC dose required to induce ovulation (Lobo 
eta!., 1982) (Kousta et al., 1997). Moreover, recent studies have indicated that body 
mass index (BMI) is significantly higher in nomesponders (Polson et al., 1989) 
(Kousta et al., 1997). Limited information is available, however, concerning the 
predictive value of initial screening characteristics for treatment outcome (Adashi, 
1996), and previous investigators were unable to identify predictors for conception 
after CC induction of ovulation (Hammond eta!., 1983) (Shoham et al., 1990) (Kousta 
eta!., 1997). All the above-mentioned studies focused on the prediction of treatment 
outcome in the entire group of infertile patients who started with CC medication. In 
contrast, we focused separately on the prediction of ovulation after CC administration 
(Imani eta!., 1998) and the prediction of conception in ovulatory CC-treated women. 
This approach seems more appropriate, because statistical bias due to selective drop 
out from the study for reasons of persistent anovulation despite increasing doses of CC 
medication is eliminated. 
Our group could recently establish that obese hyperandrogenic amenorrheic patients 
are more likely to be resistant to CC medication (Imani et al., 1998). We now report 
on initial clinical, endocrine, and sonographic screening characteristics of 
normogonadotropic oligomenorrheic or amenorrheic infertile women achieving 
ovulatory cycles after CC medication in an attempt to identify factors predicting 
chances for conception in these patients. The separate focus on the prediction of 
conception and ovulation after CC treatment may allow to differentiate among factors 
affecting oocyte quality independently from follicle development. 
SUBJECTS AND METHODS 
Subjects and study protocol 
Between February 1993 and December 1997, 160 couples presenting with 
oligomenorrhea (bleeding intervals between 35 days and 6 months) or amenorrhea 
(bleeding interval >6 months) and infertility attending our unit were included in the 
present study. Additional inclusion criteria were 1) serum FSH levels within normal 
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limits (1-10 IUIL) (Rowe eta!., 1993) (van Santbrink eta!., 1997) (Schipper eta!., 
1998) and normal serum PRL and TSH levels, 2) spontaneous menses or positive 
bleeding response to progestagen withdrawal, 3) ovulatory cycles after CC induction 
of ovulation, 4) BMI (weight divided by height squared) greater than 18, 5) age 
between 19-40 years, 6) a total motile sperm count [TMC = ejaculate volume 
(milliliters) x sperm concentration (106 I mL) x percentage of progressive motile 
sperm] of the partner above 1 million (Ombelet eta!., 1997), 7) negative history for 
any tubal pathology, and 8) no indication for intrauterine insemination. Study approval 
was obtained from the human subject committee of the Dijkzigt Hospital/Erasmus 
University, and informed consent was obtained from all subjects included. A 
standardized clinical, endocrine, and sonographic screening took place before 
initiation of induction of ovulation with CC medication. 
Ovulation after CC treatment was assessed by midluteal serum progesterone (P) 
levels above 25 nmol/L, combined with transvaginal sonographic monitoring of 
follicle growth until visualization of a preovulatory follicle (mean diameter, > 18 mm) 
and subsequent disappearance or biphasic basal body temperature charts, as described 
previously (Imani et al., 1998) Clomiphene citrate was administered at a daily dose of 
50 mg (increased to 100 and 150 mg in subsequent cycles in the case of absent ovarian 
response) from cycle days 3-7 after initiation of spontaneous or progestin-induced 
withdrawal bleeding. Conception was defmed as a positive urinary pregnancy test 
(Clearview, hCG II, Unipath Ltd., Bedford, UK) more than 3 days after the expected 
menses, and ongoing pregnancy was defmed as sonographic assessment of an 
intrauterine gestational sac with positive heart beat. 
History and clinical screening included assessment of duration of infertility, whether 
infertility was primary or secondary, cycle history, previous medication and/or 
surgery, and BMI. Endocrine screening included serum assays of FSH, LH, estradiol 
(E2), testosterone (T), androstenedione (AD), sex hormone-binding globulin (SHBG), 
and P. Fasting venous blood samples were taken on a random day between 8:00-10:00 
A.M., as indicated previously (lmani et a!., 1998). Blood samples were centrifuged 
within 2 hours after withdrawal and were stored at -20 C until assayed. Serum LH and 
FSH levels were measured by immunofluorometric assay (Amerlite, Ortho-Clinical 
Diagnostics, Amersham, Aylesbury, U.K.), as described previously (Schipper et a!., 
1998). P levels were measured by radioimmunoassay (RIA), as described previously 
(de Jong eta!., 1974). Serum E2, T, AD, and SHBG levels were estimated using RIA 
kits provided by Diagnostic Products Corp. (DPC, Los Angeles, CA), as described 
previously (Fauser et a!., 1991). Intra- and interassay coefficients of variation were 
less than 3% and 8% for FSH, less than 5% and 15% for LH, less than 16% and 17% 
for P, less than 5% and 7% for E2, less than 3% and 5% forT, less than 8% and 11% 
for AD, and less than 4% and 5% for SHBG, respectively. Transvaginal pelvic 
ultrasound (Model EUB-415, Hitachi Medical Corp., Tokyo, Japan) was performed by 
a single observer (B.I.) and included the assessment of ovarian stroma amount and 
echogenicity (arbitrarily classified from one to three per ovary), ovarian volume 
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(milliliters), and total number of follicles (both ovaries), as described previously (van 
Santbrink et al., 1997) (Pache et al., 1992). Semen analyses were performed according 
to WHO guidelines (1992) and comprised ejaculate volume (milliliters), number of 
spermatozoa per mL (1 06 spermatozoa/mL ), percentage of progressive motile 
spermatozoa, and percentage of normal forms (Organization, 1992). 
Data analysis 
A P value of 0.05 was chosen as the threshold level for statistical significance. Cox 
regression has been used for life-table analysis of conception rates during CC 
treatment (Cox, 1972). The number of ovulatory CC treatment cycles was the time 
variable for multivariate analyses. Censoring was defined as definitive discontinuation 
of CC therapy without conception or end of follow-up (February 1998). To analyze the 
effect of the severity of the cycle abnormality on chances to conceive after CC 
treatment, we arbitrarily divided the cycle histories of the patients into four categories; 
interval between periods of 5-6 weeks (n =56), 6-9 weeks (n =50), 9-26 weeks (n = 
25), and greater than 26 weeks (i.e. amenorrhea) (n = 29). The univariate relation was 
assessed between the variables listed in Table 1 and the time interval between the first 
ovulation after CC medication and conception using the Kaplan-Meier method 
(Kaplan and Meier, 1958) for categorical and the Cox regression (Cox, 1972) for 
continuous variables. The Log-rank test has been used to denote statistical significance 
in life-table analyses. The multivariate analysis was performed with the method of 
forward stepwise selection to gain a better insight into the interdependence between 
initial screening parameters. This method can explain why a variable that was 
significantly different in univariate analysis was not selected in the final modeL The 
prognostic impact of variables was expressed as a fecundability ratio, which is 
equivalent to the hazard ratio in survival analysis. For instance, a fecundability ratio of 
0.9 for an unfavorable group means that the conception rate per ovulatory CC 
treatment cycle is 10% lower compared to that in the favorable group. In some couples 
(n = 25), no sperm analysis was performed because of the short time interval between 
initiation of CC medication and conception. A statistical imputation technique has 
been applied using multiple conditional mean imputation to fill in these missing sperm 
parameters (Rubin, 1978). The value of semen parameters was estimated using the 
time until conception and patient characteristics related to sperm parameters in the 
nonmissing group. Data were analyzed using the commercially available software 
package SPSS, Inc. (Chicago, IL). 
RESULTS 
A total of 82 women (51% of the ovulatory group) conceived, and 73 ( 46%) reached 
an ongoing pregnancy from the total of 160 patients fulfilling the in/exclusion criteria. 
Sixty-nine were singleton and 4 were twin pregnancies (data not shown). Initial 
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screening parameters of 9 patients who had a miscarriage after CC (11% of overall CC 
conceptions) were not different from those of the remaining 73 patients who reached 
an ongoing pregnancy (data not shown). One woman who conceived (twin pregnancy) 
during her first CC treatment cycle was frequently monitored on an out-patient basis 
due to abdominal discomfort and enlarged ovaries. There was no case of severe 
ovarian hyperstimulation syndrome. 
The life-table analysis of cumulative conception rates (CCR) of patients who 
ovulated after CC are indicated in Figure 1 for the total group, and separately for 
different dose groups. A cumulative conception rate of 4 7% was reached within three 
cycles from first ovulation, and a CCR of 73% was reached within nine CC-induced 
ovulatory cycles. Patients using daily doses of 50, 100, and 150 mg CC reached 
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Figure 1: Life table analysis of cumulative conception rates (CCR) in 160 normogonadotropic oligo-
amenorrheic infertile patients who ovulated following CC medication. CCR's (including absolute number of 
patients at risk and number of events(= conceptions)) are presented for the total study group (upper panel) 
(vertical lines represents 95% Confidence Intervals), and separately for women who reached ovulatory CC 
cycles with 50, 100, or 150 mg daily for 5 subsequent days (lower panel). N represents the initial number of 
patients at risk per dose group. P =Log Rank test P value. 
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cumulative conception rates of 57%, 66%, and 38% within 5 ovulatory cycles, 
respectively (P lag rank= 0.25; Figure 1). At higher doses, chances for conception and 
ongoing pregnancy are not statistically significantly reduced, although absolute CCR 
(n = 18) were low in the 150-mg CC group. The overall mean duration of follow-up 
was 4 ± 3 months and 3.2 ± 2.6 ovulatory CC cycles. 
Initial screening characteristics of the overall group of patients who ovulated after 
Table 1: Initial clinicalscreening characteristics and sperm parameters of partners (median and range) of 160 
normogonadotropic oligomenorrheic or amenorrheic infertile women who ovulated after CC induction of 
ovulation (overall group) and did or did not (CC failure) conceive, endocrine, and ultrasound 
Overall group Conceived CC failure 
Screening parameters (n = 160) (n=82;51%) (n=78; 49%) Pva1uea 
Clinical 
Age (yr) 28±4 27±4 29±4 0.0001 
Infertility duration (yr) 1.9 ± 2.3 1.6±1.4 2.2±2.9 0.23 
Primary infertility (n) 116 62 54 0.40 
Amenorrhea (n) 29 18 (62) ll (38) 0.04 
Bleeding interval 
in 4 categories o.o5b 
5-6 weeks, n (%) 56 (35) 22 34 
6-9 weeks, n (%) 50 (31) 29 21 
9-26 weeks, n (%) 25 (16) l3 12 
>26 weeks, n (%) 29 (18) 18 ll 
BMI (kg/m2) 26±6 26±6 25±6 0.46 
Endocrine 
LH (IUIL) 7.6±4.2 8.2±4.3 6.9 ±4.0 0.11 
T (nmol!L) 2.3 ± 1.0 2.3 ± 1.0 2.3 ± 1.0 0.85 
AD (nmol!L) 15.0 ± 6.9 15.8 ± 7.9 14.0 ± 5.7 0.16 
FAlc 5.4 ± 3.9 5.5 ±4.1 5.1 ± 3.7 0.20 
SHBG (nmol/L) 56± 31 54±27 58 ±35 0.24 
E2 (pmol/L) 259 ± 175 229 ± 145 290 ± 198 0.10 
Ultrasound 
Mean ovarian vol (mL) 9.3 ± 3.7 9.2±3.7 9.4 ± 3.7 0.97 
Mean follicle number 12 ± 5 12± 5 12±5 0.48 
Total stroma scored 3.2 ± 1.1 3.1 ± 1.1 3.3 ± 1.2 0.66 
TMCC 73 (1.1-492) 75 (1.5-303) 72 (1.1-492) 0.32:'" 
%Normal morphology 24 (1-50) 20 (1-50) 25 (1-50) 0.34 
Values are the mean± SD. Underlined values are statistically significant. 
a Comparison ofCC-conceived vs. CC failure (univariate Cox regression). 
b Chances to conceive differ among four categories of bleeding interval. 
cFAl=Tx 100/SHBG. 
d Arbitrarily defined as one to three per ovary (both ovaries added). 
e Total motile sperm count 
r Computed with multiple imputation of missing values. 
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CC and separately for those women who conceived (n = 82) vs. those who did not (n = 
78) are depicted in Table 1. Age, the severity of cycle abnormality (oligomenorrhea 
vs. amenorrhea), and cycle duration, arbitrarily classified in four categories (see also 
Materials & Methods), were significantly different in univariate analysis. 
Age (cut-off of 30 yr), cycle history (oligomenorrhea vs. amenorrhea), and initial 
~ 0 100 
2 
co 
0:: 75 c: 
0 
:g_ 
Q) 
() 
c: 
0 () 
Q) 
.;:: 
c;; 
"3 
E 
::J 
() 2 3 4 5 6 7 
~ 100 Ovulatory CC cycles 0 
2 
co 
0:: 75 c: 
0 
li 
Q) 
() 
c: 
0 () 
Q) 
.;:: 
c;; 
"3 
E 
::J 
() 2 3 4 5 6 7 
Ovulatory CC cycles 
~ 0 100 
2 
co 
0:: 
c: 
0 
a 
Q) 
() 
c: 
0 () 
Q) 
> ~ 
:; 
E 
::J 
() 2 3 4 5 6 7 
Ovulatory CC cycles 
Figure 2 Univariate analysis of cumulative conception rates in 160 normogonadotropic oligoamenorrheic 
infertile patients per ovulatory CC cycle. Initial screening parameters shown are: I) Patient's age (cut-off 
level at 30 years) (upper panel). 2) Cycle history (oligomenorrhea versus amenorrhea) (middle panel). 3) 
Initial serum LH concentrations (cut-offlevel of7.0 IU/L) (lower panel). n represents the initial number of 
patients at risk. P = Log Rank test P value. 
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serum LH level (cut-offlevel of7.0 lUlL) in univariate analyses for CCR are depicted 
in Figure 2. The percentage of ongoing pregnancies per conception for patients with 
elevated (initial serum LH level :2':7.0 lUlL) or normal initial serum LH levels were 
84.8% and 94.4%, respectively (P value for difference in proportion ongoing 
pregnancies = 0.16, and 95% confidence interval for difference = -3% to 23%). The 
cut-off value for normal (i.e. 7.0 IU/L) was chosen on the basis of a previous study 
from our group in normoovulatory controls (mean + 1 SD) (van Santbrink et al., 
1997). 
A total number of 159 patients had complete data on the variables used in the 
multivariate analyses. Univariate analysis and forward stepwise multivariate analyses 
of all initial parameters for the prediction of chances to conceive in ovulatory patients 
treated with CC are depicted in Table 2. During the stepwise multivariate analysis for 
the prediction of chances to conceive, age, and cycle history (amenorrhea vs. 
oligomenorrhea) entered into the model (step 1 and 2, respectively). The multivariate-
adjusted fecundability ratio for age was 0.90 (95% confidence interval, 0.85-0.95), 
and that for amenorrhea 0.54 (95% confidence interval, 0.32-0.93). 
Table 2: Forward stepwise multivariate analyses of initial screening characteristics for the prediction of 
chances to conceive in 159 normogonadotropic oligo-amenorrheic infertile women who ovulated after CC 
induction of ovulation 
Analyses steps 
Screening parameters 
Clinical 
Age (yr) 
Amenorrhea (n = 29) 
Univariate 
oa 
Bleeding interval (in four categories) 0.05 
Endocrine 
LH (lUlL) 
FAlb 
AD (nmol/L) 
E2 (pmol!L) 
0.11 
0.20 
0.16 
0.10 
Multivariate 
2 
In model In model 
0.02 In model 
0.06 0.30 
0.36 0.26 
0.56 0.38 
0.38 0.15 
0.26 0.39 
Numbers are P values for inclusion in the model. Underlined numbers are significant at P < 0.05. 
a Only screening parameters with a univariate P :o; 0.2 (see Table 1) are shown. In the univariate analysis 
(step 0), three variables reach statistical significance (underlined). In step 1 of the multivariate analysis the 
variable with the highest prognostic information (age) is selected. After the first step, amenorrhea still 
reaches statistical significance and, therefore, is selected in the second step. Thereafter, no additional 
variable is statistically significant anymore, indicating that the model cannot be improved by selecting a 
subsequent parameter. 
bFAI=Tx 100/SHBG. 
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DISCUSSION 
The present prospective follow-up study was designed to evaluate whether initial 
screening characteristics of 160 normogonadotropic oligo/amenorrheic infertile 
women could predict conception during ovulatory CC-induced cycles. Although CC 
medication has been the focus of prevalent research, limited information is available 
regarding the prediction of conception as treatment outcome (Adashi, 1996). Reported 
cumulative pregnancy rates vary between 37-97%. Most studies, however, suffer from 
methodological difficulties and different inclusion/exclusion criteria. For the first time, 
our group has focused on ovulation and conception in separate steps, taking into 
account that a significant proportion (23%) of patients who remain anovulatory after 
CC medication (Imani eta!., 1998) have no chance of conception. Inclusion of these 
patients in a study focusing on conception causes statistical bias. This separate focus 
may offer a better insight into the potential predictive power of initial screening 
characteristics in a heterogeneous group of normogonadotropic oligo/amenorrheic 
infertile women (WHO class 2) for CC-induced follicle growth and ovulation, 
separately from conception. 
In the present study, CCR of 63% within six cycles and 73% within nine ovulatory 
CC-induced cycles have been reached. Two thirds of patients who conceived reached 
this end point within the first three ovulatory CC treatment cycles. This is in 
agreement with previous reports in the literature regarding CC (Garcia eta!., 1977) 
(Gorlitsky eta!., 1978) (Gysler eta!., 1982) and is similar to spontaneous conception 
chances in normoovulatory women (Tietze, 1968). This is also comparable to 
conception rates reported for exogenous gonadotropin induction of ovulation (Dor et 
a!., 1980) (Hamilton-Fairley eta!., 1991) (van Santbrink eta!., 1995) in anovulatory 
infertile patients. These observations strongly suggest that the overall detrimental 
effects of CC on cervical mucus production or endometrial receptivity and subsequent 
implantation are limited with daily CC doses up to 150 mg. Although the CCR seems 
to be lower in the high dose CC group, this fmding was not statistically significant. It 
should be noted that the sample size of this group is limited, so actual differences 
cannot be excluded. 
Previous studies were unable to identifY predictors for conception in CC induction 
of ovulation in normogonadotropic infertile women (Hammond eta!., 1983) (Shoham 
et a!., 1990) (Kousta et a!., 1997). In the present study, age and cycle history 
(amenorrhea or oligomenorrhea) were significantly different comparing patients who 
conceived vs. those who did not during CC-induced ovulatory cycles. Multivariate 
analyses revealed a fmal model including age and cycle history. The predictive power 
of age was the highest. The area under the receiver operating characteristics curve of 
the fmal model including these two factors reached 0.68 (data not shown), which is 
substantially lower than that in the previous model predicting ovulation after CC 
(0.82) (Imani eta!., 1998). For reasons of clarity, the forward stepwise approach was 
chosen (see Table 2). Backward stepwise analysis was also applied, resulting in the 
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same fmal model (data not shown). Young patients have a higher probability to 
conceive during CC-induced ovulatory cycles. The fecundability rate of the patient 
decreases by approximately 10% per year. This is in agreement with reports that 
indicate that age is an important factor for the prediction of chances for spontaneous 
conception in untreated normoovulatory subfertile patients (Eimers et a!., 1994) 
(Imani et a!., 1998) (Scott et a!., 1995). Similar fmdings have been reported for the 
prediction of chances to conceive following exogenous gonadotropin induction of 
ovulation (Dor et a!., 1980) and in vitro fertilization treatment (Templeton et a!., 
1996). 
Amenorrheic patients exhibit a 2-fold higher probability to conceive after ovulatory 
CC cycles as compared to oligomenorrheic patients. Patients with longer bleeding 
intervals also exhibit higher conception chances. We have been unable to fmd similar 
reports in the literature regarding induction of ovulation. The most likely explanation 
seems to be the following. Patients with amenorrhea have an extremely low 
probability to conceive without intervention due to anovulation before seeking help by 
a physician. Presumably, the major subfertility factor in these patients is chronic 
anovulation, which can be resolved temporarily by the use of CC medication. These 
patients are more likely to be at low risk for any other subfertility factor, such as tubal 
or sperm dysfunction. Some oligomenorrheic patients may have spontaneous 
ovulations (Minakami eta!., 1988), and some of these women may never seek medical 
intervention because of spontaneous pregnancies. Their benefit from ovulation 
induction is an increased chance for conception due to an increased number of 
ovulations with a fixed interval in a given period of time. Similar observations were 
made for pregnancy chances after artificial insemination with donor sperm in relation 
to the sperm quality of the partner. Donor insemination outcome is significantly better 
in cases with very poor sperm quality (Emperaire eta!., 1982). One should consider 
that amenorrheic patients also have a higher probability to remain anovulatory after 
CC, as demonstrated previously (lmani et a!., 1998). In contrast, regular ovulatory 
cycles are easier to induce with CC in oligomenorrheic patients but there is less chance 
of pregnancy. 
In the present study, patients with elevated initial serum LH levels have a 
significantly higher probability to conceive once ovulatory cycles have been achieved 
by CC. A recent study also indicated higher initial LH levels in patients who 
conceived after CC medication (Kousta et a!., 1997). In contrast, a poor treatment 
outcome has been observed in patients with high LH levels during the follicular phase 
of CC-induced cycles (Shoham eta!., 1990). It should be realized that we report on 
initial LH levels before initiation of CC medication, rather than during CC-induced 
cycles. Indeed, elevated LH levels may normalize only during CC-induced ovulatory 
cycles (Eden et al., 1989). These observations are in sharp contrast with reports 
regarding patients with elevated LH who perform poorly during gonadotropin 
induction of ovulation (Hamilton-Fairley eta!., 1991) or in vitro fertilization (Rowles 
et a!., 1986). We previously showed that initial LH concentrations did not predict 
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patients who would remain anovulatory after CC medication (Imani et al., 1998). The 
present observation seems to dispute previous beliefs concerning the detrimental 
effects of raised LH levels on oocyte maturation and capacity for fertilization. In 
addition, we did not observe a higher spontaneous abortion rate in patients with high 
LH levels who conceived after CC medication. This finding is also in contrast with 
previous reports on the effects of high LH concentrations on chances for spontaneous 
abortion after exogenous gonadotropins (Homburg et al., 1988) (Regan et al., 1990). 
The predictive power of the initial LH level is poor in case age enters in the final 
model, which may be due to a correlation of initial LH with age (data not shown). The 
mechanism of action of CC is not fully elucidated, and the role of LH in the 
pathogenesis of ovarian abnormalities remains open for speculation. As an example, 
female siblings of male patients described with an activating mutation of the LH 
receptor (so-called familial male testotoxicosis) seem to be without a clear phenotype 
(Fauser et al., 1999) 
Total motile sperm count is not a predictor in univariate or multivariate analyses of 
prediction of conception in the present study population. This is in agreement with the 
observation that a large overlap exists between semen characteristics of males from 
fertile vs. subfertile couples (Ombelet et al., 1997). Moreover, it can be speculated that 
couples with better sperm parameters have already conceived spontaneously before 
seeking medical intervention. 
In summary, it can be concluded that body weight and hyperandrogenemia are the 
predominant predictors for ovulation after CC treatment, whereas age and cycle 
history dictate pregnancy chances in ovulatory women. This stresses for the first time 
the important concept that follicle growth and oocyte quality (and subsequent capacity 
to be fertilized in vivo) are differentially regulated during induction of ovulation, 
confirming observations during in vitro fertilization. 
References 
Adashi EY. Ovulation induction: clomiphene citrate. In: Adashi EY, Rock JA, Rosenwaks Z, editors. 
Reproductive endocrinology, surgery, and technology. Philadelphia: Lippencott-Raven, 1996:1182-1206. 
Cox DR. (1972) Regression models and life tables. J R Statist Soc B. 34, 187-220. 
de Jong FH, Baird DT, van der Molen HJ. (1974) Ovarian secretion rates of oestrogens, androgens and 
progesterone in normal women and in women with persistent ovarian follicles. Acta Endocrinol 
(Copenh). 77, 575-87. 
Dor J, Itzkowic DJ, Mashiach S, Lunenfeld B, Serr DM. (1980) Cumulative conception rates following 
gonadotropin therapy. Am J Obstet Gynecol. 136, 102-5. 
Eden JA, Place J, Carter GD, Alaghband-Zadeh J, Pawson ME. (1989) The role of chronic anovulation in 
the polycystic ovary syndrome: normalization of sex-hormone-binding globulin levels after clomiphene-
induced ovulation. Clin Endocrinol (Oxj). 30, 323-32. 
Eimers JM, te Velde ER, Gerritse R, Vogelzang ET, Looman CW, Habbema JD. (1994) The prediction of 
the chance to conceive in subfertile couples. Fertil Steril. 61,44-52. 
Emperaire JC, Gauzere-Soumireu E, Audebert AJ. (1982) Female fertility and donor insemination. Fertil 
Steril. 37, 90-3. 
98 
Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD. (1991) Serum bioactive and 
immunoreactive luteinizing hormone and follicle- stimulating hormone levels in women with cycle 
abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab. 73, 811-7. 
Fauser BC, Conway GS, Franks S, Genetics of female reproductive dysfunction. Fauser BC, Rutherford, A. 
J., Strauss, J. F. 3d, and Steirteghem, A. C. Molecular Biology in Reproductive Medicine. Parthenon 
Publishing. London. Genetics of female reproductive dysfunction. In: Fauser BC, Rutherford AJ, Strauss 
JFd, Steirteghem AC, editors. Molecular Biology in Reproductive Medicine. London: Parthenon 
Publishing, 1999. 
Garcia J, Jones GS, Wentz AC. (1977) The use of clomiphene citrate. Fertil Steril. 28,707-17. 
Gorlitsky GA, Kase NG, Speroff L. (1978) Ovulation and pregnancy rates with clomiphene citrate. Obstet 
Gynecol. 51,265-9. 
Gysler M, March CM, Mishell DR, Jr., Bailey EJ. (1982) A decade's experience with an individualized 
clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril. 37, 161-7. 
Harnilton-Fairley D, Kiddy D, Watson H, Sagle M, Franks S. (1991) Low-dose gonadotrophin therapy for 
induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod. 6, 1095-9. 
Hammond MG, Hahne JK, Talbert LM. (1983) Factors affecting the pregnancy rate in clomiphene citrate 
induction of ovulation. Obstet Gynecol. 62, 196-202. 
Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. (1988) Influence of serum luteinising hormone 
concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. Bmj. 
297, 1024-6. 
Bowles CM, Macnamee MC, Edwards RG, Goswamy R, Steptoe PC. (1986) Effect of high tonic levels of 
luteinising hormone on outcome of in-vitro fertilisation. Lancet. 2, 521-2. 
Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. (1998) Predictors of patients remaining 
anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic 
infertility. J Clin Endocrinol Metab. 83,2361-5. 
Kaplan EL, Meier P. (1958) Nonparametric estimation from incomplete observations. JAm Statist Assoc. 
53,457-81. 
Kousta E, White DM, Franks S. (1997) Modem use of clomiphene citrate in induction of ovulation. Hum 
Reprod Update. 3, 359-65. 
Lobo RA, Gysler M, March CM, Goebelsmann U, Mishell Jr DR. (1982) Clinical and laboratory predictors 
of clomiphene response. Fertil Steril. 37, 168-174. 
Macgregor AH, Johnson JE, Bunde CA. (1968) Further clinical experience with clomiphene citrate. Fertil 
Steril. 19, 616-22. 
Minakarni H, Abe N, Izumi A, Tamada T. (1988) Serum luteinizing hormone profile during the menstrual 
cycle in polycystic ovarian syndrome. Fertil Steril. 50, 990-2. 
Ombelet W, Bosmans E, Janssen M, Cox A, Vlasselaer J, Gyselaers W, et al. (1997) Semen parameters in a 
fertile versus subfertile population: a need for change in the interpretation of semen testing. Hum 
Reprod. 12, 987-93. 
Opsahl MS, Robins ED, O'Connor DM, Scott RT, Fritz MA. (1996) Characteristics of gonadotropin 
response, follicular development, and endometrial growth and maturation across consecutive cycles of 
clomiphene citrate treatment. Fertil Steril. 66, 533-9. 
Organization WH. (1992) WHO laboratory manual for the examination of human semen and sperm-cervical 
mucus interaction, Cambridge University Press, Cambridge. 
Pache TD, Wladirniroff JW, Hop WC, Fauser BC. (1992) How to discriminate between normal and 
polycystic ovaries: transvaginal US study. Radiology. 183,421-3. 
Polson DW, Kiddy DS, Mason HD, Franks S. (1989) Induction of ovulation with clomiphene citrate in 
women with polycystic ovary syndrome: the difference between responders and nonresponders. Fertil 
Steril. 51,30-4. 
Regan L, Owen EJ, Jacobs HS. (1990) Hypersecretion of luteinising hormone, infertility, and miscarriage. 
Lancet. 336, 1141-4. 
Rowe PJ, Comhaire FH, Hargreave TB, Mellows HJ. (1993) WHO manual for the standardized 
investigation and diagnosis of the infertile couple., Cambridge University Press,Cambridge, UK. 
Multiple imputation in sample surveys - a phenomenological Baysian approach to nonresponse. Proceedings 
of the survey Research methods section of the American Statistical Association; 1978. 
• 
Chapter 8: Prediction of conception in CC-ovulatory patients 99 
Schipper I, de Jong FH, Fauser BC. (1998) Lack of correlation between maximum early follicular phase 
serum follicle stimulating hormone concentrations and menstrual cycle characteristics in women under 
the age of 35 years. Hum Reprod. 13, 1442-8. 
Scott RT, Opsahl MS, Leonardi MR, Neall GS, Illions EH, Navot D. (1995) Life table analysis of pregnancy 
rates in a general infertility population relative to ovarian reserve and patient age. Hum Repro d. 10, 
1706-10. 
Shepard MK, Balmaceda JP, Leija CG. (1979) Relationship of weight to successful induction of ovulation 
with clomiphene citrate. Fertil Steril. 32, 641-5. 
Shoham Z, Borenstein R, Lunenfeld B, Pariente C. (1990) Hormonal profiles following clomiphene citrate 
therapy in conception and nonconception cycles. Clin Endocrinol (Oxj). 33, 271-8. 
Templeton A, Morris JK, Parslow W. (1996) Factors that affect outcome of in-vitro fertilisation treatment. 
Lancet. 348, 1402-6. 
Tietze C. (1968) Fertility after discontinuation of intrauterine and oral contraception. International journal 
of fertility. 13,385-389. 
van Santbrink EJ, Donderwinkel PF, van Dessel TJ, Fauser BC. (1995) Gonadotrophin induction of 
ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod. 
10, 1048-53. 
van Santbrink EJ, Hop WC, Fauser BC. (1997) Classification of normogonadotropic infertility: polycystic 
ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil 
Steril. 67, 452-8. 

9 
A nomogram to predict live birth probability after clomiphene 
citrate induction of ovulation in normogonadotropic 
oligoamenorrheic infertility 
ABSTRACT 
Objective: To establish whether initial screening characteristics ofnormogonadotropic 
anovulatory infertile women can aid in predicting live birth after induction of 
ovulation with clomiphene citrate (CC). 
Design: Prospective longitudinal single-center study. 
Setting: Specialist academic fertility unit. 
Patient(s): Two hundred fifty-nine couples with a history of infertility, 
oligoamenorrhea, and normal follicle-stimulating hormone (FSH) concentrations who 
have not been previously treated with any ovulation-induction medication. 
Intervention(s): 50, 100, or 150 mg of oral CC per day, for 5 subsequent days per 
cycle. 
Main Outcome Measure(s): Conception leading to live birth after CC administration. 
Result(s): After receiving CC, 98 (38%) women conceived, leading to live birth. The 
cumulative live birth rate within 12 months was 42% for the total study population and 
56% for the ovulatory women who had received CC. Factors predicting the chances 
for live birth included free androgen index (testosterone/sex hormone-binding 
globulin ratio), body mass index, cycle history (oligomenorrhea versus amenorrhea), 
and the woman's age. 
Conclusion(s): It is possible to predict the individual chances of live birth after CC 
administration using two distinct prediction models combined in a nomogram. 
Applying this nomogram in the clinic may be a step forward in optimizing the 
decision-making process in the treatment of normogonadotropic anovulatory 
infertility. Alternative first line of treatment options could be considered for some 
women who have limited chances for success. 
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INTRODUCTION 
Anovulation represents the most frequent cause of female infertility, and in most 
women normal serum follicle-stimulating hormone concentrations are found. Since its 
introduction (Greenblatt et al., 1961) clomiphene citrate (CC) has been used 
worldwide as first choice medication in the treatment of anovulatory infertility. Since 
the early seventies CC treatment was restricted to normogonadotropic 
oligoamenorrheic infertility (WHO group 2) (Rowe et al., 1993). A significant 
proportion of these women, however, remains anovulatory after CC medication. Out 
of the 75% ovulatory CC patients, approximately 50% will conceive within 6 CC-
induced cycles (Imani et al., 1998) (Imani et al., 1999). 
Assessment of pregnancy chances after CC induction of ovulation has been the 
subject of several investigations, all of which focused on the entire group of 
anovulatory patients who start with CC therapy (Macgregor et al., 1968) (Gorlitsky et 
al., 1978) (Shepard et al., 1979) (Hammond et al., 1983) (Polson et al., 1989) (Opsahl 
et al., 1996) (Kousta et al., 1997). These investigators have failed to identify 
predictors of CC treatment outcome. In contrast, our group focused on prediction of 
ovulation and conception separately (Imani et al., 1998) (Imani et al., 1999). This 
approach in life table analysis for prediction of pregnancy chances seems mandatory 
for the following statistical reasons. Discontinuation of CC therapy due to persistent 
anovulation is clearly an informative selective drop-out since chances for CC 
treatment outcome are different compared to women who continue CC therapy. 
Therefore, inclusion of both CC responders and CC non-responders in a life table 
analysis for prediction of conception should be avoided. 
We developed two distinct prediction models applying multivariate analyses (Imani 
et al., 1998) (Imani et al., 1999). The first model predicts ovarian response after CC in 
the entire group of anovulatory patients on the basis of initial screening characteristics 
such as; free androgen index (testosterone/sex hormone-binding globulin ratio), body 
mass index (BMI), cycle history (oligomenorrhea versus amenorrhea) and mean 
ovarian volume (Imani et al., 1998) (Imani et al., 2000) . The second model predicts 
the chances of conception exclusively in those women who have reached ovulatory 
cycles after CC and includes woman's age and cycle history (Imani et al., 1999). 
Although scientifically sound, this approach seems difficult to apply in the daily 
clinical practice. Moreover, the question remains unanswered whether the chances of 
having a live birth after CC can be predicted prior to the initiation of medication. By 
combining both prediction models a nomogram may be developed predicting chances 
of a given anovulatory patient to conceive resulting in live birth after CC. 
Anovulatory patients present with a wide range of chances to conceive after CC. 
This may be due to differences in the underlying ovarian abnormalities, patient's age, 
body weight, and individual differences in the anti-estrogenic effects of CC on cervical 
mucus or endometrium. Applying a nomogram in the clinic may render the ovulation 
induction protocols more patient tailored and more cost-effective. Patients with a poor 
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predicted chance to conceive could be advised to refrain from CC therapy and start 
with an alternative first line treatment modality such as weight reduction, insulin 
sensitizing agents, or exogenous gonadotropins. Particularly in women of advanced 
age precious time to ascertain that CC treatment is ineffective may be used for a more 
effective approach as the frrst line therapy. We now report the construction of a 
nomogram to identifY characteristics upon initial screening of a large cohort of 
normogonadotropic anovulatory infertile women predicting the individual chance of 
pregnancy leading to live birth after CC induction of ovulation. 
MATERIALS AND METHODS 
Subjects and study protocol 
Between February 1993 and May 1999, two hundred and fifty nine patients attending 
our infertility unit were included in the present study using the following inclusion 
criteria: (a) oligomenorrhea (bleeding intervals between 35 days and 6 months) or 
amenorrhea (bleeding interval > 6 months), (b) serum follicle-stimulating hormone 
(FSH) levels within normal limits (1-10 IU/L) (Rowe et al., 1993) (van Santbrink et 
al., 1995), (c) normal serum prolactin and thyroid-stimulating hormone levels, (d) 
spontaneous menses or positive bleeding response to progestagen withdrawal, (e) body 
mass index (BMI) (weight divided by the square of the patients height)> 18 kg/m2, (f) 
between 19-40 years of age, (g) no previous use of ovulation induction agents, (h) a 
total motile sperm count [TMC =ejaculate volume (milliliters) x sperm concentration 
(1 06 I mL) x percentage of progressive motile sperm] of the partner above 1 million, 
(i) negative history of any tubal pathology, and fmally G) no indication for intrauterine 
insemination. Institutional Review Board approval was obtained from the human 
subjects committee of the Erasmus University Medical Center Rotterdam and 
informed consent was obtained from all subjects. 
Standardized initial clinical, sonographic, and endocrine screening took place prior 
to initiation of CC ovulation induction, as described previously (Imani et al., 1998) 
(Imani et al., 1999) (Imani et al., 2000). Clinical screening included age, type of 
infertility, cycle history, BMI, waist-to-hip ratio (WHR), and previous medication 
and/or surgery. Transvaginal sonography (TVS) included assessment of the ovarian 
stroma echogenicity (arbitrarily classified from 1 to 3 per ovary), ovarian volume (mL) 
and total number of follicles (both ovaries), as described previously (Pache et al., 
1992) (van Santbrink et al., 1997). Sonographic monitoring was performed by a single 
observer (B.I.). Endocrine screening included serum assays for FSH, luteinising 
hormone (LH), estradiol (E2), androstenedione (AD), testosterone (T), and sex-
hormone binding globulin (SHBG), fasting insulin and glucose, free and total insulin-
like growth factor-! (IGF-I), inhibin B and leptin concentrations, as described 
previously (Imani et al., 2000). Hormone assays used and the intra and inter assay 
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coefficients of variation valid for this study have all been described previously (Imani 
et al., 1998) (Imani et al., 1999) (Imani et al., 2000). 
The treatment protocol, assessment of ovarian response and conception after CC 
have also been described previously (Imani et al., 1998) (Imani et al., 1999). In brief, 
initial CC doses were 50 mg/day starting on cycle day 3 after a spontaneous or 
progestagen-induced withdrawal bleeding. In case of absent ovarian response, doses 
were increased to 100 and 150 mg I day in subsequent cycles. Ovulation after CC 
medication was assessed by sonographic monitoring of follicle growth and rnidluteal 
progesterone > 25 nmol/L. Conception was defmed as a positive urinary pregnancy 
test ( clearview, hCG II, Unipath Ltd, Bedford, UK) more than 3 days after the 
expected menses. Live birth was defmed as delivery of a baby. Information regarding 
deliveries and the health condition of the babies born was collected using the hospital 
records. In the case of home delivery we collected information directly from the 
patient and her general practitioner or midwife. 
Data analysis 
The statistical analysis of conception leading to live birth in anovulatory patients after 
CC should take into account the following two steps: ovulatory response to CC and 
conception in case of ovulation. Patients remaining anovulatory after CC (CRA = 
clomiphene resistant anovulation) are considered to have no chance to conceive with 
this therapy. Therefore, the cumulative rate of conception leading to live birth was 
calculated by multiplying the chance of achieving ovulation after CC, with the 
estimated Kaplan-Meier (Kaplan and Meier, 1958) cumulative probabilities for 
conception in the group of ovulatory women after CC. 
A prediction model of the probability of conception resulting in live birth within 6 
months after initiation of CC ovulation induction was constructed by combining the 
previously published prediction model for the chance to be CRA (Imani et al., 1998) 
with a prediction model for the probability of conception leading to live birth in 
ovulatory patients after CC. The current study differs from the previously published 
model predicting chances for conception (Imani et al., 1999) with respect to the 
starting point of follow-up (initiation of CC therapy versus first ovulation after CC). In 
order to implement these fmdings in clinical practice we included months rather than 
ovulatory cycles and live birth instead of ongoing pregnancy in the current analysis. A 
nomogram was constructed by combining the model to predict ovulation in the entire 
group of women with the model predicting live birth in ovulatory CC patients. 
To determine the goodness-of-fit of the combined prediction model, patients were 
divided into 5 equal groups according to quintiles of the predicted probability of 
conception leading to live birth. Using a Chi-square test, the mean predicted 
probability within each group was compared to the observed probability, calculated by 
the Kaplan-Meier method described in the previous paragraph. Data were analyzed 
using the commercially available software package SPSS (Chicago, Ill, USA). 
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RESULTS 
From the total number of 259 patients fulfilling the in/exclusion criteria and treated 
with CC, 186 (72%) suffered from primary infertility, and 62 (24%) from amenorrhea. 
One hundred and ten patients (43%) were obese (BMI > 27), 160 patients (62%) 
presented with an elevated FAI (FAI > 4.5) and 100 patients (39%) with 
hyperandrogenemia (T;::: 3.2 nmol/L and/or AD ;::: 16.3 nmol/L (Fauser et al., 1991) 
(van Santbrink: et al., 1997)). In 195 patients (75%) polycystic ovaries (mean ovarian 
volume;::: 10.8 mL and/or mean follicle number per ovary:?: 10 (Pache et al., 1992) 
(van Santbrink: et al., 1997)) were diagnosed. One hundred and twenty-one patients 
(47%) presented with elevated initial LH (LH:?: 7.0 lUlL (van Santbrink: eta!., 1997)) 
serum level. Sixty-five patients (25%) remained anovulatory after CC medication 
despite the maximum CC dose (150 mg/day) and were considered as CRA. Eighty-
three patients (32%) presented with ovulatory cycles after CC but failed to conceive. 
A total number of 111 ( 43%) women conceived after CC treatment and 11 (1 0% of 
conceptions) miscarried. There was one case of ectopic pregnancy and one case of 
intrauterine death. A total number of 98 (38%) patients had a live birth. Sixty-seven 
patients delivered at the hospital and could leave the unit within 24 hours. Nineteen 
patients were hospitalized for pre and postnatal care. In 4 pregnant women anti-
hypertensive medication was required. There was no case of maternal or fetal death. In 
15 women an instrumental delivery and in 13 patients a cesarean section was 
performed. At birth the mean± SD gestational age was 39.3 ± 2.8 weeks and the mean 
weight of the babies was 3142 ± 590 gram. There was no case of postpartum death in 
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Figure 1 Cumulative percentage of women reaching first ovulation and first conception ending in a live 
birth in 259 normogonadotropic oligoamenorrheic infertile patients treated with CC. Solid line = first 
ovulation after CC (n=l94; 75%); dashed line= first conception ending in a live birth (n=98; 38%). 
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the first year after the delivery. No case of congenital abnormalities was reported. 
Odds ratios of screening characteristics separately for ovulation in the entire 
population and live birth in ovulatory CC women are presented in Table 1. Screening 
characteristics were included on the basis of significance in previous multivariate 
analysis predicting ovulation (F AI, BMI, cycle history, ovarian volume, leptin), 
predicting pregnancy in ovulatory patients (age, cycle history) and biological 
relevance for ovarian dysfunction (LH, hyperandrogenemia, insulin, insulin/glucose 
ratio, inhibin B, free IGF-I) or pregnancy prediction (infertility history, bleeding 
interval in case of oligomenorrhea, total motile sperm count). The cumulative rates of 
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Figure 2: The impact of cycle history on cumulative ovulation and live birth rates in 259 
normogonadotropic oligoamenorrheic infertile patients treated with CC. A: solid line = oligomenorrheic 
patients (n = 197); B: dashed line= amenorrheic patients (n = 62). P value represents differences applying 
LogRank test (A: P < 0.001; B: P value= not applicable in the overall WHO 2 anovulatory patients. P < 
0.00 I in ovulatory patients following CC). 
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first ovulation and first conception ending in live birth are depicted in Figure 1. The 
impact of cycle history on cumulative ovulation and live birth rates after CC is 
depicted in Figure 2. 
Prediction of conception leading to live birth after CC applying a nomogram has 
been depicted in Figure 3. This nomogram comprises two separate steps. In the left 
panel the probability of ovulation after CC can be estimated applying F AI, BMI, and 
cycle history (oligomenorrhea versus amenorrhea). Drag and drop the chance to 
ovulate after CC from the left to the right panel. In the right panel the predicted 
probability to conceive within 6 months after initiation of CC medication resulting in 
live birth is indicated, combining the probability of ovulation after CC with age and 
cycle history (oligomenorrhea versus amenorrhea) of the patient. Mean ovarian 
volume, and serum leptin levels comprise the least predictive contribution to the model 
(Imani et al., 1998) (Imani et al., 2000) and therefore were excluded from the left 
panel of this nomogram. 
The P-values for the Chi-square goodness-of-fit test was 0.49, indicating no 
statistically significant lack of fit between the observed and predicted probability of 
live birth within the 5 groups (see also Materials & Methods; data not shown). 
DISCUSSION 
Currently, CC represents the first line treatment strategy for all patients with 
normogonadotropic anovulatory infertility. The present study confirms that CC is safe 
and convenient with limited chances for complications such as multiple pregnancy or 
OHSS. However, only 38% of treated women may conceive after CC resulting in live 
birth which is substantially less than generally assumed. It may represent a distinct 
step forward if patients with even lower chances for live birth after CC could be 
identified in advance. 
Previous attempts by retrospective studies in the entire group of anovulatory patients 
failed to identifY factors predicting ovulation (Gorlitsky eta!., 1978) (Shepard eta!., 
1979) (Polson et al., 1989) or conception (Gorlitsky et al., 1978) (Hammond et al., 
1983) (Kousta et al., 1997) after CC. In contrast, we focused on predictors of CC 
treatment outcome in a prospective fashion in the current longitudinal cohort study. 
For the first time we used ovulation and conception as separate endpoints, taking into 
account that a significant proportion of patients remains anovulatory during CC 
medication. These women are not exposed to the chances of becoming pregnant. 
Univariate and multivariate analyses were performed in these two separate settings. 
The fust multivariate model consisting ofF AI, BMI, cycle history, and mean ovarian 
volume predicts chances of remaining anovulatory after CC (Imani et al., 1998). The 
second model consisting of age and cycle history predicts chances for conception only 
in women who respond to CC (Imani et al., 1999). Observed screening characteristics 
Table 1: Odds ratios (OR) of initial screening characteristics in relation to the occurrence of ovulation in the entire group of normogonadotropic 
oligoamenorrheic infertile women·(n=l94 of259) or live birth in ovulatory women after CC (n=98 of 194) 
Screening characteristics 
Clinical 
Endocrine 
Ultrasound 
Age (per yr) a 
Prima1y vs. secondmy infertility b 
Oligomenorrhea vs. amenorrhea a,c,d 
Bleeding interval in case of oligomenorrhea b,' 
5-6 weeks 
6-9 weeks 
9-26 weeks 
BMI (kg/m2) ' 
Waist to hip ratio (WHRper 0.1) b 
LH (IUIL) b 
FAib,r 
Hyperandrogenemia (elevated T and I or AD) b 
Insulin (mU/L) b 
Insulin/glucose ratio b 
Inhibin B (ng/L) b 
Free IGF-I (ng/mL) b 
Leptin (ng/mL)' 
PCO versus non-PCO '· g 
Total motile sperm count I 104 b 
Ovulation following CC 
1.05 (0.98- 1.12) 
1.23 (0.64- 2.34) 
4.34 (2.34- 8.05) 
8.30 (3.29 -20.98) 
3.64 (1.75 -7.55) 
2.90 (1.25- 6.73) 
0.92 (0.88- 0.96) 
0.60 (0.40- 0.89) 
0.97 (0.91- 1.03) 
0.83 (0.78- 0.89) 
0.36 (0.20- 0.65) 
0.95 (0.92- 0.98) 
0.87 (0.77- 0.97) 
1.00 (0.99- 1.0 I) 
0.91 (0.77- 1.09) 
0.97 (0.95 - 0.99) 
0.59 (0.29- 1.22) 
Live birth in ovulatory women following CC 
0.90 (0.85- 0.94) 
0.71 (0.44 -1.15) 
0.77 (0.47 -1.28) 
0.65 (0.36- 1.18) 
0.87 (0.50- 1.51) 
0.83 (0.42- 1.63) 
1.00 (0.97- 1.04) 
1.08 (0.81 - 1.42) 
1.04 (1.00- 1.09) 
1.06 (1.01-1.11) 
1.67 (1.10 -2.54) 
0.99 (0.97- 1.02) 
0.99 (0.90 - 1.08) 
1.00 (0.99- 1.01) 
1.10 (0.96 -1.25) 
1.02 (1.00- 1.03) 
0.98 (0.63- 1.54) 
1.00 (0.81-1.23) 
a Characteristics predicting conception in ovulatory CC patients applying multivariate analysis as published previously (Imani et al., 1999) 
b Biological relevant characteristics for ovarian dysfunction or pregnancy prediction in normogonadotropic anovulation 
' Characteristics predicting ovulation following CC applying multivariate analysis as published previously (Imani et al., 1998) (Imani et al., 2000) 
d The oligomenorrheic patients are 4 times more likely (OR= 4.34) to ovulate after CC compared to amenorrheic patients. However the chance for a live birth 
after CC is 23% less (OR= 0.77) compared to amenorrheic patients. 
'Amenorrhea is reference categmy for the categories of bleeding interval in oligomenorrhea. 
r F AI = T x 1 00 I SHBG 
g Polycystic ovaries= mean ovarian volume;:: 10.8 mL and/or mean follicle number per ovary;:: 10 (van Santbrink eta!., 1997) 
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involved in the prediction of ovulation after CC medication are distinctly different 
from predictors of conception in ovulatory CC patients. In the current study we 
combine both prediction models in a nomogram to predict chances of live birth in the 
entire group of normogonadotropic anovulatory patients. For reasons of its 
applicability in clinical practice we converted analysis to month rather than treatment 
cycles and used live birth rather than pregnancy as the outcome. The estimation of 
chances to ovulate is a crucial step in evaluating the probability of conception resulting 
in live birth after CC therapy. This is the reason for the involvement of two steps in the 
presented nomogram. Cycle history is the only factor which is present in both steps. 
Amenorrheic patients are less likely to ovulate after CC medication, but once they 
ovulate chances for live birth are higher compared to oligomenorrheic women. A 
biologically plausible explanation is that the occurrence of other factors contributing to 
a reduced fertility is less likely since these women never had the chance to conceive. 
BMI does not influence live birth rate in patients who ovulate following CC. 
Moreover, live birth rate in CC-ovulatory PCO vs. CC-ovulatory non-PCO patients are 
comparable. Interestingly, age does not affect chances for ovulation, but is involved in 
pregnancy chances once ovulation has been reached (lmani et al., 1998) (Imani et al., 
1999) . This is in agreement with reports concerning an association between reduced 
treatment outcome after in vitro fertilization and patient's advanced age (Scott et al., 
1995) 
The major aim was to render the present nomogram as easy as possible for use in 
daily clinical practice. Therefore, ovarian volume (which was included in the previous 
multivariate model predicting ovulation (Imani et al., 1998) has been excluded from 
the present nomogram. The additional predictive contribution of this prognostic factor 
to the model is negligible (a decrease in the area under the receiver characteristic curve 
of the model to predict patients remaining anovulatory from 0.82 to 0.80 (Imani et al., 
1998). We also demonstrated previously that serum leptin concentrations (an 
endocrine marker associated with obesity (Rouru et al., 1997)) predict chances of 
remaining anovulatory after CC (lmani et al., 2000). Leptin has also been excluded 
from the present nomogram since this assay is not available in most hospital 
laboratories. Instead, information for BMI can be generated easily with only a minor 
decrease in AUC of the prediction model (0.85 instead of 0.82). Therefore, serum T 
and SHBG levels are the only endocrine factors that should be assessed for the present 
nomogram. Indeed, both obesity and hyperandrogenernia are associated with 
polycystic ovary syndrome known to exhibit low chances for success during CC 
ovulation induction. Remaining biological plausible factors involved in ovarian 
dysfunction in normogonadotropic anovulation such as LH (Fauser et al., 1991), 
insulin/glucose ratio's (Poretsky et al., 1999), inhibin B (Anderson et al., 1998) and 
free IGF-I (Thierry van Dessel et al., 1999) failed to predict ovulation or conception 
and were therefore excluded from the nomogram. 
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In summary, the present study demonstrates for the first time that a nomogram can be 
developed on the basis of initial screening characteristics predicting chances of live 
birth after CC for a given patient. An external validation of the present nomogram is 
mandatory to be able to defme a clear cut-off level in the chances for live birth after 
CC for the decision making in routine daily clinical practice. For instance, a cut-off 
level of20% chance ofhaving a live birth (which comprises 19% of the overall WHO 
2 anovulatory patients) could be chosen. These patients could be advised to refrain 
from CC therapy and start with an alternative first line treatment modality such as 
weight reduction, exogenous gonadotropins, insulin sensitizing hormones, or in vitro 
fertilization particularly in women with an advanced age. This would render CC 
ovulation induction strategies more patient tailored and could improve overall cost 
effectiveness. 
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High Singleton Live Birth Rate Following Classical Ovulation 
Induction in Normogonadotrophic Anovulatory Infertility 
(WH02) 
ABSTRACT 
BACKGROUND: Medical induction of ovulation using Clomiphene citrate (CC) as 
first line and exogenous gonadotrophins as second line forms the classical treatment 
algorithm in normogonadotrophic anovulatory infertility. Because the chances of 
success following classical ovulation induction are not well established, a shift in first 
line therapy can be observed towards alternative treatment. Our aim was to (1) reliably 
assess the probability of singleton live birth following classical induction of ovulation 
and (2) construct a prediction model, based on individual patient characteristics 
assessed upon standardised initial screening, to help identify patients with poor 
chances of success. METHODS: Two hundred and forty consecutive women visiting a 
specialist academic fertility unit with a history of infertility, oligomenorrhea or 
amenorrhea, and normal follicle-stimulating hormone (FSH) and estradiol (E2) serum 
concentrations (WHO group 2) were prospectively followed. The women were not 
treated before with ovulation inducing agents. All patients commenced with CC. 
Patients who did not ovulate within 3 treatment cycles of incremental daily doses up to 
150 mg for 5 consecutive days or ovulatory CC patients who did not conceive within 6 
cycles, subsequently underwent gonadotrophin induction of ovulation applying a step-
down dose regimen. The main outcome measure was pregnancy resulting in singleton 
live birth. Cox regression was used to construct a multivariable prediction model. 
RESULTS: Overall, 134 pregnancies ending in a singleton live birth occurred (56% of 
women). The cumulative pregnancy rate after 12 and 24 months of follow-up was 50% 
and 71%, respectively. PCOS patients (49%), clearly non-PCOS patients (13%) and 
the in-between group did not differ in prognosis (P = 0.9). The multivariable Cox 
regression model contained the woman's age, the insulin/glucose ratio and the 
duration of infertility. With a cut-offvalue of 30% for low chance, the model predicted 
probabilities at 12 months lower than this cut-off for 25 out of 240 (10%) patients. 
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CONCLUSIONS: Classical ovulation induction gives very good results in 
normogonadotrophic anovulatory infertility. Alternative treatment options may not be 
indicated as first line therapy in these patients, except for subgroups with poor 
prognosis. These women can be identified by older age, longer duration of infertility 
and higher insulin/glucose ratio. 
INTRODUCTION 
Anovulation is a common cause of infertility, diagnosed in at least 25% of couples 
with fertility problems. In the great majority of these women the underlying cause is 
described as 'pituitary-ovarian dis balance', where serum follicle-stimulating hormone 
(FSH) and estradiol (E2) levels are within normal limits (also described as World 
Health Organization (WHO) group 2) (World Health Organization, 1993), (The 
ESHRE Capri Workshop Group, 1995). Patients suffering from the polycystic ovary 
syndrome (PCOS) are considered a subgroup of WHO 2 (Laven et al., 2002). Since 
the early 60s patients can be treated effectively with the anti-estrogen Clomiphene 
Citrate (CC) as well as exogenous gonadotrophins. CC is generally applied as first line 
treatment in these women, due to low costs and minor chances for side effects or 
complications. Traditionally, exogenous gonadotrophins (especially FSH) is 
considered the second line therapy in case of failure to ovulate or conceive following 
CC. This treatment modality requires frequent monitoring due to inherent risks of 
multiple follicle development resulting in increased chances for ovarian 
hyperstimulation syndrome and multiple gestation, especially in PCOS patients 
(Messinis and Milingos, 1997), (Legro, 1998). Over the years, numerous (mainly 
retrospective) studies have established the overall effectiveness of either CC 
(Hammond et al., 1983), (Kousta et al., 1997) or FSH (White et al., 1996), (van 
Santbrink and Fauser, 1997), (Fauser and Van Heusden, 1997) in varying groups of 
patients. However, data concerning a prospective follow-up of a coherent CC and FSH 
treatment strategy in a well-defined group of patients are not yet available. 
Over the last 10 years, increased attention is focussed towards alternative treatment 
options such as the insulin sensitizing agents (Heard et al., 2002), (Nestler et al., 
2002), (Glueck et al., 2002), aromatase inhibitors (Mitwally and Casper, 2001), 
laparoscopic surgery of ovaries (Cohen, 1996), (Farquhar et al., 2001) or assisted 
reproduction such as intra- uterine insemination (lUI) or in-vitro fertilization (IVF) 
(Buyalos and Lee, 1996), (Child et al., 2001). Most promising results of up to 80% 
pregnancies have been reported by individual studies, but the majority of these reports 
involves a limited number of selected patients, and is retrospective and uncontrolled. It 
is often suggested that the multiple birth rate is reduced in comparison with ovulation 
induction, but reliable information on multiple births is mostly lacking. 
There seems to be an obvious need to firmly establish the success and complication 
rates of the conventional approach for ovulation induction (involving CC and FSH) in 
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a large unselected cohort of patients. The current report contains an integrated analysis 
of chances for pregnancies resulting in singleton live childbirth, extending previously 
reported outcomes separately for CC (Imani et al., 2002b) and FSH (Imani et al., 
2002a), (Mulders et al., 2003). In addition, a prediction model is presented to help 
identify patients with poor chances of success. This information may serve as point of 
reference for future studies involving alternative approaches for ovulation induction. 
SUBJECTS AND METHODS 
Subjects 
Between November 1992 and May 1999, a consecutive series of240 women attending 
our infertility unit were included in the present study using the following inclusion 
criteria: [1] oligomenorrhea (bleeding intervals between 35 days and 6 months) or 
amenorrhea (bleeding interval> 6 months), [2] normal serum FSH (1-10 IU/1) and E2 
(150-400 pmol/1) levels (van Santbrink et al., 1997), [3] normal serum prolactin and 
thyroid-stimulating hormone levels, [4] spontaneous menses or positive bleeding 
response to progestagen withdrawal, [5] body mass index (BMI: weight divided by the 
square of the patient's height)> 18 kg/m2, [6] between 19 and 40 years of age, [7] no 
previous use of ovulation induction agents, [8] a total motile sperm count (TMC = 
ejaculate volume [ml] x sperm concentration [10%nl] x percentage of progressive 
motile sperm) of the partner above 1 million, [9] negative history of or screening for 
any tubal pathology, and finally [10] no indication for lUI. Institutional review board 
approval was obtained from the human subjects committee of the Erasmus Medical 
Center and informed consent was obtained from all study participants. 
The standardized initial clinical, sonographic and endocrine screening took place 
prior to the initiation of CC ovulation induction, as had been described previously 
(Imani et al., 2002b ). The clinical screening included patient's age, type of infertility 
(primary or secondary), cycle history (amenorrhea or oligomenorrhea), BMI, waist-to-
hip ratio (WHR), and previous medication and/or surgery. Transvaginal sonography 
included assessment of ovarian volume (ml), and total number of follicles, as 
described previously (Pache et al., 1992). Endocrine screening included serum assays 
for FSH, luteinizing hormone (LH), E2, androstenedione (AD), testosterone (T), sex-
hormone binding globulin (SHBG), and fasting insulin and glucose. Hormone assays 
used and the intra-assay and inter-assay coefficients of variation valid for this study 
have all been described previously (Imani et al., 2000). 
The treatment protocol and the assessment of ovarian response and pregnancy after 
CC administration have also been described previously (Imani et al., 2002b). In brief, 
the women received initial CC doses of 50 mg/day from cycle day 3 until day 7 after a 
spontaneous or progestagen-induced withdrawal bleeding. In cases of absent ovarian 
response, the daily dosage was increased to 100 and 150 mg in subsequent cycles. 
Ovulation after CC or FSH medication was assessed by sonographic monitoring of 
116 
disappearance of the preovulatory follicle and/or the fmding ofmidluteal progesterone 
levels > 25 nmol/L. In case of CC resistant anovulation (CRA), i.e. absent ovulation 
after 3 months (despite stimulation with a maximum daily CC dose of 150 mg), or if 
pregnancy failed to occur within 6 ovulatory cycles, ovulation induction with 
exogenous recombinant FSH (Puregon®, Organon NV, Oss, The Netherlands) was 
applied as second line treatment, using a decremental dose regimen as published 
previously (van Santbrink and Fauser, 1997). The FSH response dose was assessed 
during the first cycle applying a low-dose, step-up regimen (Imani et al., 2002a), 
(Mulders et al., 2003). 
Pregnancy was defmed as a positive urinary pregnancy test (clearview, hCG II, 
Unipath Ltd, Bedford, UK) at least 3 days after the expected menses. Ongoing 
pregnancy was defmed as sonographic assessment at 12 weeks amenorrhea of an 
intrauterine gestational sac with positive heartbeat. Live birth was defmed as the 
delivery of a baby after at least 28 weeks gestational age. Information regarding 
deliveries and the health condition of the babies born was collected using the hospital 
records. In cases of home delivery, we collected the information directly from the 
patient and her general practitioner or midwife. 
Statistical analysis 
The Kaplan-Meier method was used to estimate the cumulative pregnancy rate leading 
to singleton live birth. The length of the period from start of CC treatment until the 
first pregnancy leading to live birth was the time variable in this analysis. Conceptions 
that ended in miscarriage were ignored by the analysis, and in these cases follow-up 
continued until pregnancy resulting in singleton live birth occurred. Patients who had a 
pregnancy ending in premature birth, stillbirth or multiple live birth, were considered 
censored at conception. Patients who did not become pregnant were censored at their 
time of last treatment. Spontaneous pregnancies resulting in singleton live birth that 
occurred during the first or second month after the end of treatment were also included 
in the analysis. 
Cox regression was used for univariable and multivariable analysis relating initial 
screening characteristics to the cumulative pregnancy rate leading to singleton live 
birth. In univariable analysis the log-rank test was used, and a P-value < 0.05 was 
considered as statistically significant. A multivariable prediction model was 
constructed using a backward stepwise elimination method with P < 0.15 for exclusion 
of predictors, corresponding to Akaike's Information Criterion (Akaike, 1973). 
Predictor variables with univariable P < 0.5 were candidate variables for the 
multivariable model. These 'liberal' P-values were chosen because the resulting model 
may be expected to have a better predictive performance in new patients than when the 
strict P < 0.05 criterion is used (Harrell et al., 1996). The prediction model was 
corrected by a shrinkage factor, determined by a bootstrapping technique with 200 
replications, to provide better predictions in new patients (Van Houwelingen and Le 
Cessie, 1990), (Harrell et al., 1996). The discriminative ability of the prediction model 
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was assessed by the c-statistic, which is similar to the area under the receiver operating 
characteristic (ROC) curve for dichotomous outcomes, and can range from 0.5 to 1.0 
(Harrell et al., 1985). The bootstrap technique was used again, this time to correct the 
optimism in the apparent c-statistic (Harrell et al., 1996). Missing values occurred for 
some screening characteristics. The technique of multiple imputation was used to 
avoid loss of information due to missing data in multivariab1e analyses (Little, 1992). 
Missing data occurred in the WHR ( 45% missing), semen analysis (25% missing) and 
in the insulin-glucose ratio (26% missing). Statistical analyses were performed with 
SPSS for Windows (version 10) and S+ 2000. 
RESULTS 
Following induction of ovulation, 162 pregnancies occurred in 159 (66%) patients. 
One hundred and forty seven (90% of pregnancies) were ongoing pregnancies 
(positive heart action upon ultrasound at 12 weeks amenorrhea), whereas 15 
miscarried within 12 weeks. Of the 147 ongoing pregnancies, 137 were singleton and 
10 were multiple (7% of ongoing pregnancies). Of the singleton ongoing pregnancies, 
two ended in premature birth and one in stillbirth. All other ongoing pregnancies 
ended in live birth (134 singleton and 10 multiple). The cumulative pregnancy rate 
resulting in singleton live birth is shown in Figure 1. After 6, 12, 18 and 24 months of 
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Figure 1: Cumulative pregnancy rate resulting in singleton live birth of a consecutive series of 240 
normogonadotrophic anovulatory infertile women undergoing classical ovulation induction (CC as first line, 
followed by FSH as second line therapy if required), calculated by the Kaplan-Meier method, with 95% 
Confidence interval. 
118 
follow-up, respectively 32%, 50%, 63% and 71% of patients presented with a 
singleton pregnancy resulting in live birth of a baby. The cumulative chance after 24 
months increased to 74% in case multiple live births were included, and to 76% for all 
ongoing pregnancies. The median time taken to reach pregnancy resulting in singleton 
live birth was 11.7 months. The median follow-up of the women who did not reach 
this endpoint was 10 months, with a maximum follow-up of 4 years. Their median 
duration of CC-treatment was 5.9 months (range 1 to 18) during which a median 
number of 5.0 (range 1 -13) CC-cycles were performed. The median duration ofFSH 
treatment of the women who did not reach the endpoint was 7.0 months (range 1 to 34) 
with a median number of 5.0 (range 1 -13) FSH treatment cycles. 
Figure 2 shows the fate of the women participating in the study. All 240 women 
started with CC, and 57 (24%) of them were found to be CRA. CC outcome in the 
remaining 183 women was 112 pregnancies: 98 ongoing singleton and 4 ongoing twin 
pregnancies (4% of CC-pregnancies) resulting in live birth, 11 pregnancies ending in 
miscarriage (10% of CC-pregnancies) and 1 ending in stillbirth. There was one 
additional miscarriage, in a woman who became pregnant again after a ftrst 
miscarriage. There were 84 women who started FSH induction of ovulation after 
unsuccessful CC-treatment. In 44 women an ongoing pregnancy was subsequently 
achieved, resulting in 36 singleton, 4 twin, one triplet and one quadruplet live birth 
(14% multiple births) and 2 stillbirths. There were 3 pregnancies that miscarried (6% 
of 47 pregnancies). The miscarriage rate was not statistically significant between CC 
and FSH (P = 0.7). Almost 50% (33 out of 71) of the CCF patients did not proceed to 
FSH treatment and should be considered as dropout. They did not differ from the 
patients who started FSH treatment in any of the screening characteristics, except for 
the level of endogenous FSH: the mean level was 4.1 (SD 1. 7) IU/1 versus 5.1 (SD 1.6) 
IU/1 in the group that started FSH treatment (P = 0.01). 
The primary screening characteristics are presented in Table 1 for women who did 
reach a pregnancy leading to singleton live birth and for those who did not. Successful 
patients were younger, infertile for a shorter period of time, thinner, had marginally 
higher FSH, higher LH and lower insulin/glucose ratios. The fmal column indicates 
the screening characteristics that had an independent contribution to the multivariable 
prediction model: age, the insulin/glucose ratio and the duration of infertility. Figure 3 
shows the distribution of the predicted probabilities calculated by this model (after 
shrinkage) for the 240 patients in this study. The individual predicted probabilities 
ranged from 15% to 82%. When we would consider a predicted probability at 12 
months below 30% as poor prognosis, the model was able to identify 25 out of 240 
( 10%) as poor prognosis patients. 
In an additional analysis, we defmed WHO 2 patients as defmitive PCOS in case 
they presented with elevated FAI and polycystic ovaries (Laven et al., 2002) (49% of 
the 240 patients)- in accordance with a recent PCOS consensus meeting -and clearly 
non-PCOS when F AI was normal and no signs of polycystic ovaries were present 
(13% of patients). The remaining women formed the in-between group of possible 
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PCOS (38% of patients). Kaplan-Meier analysis for pregnancy leading to singleton 
live birth showed no difference between these groups: P = 0.9. 
DISCUSSION 
The current prospective study demonstrates a cumulative chance of pregnancy 
resulting in singleton live birth of 71% within 2 years of classical ovulation induction 
(CC medication followed by exogenous FSH as second line therapy) in a well-defmed 
group of normogonadotrophic anovulatory infertile women (WHO group 2). The 
chance increased to 74% in case multiple live births were included, and to 76% for all 
ongoing pregnancies. Of all live births, only 7% were multiple births. These figures 
compare favorably with the outcome of alternative, more complex treatment 
algorithms (Heard et al., 2002)-(Child et al., 2001). Again, many studies involving 
alternative therapies are retrospective, and involve a small and selected group of 
patients. Moreover, singleton live birth is rarely used as an endpoint. The above 
mentioned observations are in favor of the contention that classical ovulation induction 
should remain the first line treatment of choice in these women. 
A prognostic model based on age of the woman, the insulin/glucose ratio and the 
duration of infertility predicts probabilities of pregnancy resulting in singleton live 
birth at 12 months ranging from 15% to 82%. The apparent c-statistic of the model 
was 0.64, and the optimism-corrected value was 0.61, indicating only a moderate 
discriminative ability. However, the model is able to identify patients with low 
chances for success applying classical ovulation induction who may therefore qualify 
for alternative first line treatment options such as insulin sensitizing agents, assisted 
reproductive technologies or laparoscopic ovarian surgery. For example, a probability 
lower than 30% was predicted in 25 (10%) out of the 240 patients. However, this cut-
off value for low chance of 30% is arbitrarily chosen and other values may be just as 
valid. In a general infertility setting, the individual choice between several treatment 
options should depend on the chances of success, the complication rates, the burden to 
the patient and costs. Taking these considerations into account, clinicians can choose 
any desired cut-off value for the chance of success of ovulation induction, and derive 
from Figure 3 how many patients will be identified as having a low chance of success. 
In previous studies by our group with regard to outcomes following CC alone, a 
history of amenorrhea (as opposed to oligomenorrhea) was found to be an adverse 
factor for ovulation (Imani et al., 1998), but a positive factor for pregnancy once 
ovulation was achieved (Imani et al., 1999). In the current study, amenorrhea has no 
effect on outcome, indicating that probably both effects level out, as has been noticed 
previously (Imani et al., 2002b). Additional factors involved in the prediction oflife 
birth following CC included F AI, BMI and female age. Previously identified screening 
characteristics involved in the prediction of ongoing pregnancy following FSH 
ovulation induction include IGF-1 and T concentrations and age (Mulders et al., 2003). 
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Figure 2 Outcomes during classical induction of ovulation in 240 normogonadotrophic anovulatory infertile 
women. 
* Drop out after CC occurred in 44 patients. In 13 cases because the couple no longer had an active child 
wish, in 7 cases because further treatment was found too burdensome, in 9 cases because of medical 
problems and in 15 cases because an other therapy was started (IVF, or IUI). 
** two women with miscarriages following CC presented with an ongoing pregnancy after a subsequent 
second (I patient) or third (1 patient) pregnancy with CC. 
*** FSH treatment was discontinued by 37 patients without getting pregnant In 3 cases because the couple 
no longer had an active child wish, in 1 case because treatment was found too burdensome, in 6 cases 
because of medical problems and in 22 cases because the couples started another therapy (IVF). Five 
couples had not yet planned another treatment at the end of follow-up. 
**** Multiple ongoing pregnancies with CC occurred four times, all of which were twins. With FSH, 6 
multiple live birth occurred (4 twins, 1 triplet and 1 quadruplet). CCF = CC failure (absence of pregnancy 
despite ovulatory CC cycles. CRA = clomiphene resistant anovulation. 
Table 1 Clinical, endocrine and ultrasound screening characteristics (mean± SD) of 240 normogonadotrophic anovulatory infertile women before initiation of 
classical ovulation induction (CC as first line, and FSH as second line therapy), and separately for women who did and those who did not reach a pregnancy resulting 
in singleton live birth. 
Overall grouo 
(N=240) 
Screening parameters 
Age (yr) 27.8 ± 4.3 
Duration ofinfertility (yr) 2.1 ±2.1 
%Primary infertility (patients) 75% (n = 181) 
%Oligomenorrhea (patients) 78% (n = 187) 
BMI (kg/m2) 26.9± 6.2 
WHR 0.8±0.1 
FAI (TxlOO/SHBG) 6.2±4.6 
FSH (IU/1) 4.7 ± 1.5 
LH (IU/1) 7.6 ± 4.3 
E2 (pmol/1) 240 ± 136 
Insulin/glucose ratio 3.4 ± 2.1 
%Polycystic ovaries (n patients) 3 74% (n= 178) 
Total motile sperm count (TMC) 4 68 (0- 693) 
1 P value of log-Rank test 
Pregnancy resulting in singleton live birth 
No Yes 
(N =106) (N= 134) 
28.7 ± 4.5 27.1 ±4.0 
2.5 ± 2.5 1.9 ± 1.6 
72% (n=76) 78% (n = 105) 
79% (n = 84) 77%(n=103) 
27.7 ± 6.8 26.2 ± 5.6 
0.8±0.1 0.8±0.1 
6.3 ±4.7 6.2±4.6 
4.4± 1.4 4.8 ± 1.5 
7.2±4.0 7.9±4.6 
249 ± 139 233 ± 133 
3.6 ± 2.4 3.2 ± 1.8 
75% (n = 79) 74% (n=99) 
52 (1 - 662) 80 (0- 693) 
P value1 
< 0.001 
0.02 
0.17 
0.9 
0.02 
0.28 
0.5 
0.07 
0.04 
0.2 
0.04 
0.8 
0.9 
Multivariable 
Hazard Ratio (95% CI) 2 
0.91 (0.87- 0.95) 
0.91 (0.81 - 1.02) 
0.87 (0.79- 0.96) 
2 The Hazard Ratios for pregnancy resulting in singleton live birth with 95% Confidence Interval (CI) of the screening characteristics that were selected into the 
multi variable model. 
The formula (after shrinkage) to calculate the 12 month predicted probability for a new patient is: 
1- EXP[ -8.3 * EXP[ -0.072*age (yrs)- 0.107*(insulin/glucose ratio)- 0.069*duration(yrs) ]]; 'EXP' denotes the standard exponential function. 
3 Polycystic ovaries are defined as mean ovarian volume 2: 10.8 and/or mean follicle number per ovary 2: 10 (van Santbrink eta!. Fertil Steril1997 (van Santbrink et al., 
1997)). 
4 For total motile sperm count median and range is given instead of mean and standard deviation. 
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Almost 50% of the CC failure (CCF) patients did not proceed to FSH treatment and 
should be considered as dropout. In general, dropouts may cause bias in the estimates 
of outcome when their prognosis differs from the patients who did not drop out 
('selective dropout'), as noted in a previous study (Imani et al., 2002b ). However, the 
screening characteristics that were predictive of success were similar between these 
patients and the patients who continued with FSH treatment. Only endogenous FSH 
levels were different, but since that screening characteristic was not associated with 
outcome in the prognostic model, we conclude that there is no indication of selective 
dropout. The 3 7 women who did not reach the endpoint following FSH treatment had 
received a median number of 5 treatment cycles, which is close to the standard number 
of treatment cycles according to protocol. Therefore they are not to be considered as 
dropouts. 
It is generally perceived that the majority of patients that qualify for exogenous 
gonadotrophins for ovulation induction suffer from PCOS (White et al., 1996), (Fauser 
and Van Heusden, 1997). However, scientific evidence to support this believe is scant. 
We have recently established that 70% of women suffering from normogonadotrophic 
anovulation present with polycystic ovaries as diagnosed by ultrasound, and 61% with 
endocrine signs associated with PCOS (i.e. hyperandrogenemia) (Laven et al., 2002). 
However, insulin resistance- as defined by an increased fasting insulin/glucose ratio -
could only be observed in 21% of women, whereas 44% were obese. All these clinical, 
endocrine and ultrasound abnormalities are involved in ovarian dysfunction in PCOS, 
and may therefore potentially predict response and outcome of ovarian stimulation by 
exogenous FSH (Balen et al., 1993), (Fulghesu et al., 1997). We were therefore 
surprised to find that none of these features - except for insulin resistance - could be 
identified in the current study as predictor of pregnancy in multivariable analysis. 
Moreover, in case the overall heterogeneous WHO 2 group was classified according to 
defmitive PCOS or definitive non-PCOS (see results section for details) again no 
differences in pregnancy chances could be observed. Not even obesity (defmed as 
elevated BMI) or abnormal fat distribution ( defmed as WHR) was capable of 
predicting outcome, despite much emphasis in recent literature on the impact of 
overweight (Hamilton-Fairley et al., 1992) and weight reduction (Norman et al., 2002) 
on success of fertility therapies in anovulatory women. These discrepancies clearly 
underline the need for properly designed, prospective studies in a well defmed patient 
population. 
In conclusion, the current study shows that overall normogonadotrophic anovulatory 
women have good prospects of singleton live birth when treated according to the 
classical induction of ovulation algorithm, including CC as first line treatment 
followed by exogenous FSH as second line. Using a multivariate prediction model, 
individual women with chances for success (far) above or below average can be 
identified. For women with a predicted low chance, the use of alternative treatment 
strategies may be appropriate. 
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Individualizing the treatment protocol 
The prediction models discussed so far in part II of this thesis may serve several 
purposes: they a) may be used to inform patients about the prospects of the outcome of 
treatment, b) serve as a basis of decision making about which course of treatment is to 
be preferred for an individual patient and fmally, c) be used to individualize and 
optimize the treatment protocol. For the first purpose (a), it suffices the have an easy to 
use tool that will allow the clinician to calculate the prognosis of the patients, given 
their characteristics. Examples of such tools are a score chart, such as the one used in 
Chapter 7 for the prediction of the chance to be CRA, or a nomogram, such as the one 
presented in Chapter 9 to calculate the chance of pregnancy leading to live birth with 
CC treatment. The second purpose (b) involves knowledge on the individual 
preferences of patients for the possible outcomes that may result from treatment. These 
preferences may concern the time required to achieve a pregnancy, the burden of 
treatment or whether there is a chance of a twin or higher order multiple pregnancy. 
From literature we know that preferences are difficult to assess and the values obtained 
from individual patients are very unreliable (Roest et al., 1997). The third purpose (c) 
requires the calculation of the cumulative pregnancy chances for various alternative 
treatment protocols and relating these to the costs, for patient groups defmed by the 
predictive variables. The result will be a new treatment protocol that is individualized 
and optimized with respect to effects and costs. Of the three purposes mentioned this is 
the one most likely to be of practical value, and it will be pursued here. 
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EFFICIENCY PROBLEM 
The current sequence of treatment is from the least burdensome and cheapest to the 
most burdensome and most costly treatment. The question is whether the sequence of 
treatments can be made more cost-effective by using information on individual patient 
characteristics and the response of the patient in previous treatment steps. 
Our aim is to investigate for which patient groups the current linear protocol may be 
replaced with a protocol in which: 
1. The CC step, the GOI-step or both may be skipped, based on the patient's 
characteristics and (for the second option) on fmdings during the CC 
treatment (was the patient CRA or a Clomiphene Failure; what was the CC-
dose at first ovulation?) 
2. Further treatment is stopped, based on the patient's characteristics and 
fmdings during treatments so far, or no treatment is started because the 
spontaneous pregnancy chances of the patient are still good enough. 
The identification of patient groups for whom a change of treatment protocol would 
be cost-effective is based on the prediction models for the chance of response (ongoing 
pregnancy) and an estimate of the costs of treatment. 
PREDICTION OF PREGNANCY CHANCES 
So far in this thesis, prediction models have been presented for the chance of 
pregnancy with CC (Chapters 7, 8 and 9) and the overall prognosis of ovulation 
induction (CC + GOI) in Chapter 10. For the cost-effectiveness analysis, additional 
prediction models are needed for the GOI step separately, for the outcome of IVF 
treatment as well as for the chances to become pregnant spontaneously. 
Prediction of outcome of GOI 
A separate study has been performed to obtain a prediction model for the outcome 
after GOI (Mulders eta!., 2003a). For this purpose 154 patients were included that all 
had a history of CC treatment either ending with CRA of Clomiphene Failure. There 
were 67 (= 44% cumulative) ongoing pregnancies. A multivariable Cox regression 
model was constructed based on the initial serum insulin-like growth factor-! (IGF-1), 
testosterone and the woman's age. The response during the_CC treatment (CRA versus 
Clomiphene Failure) was not associated with the cumulative chance of ongoing 
pregnancy (P = 0.6). 
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Prediction of outcome of IVF 
From the Rotterdam cohort of 240 patients that was analyzed in Chapter 10, only 26 
patients started NF after having received foregoing CC and GOI treatments without 
success (Mulders et al., 2003c). These patients were compared with a control group of 
NF patients with tubal pathology. Compared to the controls, women with WHO II 
anovulatory infertility had an elevated risk of cancellation of an NF treatment cycle 
because of inadequate ovarian response to stimulation, but the pregnancy rates were 
similar. No predictors for pregnancy after NF could be identified within this small 
group of patients. We therefore based our calculations of the prognosis with IVF on 
the Templeton model (Templeton et al., 1996). This model was built on the data from 
the national NF registry in the United Kingdom, and is based on a very large number 
of patients from the period 1991-'94. The overalllivebirth rate in the first cycle was 
14%. Since the results of IVF may have improved over time due to technological 
developments, we corrected the baseline pregnancy rate of this model with recent 
published data from the national Dutch NF registration (Kremer et al., 2002), which 
had an ongoing pregnancy rate per cycle of 19% during the period 1998-2000. 
Pregnancy chances with NF were subsequently calculated for ages under and above 
30 years as 24% and 19% respectively per treatment cycle. Assuming that on average 
2.1 cycles will be performed (Kremer et al., 2002), the overall pregnancy chances with 
NF are 50% and 40% respectively. 
Prediction of spontaneous pregnancy chances 
Although some patients became pregnant spontaneously before as well as between 
treatments, we do not have reliable estimates of the chances on spontaneous pregnancy 
for our own patient group. Fortunately, predictive models for spontaneous pregnancy 
chances have been published, including prognosis for patients with ovulation disorders 
(Collins et al., 1995), (Snick et al., 1997). For our analysis we will use the Snick 
model (Snick et al., 1997), since this model was developed on patients who were 
directly referred by general practitioners, which is also the case for our patient group. 
The Snick model provides estimates dependent on age, duration of infertility, type of 
infertility (primary or secondary) and diagnosis. We will assume for the WHO II 
patients that the duration of infertility is shorter than 2 years and that infertility is 
primary. For women with an ovulation disorder and age under 30, the model predicts a 
spontaneous pregnancy chance within one year of 20%. However, we may assume that 
amenorrheic women do not ovulate, and therefore have a zero chance of spontaneous 
pregnancy. This implies that oligomenorrheic women must have a pregnancy chance 
that is above the average for women with an ovulation disorder. In our group of 240 
patients, 22% had amenorrhea. Therefore, the following equation should hold: 20% = 
22% x 0 + 78% x P(pregnant I oligomenorrhea). From this equation follows that the 
spontaneous pregnancy chance for oligomenorrheic women, younger than 30 may be 
estimated as being 0,20/0,78 = 26%. For women of30 years or older the calculation is 
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similar: the Snick model predicts 15% for the whole group of women with an 
ovulation disorder. In case of oligomenorrhea, the prognosis is then equal to 0,15/0,78 
= 19%. 
Summary of the predictors 
The prediction models for outcome of CC presented in Chapters 7, 8 and 9 (Imani et 
al., 1998), (lmani et al., 1999), (Imani et al., 2002), models for GOI and NF (Mulders 
et al., 2003a), (Mulders et al., 2003c), the fmdings from literature concerning the 
outcome of GOI (Mulders et al., 2003b) and the results from the 'overall' analysis for 
ovulation induction (CC + GOI) in Chapter 10 (Eijkemans et al., 2003) show that 
body mass index (BMI), female age, the severity of cycle disturbance (oligo- or 
amenorrhea), serum androgen levels and ultrasound characteristics of the ovaries are 
related to the outcomes of treatment. Table 1 gives a resume of the predictors that play 
a role in the treatment of these patients. 
Table 1: Predictors for chances on outcome of the three treatment modalities 
Predictor 
Age 
BMI 
Oligo/amenorrhea 
Androgens 
Ovaries 
(Imani et al., 1998) 
(Imani eta!., 1999) 
CRA" 
X 
X 
X 
X 
Pregnancy with Pregnancy 
CC in non- CRA with GOIC 
atientsb 
X X 
X 
X 
Pregnancy Spontaneous 
withiVFd pregnancyc 
X X 
X 
(Mulders eta!., 2003a): this study also found that IGF-I was predictive of pregnancy chances with GOL 
Since IGF-I is not part of the standard initial hormonal assessment, we decided to leave it out of our 
analysis. 
d (Templeton et a!., 1996) 
(Snick et a!., 1997) 
COSTS OF TREATMENT 
The costs of the three treatment options were calculated from a societal perspective, as 
the product of volumes and prices. On the data of the 240 patients that were used in 
the overall analysis in Chapter 10 (Eijkemans et al., 2003), the average costs per 
treatment cycle were calculated. The total costs of treatment depend on the number of 
treatment cycles, which is related to the prognosis: the higher the pregnancy chances, 
the sooner the patient will become pregnant, needing less cycles. Therefore, we will 
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present the costs per cycle separately and postpone the calculation of the total costs to 
the fmal cost-effectiveness analysis. 
Costs per cycle of CC treatment 
In calculating the costs of a CC treatment cycle, we had to make a number of 
simplifying assumptions on the amount of medication and tests used during one cycle 
of CC treatment. These assumptions are shown in Table 2, together with the prices per 
unit. 
The dose escalation only applies to patients who do not ovulate with the previous dose, 
and will occur two times in patients who turn out to be CRA. Therefore, the costs per 
cycle are higher for CRA patients than for non-CRA patients: they amount to € 30,76 
and € 16,10 respectively. The average costs per cycle for all patients were € 18,96. 
Table 2: Prices and assumptions on the volume per cycle ofCC treatment 
Medication Clomid 
Progesterone 
assessment 
Pregnancy test 
Price 
I 0 tablets of 50 mg: 
€4,62 
€25 
€ 10 
Costs per cycle of GOI treatment 
Volume per cycle 
Each cycle 5 days, dose escalating from 50mg/day in 
the first cycle, to max 150 mg/day in subsequent 
cycles 
1 x first cycle, in subsequent cycle only when the 
daily dose was increased 
Average 1x per 2 cycles 
In calculating the costs of a GOI treatment cycle we made the assumptions mentioned 
in Table 3. 
In total, the costs of ovulation induction with gonadotrophins were € 785 per cycle, 
which is more than 40 times as high as the costs per CC-cycle. 
Table 3: Prices and assumptions on the volume per cycle of GOI treatment 
Medication Recombinant FSH, 
per ampoule 75 IE 
Echo 
Injection hCG, 5000 IE 
Pregnancy test 
Price Volume per cycle 
€ 33,54 Mean number of ampoules: 17,7 per cycle 
€40 Mean: 4,4 per cycle 
€4,63 Only in non-cancelled cycles. 
€ 10 Every cycle 
130 
Costs per cycle of IVF treatment 
For the costs of NF we used data from the literature, because our own data were too 
limited to give reliable estimates. The costs of NF in the Netherlands have been 
determined in the study by Goverde et al. (Goverde et al., 2000). That study gave an 
estimate of the costs per IVF cycle of DFL 3.350 (price level of 1995), i.e. € 1.529, 
about twice as high as the price per cycle of GO I. 
OPTIMIZATION OF THE TREATMENT PROTOCOL BASED ON THE COSTS 
PER ONGOING PREGNANCY 
Here we present the results of the cost-effectiveness calculations. First we will define 
patient groups according to combinations of the most important predictor variables. 
Next we determine -for every patient group- the total costs and ongoing pregnancy 
rate of each treatment. Then the treatment strategies will be compared in cost-
effectiveness, and fmally alternatives will be discussed. 
Predictors and patient groups 
We have seen that body mass index (BMI), female age, the severity of cycle 
disturbance (oligo- or amenorrhea), serum androgen levels and ultrasound 
characteristics of the ovaries were predictive of outcome of treatment. An 
individualized treatment protocol based on all these characteristics would be too 
complicated. Therefore, we restricted the number of predictors to be used in the cost-
effectiveness analysis to the 4 most important ones: age, the severity of cycle 
disturbances (oligo- or amenorrhea), androgen levels expressed as normal or elevated 
(Androstenedione >=16.3 nmol!L 6r testosterone >= 3.2 nmol!L), and Body Mass 
Index (BMI). Age and BMI were dichotomized, so that 16 (=2x2x2x2) different 
patient groups resulted. The patient groups are presented in Table 4 together with their 
frequency of occurrence in the Rotterdam cohort of 240 patients. 
The prediction models for the chance to be CRA, the pregnancy chance with CC in 
non-CRA patients and the pregnancy chance with GOI were re-estimated with the 
dichotomized predictors as defmed here. Shrinkage of regression coefficients was 
applied, just as it had been done in the original models. 
Comparison of treatment strategies 
The costs and pregnancy chances of the three treatments were calculated for the 16 
patient groups. Next, these results were incorporated in the treatment strategies that we 
want to compare. We performed a cost effectiveness analysis of a strategy in which the 
CC step is skipped and treatment starts with GOI followed by NF (GOI + NF), and a 
strategy in which the GOI step is skipped and treatment after unsuccessful CC is IVF 
(CC + NF). These two alternative treatment strategies will be compared to the 
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Table 4: Definition of the 16 patient groups 
Age Cycle duration Androgens BMI %of patients 
Age< 30 0 ligomenorrhea Normal BMI<27 18.8% 
BMI?:27 13.3% 
Elevated BMI<27 10.0% 
BMI?:27 10.0% 
Amenorrhea Normal BMI<27 5.4% 
BMI?:27 2.9% 
Elevated BMI<27 5.0% 
BMI?:27 3.3% 
Age ?: 30 Oligomenorrhea Normal BMI<27 8.8% 
BMI?:27 9.2% 
Elevated BMI<27 5.0% 
BMI?:27 2.9% 
Amenorrhea Normal BMI<27 2.5% 
BMI?:27 0.8% 
Elevated BMI<27 1.3% 
BMI?:27 0.8% 
reference strategy CC + GOI + IVF. Next to this, the decision to stop further 
treatment, or even not commence with treatment, will be analyzed by comparing the 
prognosis after treatment with the spontaneous pregnancy prognosis. 
The costs and the ongoing pregnancy chances of the various treatment strategies are 
compared to those of the· reference strategy, and the incremental cost-effectiveness 
ratio (extra costs per extra ongoing pregnancy) will be calculated. In case the costs are 
higher and at the same time the pregnancy chances are lower, the alternative strategy is 
unacceptable (it is dominated by the reference strategy). In the reverse case, with 
lower costs and higher ongoing pregnancy chances we have a 'win-win' situation (the 
alternative dominates the reference strategy). In the two other possibilities (higher 
costs together with higher ongoing pregnancy chances, or when both are lower) the 
height of the cost-effectiveness ratio determines whether the alternative is acceptable. 
If the cost-effectiveness ratio is below the threshold-value of € 10.000 per extra 
ongoing pregnancy, we consider the alternative acceptable. We also explored a lower 
and a higher value for the threshold cost-effectiveness ratio, of € 5.000 and € 20.000 
respectively. 
For the comparison of the alternative treatment strategies with the strategy CC + 
GOI + IVF we have to make a few additional assumptions. The flowchart in Chapter 
10 showed that not all patients continue with GOI after unsuccessful CC treatment. 
We have seen that 81% of the CRA patients, but only 54% of the Clomiphene 
Failures, continued treatment with GO I. Further, only 59% of the patients who were 
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not pregnant after GOI continued with IVF. We will assume that in the alternative 
treatment strategies the same percentage of non-pregnant patients move to the next 
treatment step after CC resp. GO I. 
The results of the cost-effectiveness analysis are presented in Table 5. The treatment 
strategy GOI + IVF (i.e. skip CC) is either dominated by the reference strategy or 
produces more ongoing pregnancies against costs per pregnancy that vary between € 
30.000 and € 70.000, which is above threshold value. Therefore this strategy would 
not be acceptable for any patient group. Under the lower as wel as under the higher 
threshold value, the conclusion remains the same. 
The other alternative treatment strategy, CC + IVF (i.e. skip GOI), produces less 
pregnancies and lower costs than the reference strategy. Therefore, the cost-
effectiveness ratio represents the extra costs per extra ongoing pregnancy of the 
reference strategy compared to the strategy CC+IVF. The ratio is within the threshold 
for acceptability of € 10.000, except for women over 30 years of age who have 
elevated androgen levels. For them, GOI after CC hardly gives extra ongoing 
pregnancies but does increase the costs substantially, with a cost-effectiveness ratio of 
€ 96.000. This concerns about 14% of the group of patients that is not pregnant after 
CC and who would start GOI treatment. 
Other alternatives 
Apart from skipping treatment steps, one could also consider stopping treatment in 
case of very poor prognosis, or not start at all in case the spontaneous pregnancy 
chances are still high enough. These options may be evaluated by calculating the extra 
costs per extra ongoing pregnancy of continuing treatment compared to trying to 
become pregnant spontaneously. We make the simplifying assumption that trying to 
become pregnant spontaneously doesn't require extra costs. 
The extra costs per extra ongoing pregnancy of the reference strategy 
(CC+GOI+IVF) compared to the spontaneous pregnancy chances vary between € 
1,260 and € 8,500. Assuming that spontaneous pregnancy chances are unaffected after 
unsuccessful CC treatment, the cost-effectiveness ratio of continuing with GOI + IVF 
after CC compared to trying to become pregnant spontaneously varies between € 4,840 
and € 20,260 per pregnancy. Finally, the cost-effectiveness ratio of continuing with 
IVF after unsuccessful GOI compared to trying to become pregnant spontaneously 
varies between € 6,420 and € 15,290. The highest values suggest that indeed there are 
patient groups for whom continuing treatment is not efficient under the threshold value 
of € 10.000 per extra ongoing pregnancy. However, we note that it is likely that the 
spontaneous pregnancy chances of patients who didn't become pregnant with CC or 
GOI are lower than assumed here (a.o. because the couples with better chances already 
will have become pregnant). Therefore, the cost-effectiveness ratios are probably 
lower than we have calculated and we cannot conclude for any patient group that 
stopping treatment is efficient. 
Table 5 Costs and effects of two alternative treatment strategies (GOI + IVF and CC + IVF) compared to the reference strategy CC + GOI + IVF 
~eference strategy: CC+GOI+IVF Alternative I: GOI+IVF [Alternative 2: CC+IVF 
Age Cycle duration Androgens BMI Pregnancy Costs Costs/ Pregnancy Costs CIE ratio* Pregnancy Costs C/E ratio* 
chance preg chance chance 
Age< 30 Oligomenorrhea Normal BMI<27 0.76 808 1,064 0.71 3,422 -** 0.72 763 1,023 
BMI:0:27 0.73 947 1,291 0.71 3,422 - 0.68 893 1,023 
Elevated BMI<27 0.71 1,074 1,521 0.61 3,877 - 0.68 903 6,315 
BMI:0:27 0.64 1,473 2,289 0.61 3,877 - 0.61 1,235 6,315 
Amenorrhea Normal BMI <27 0.75 944 1,261 0.71 3,422 - 0.7 891 1,023 
BMI:0:27 0.68 1,419 2,092 0.71 3,422 70,284 0.6 1,337 1,023 
Elevated BMI<27 0.63 1,626 2,562 0.61 3,877 - 0.59 1,362 6,315 
BMI:0:27 0.55 2,351 4,237 0.61 3,877 30,126 0.49 1,964 6,315 
Age::': 30 Oligomenorrhea Normal BMI <27 0.54 1,533 2,844 0.5 4,160 - 0.5 1,203 9,132 
BMI:0:27 0.52 1,673 3,195 0.5 4,160 - 0.48 1,311 9,132 
Elevated BMI<27 0.49 1,826 3,742 0.41 4,533 - 0.48 1,318 96,057 
BMI:0:27 0.45 2,201 4,916 0.41 4,533 - 0.44 1,586 96,057 
Amenorrhea Nonnal BMI<27 0.56 1,630 2,931 0.5 4,160 - 0.52 1,278 9,132 
BMI:0:27 0.5 2,097 4,160 0.5 4,160 - 0.45 1,640 9,132 
Elevated BMI<27 0.46 2,305 5,038 0.41 4,533 - 0.45 1,661 96,057 
BMI:0:27 0.39 2,971 7,550 0.41 4,533 77,269 0.38 2,135 96,057 
Average 0.66 1,438 2,165 0.67 3,915 287,937 0.59 1,194 3,454 
* CIE ratio: the extra costs per extra ongoing pregnancy of the treatment strategy compared with the reference strategy CC + GOI + IVF. 
**With"-" the cases are indicated in which the strategy is dominated by the reference strategy (i.e. the strategy has higher costs and lower pregnancy chances than 
the reference strategy). 
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CONCLUSIONS 
For most patients, the current standard treatment protocol is cost-effective. An 
exception may be made for women above 30 years of age with elevated androgen 
levels, for whom the treatment with gonadotrophins could be skipped. 
The strong association between outcome of treatment and obesity (for CC from our 
own analysis, for gonadotrophins mainly from literature) implies that chances could be 
improved by reducing overweight. This concerns 30-40% of the WHO II group. 
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Discussion and conclusions part I 
The first part of this thesis addresses two research questions from clinical reproductive 
medicine in a large historical natural fertility population. Here, we will summarize 
answers to these questions and discuss their implications for clinical practice. Next, 
specific aspects of natural fertility in the study population and consequences for 
interpretation of some of the results will be considered. Finally, a discussion is 
presented on the opportunities and limitations in general of historical demographic 
data to study research questions from clinical reproductive medicine, and topics for 
further research are proposed. 
ANSWERS TO THE RESEARCH QUESTIONS 
1. What is the variation in female reproductive life span? Is the reproductive 
life span correlated to fertility at young age and if so, how strong is this 
correlation? 
The median age at last childbirth was 41 years, which is compatible with the values 
found in many other natural populations. The variation is large: 80% of the women 
had their last child between ages 33 and 45. The estimates of the end of effective 
fertility -derived from the distribution of age at last childbirth- at ages 20, 25, 30, 35 
and 40 were 5%, 8%, 11%, 19% and 47% respectively. A part of this variation is 
explained by the fertility at young age. Women with higher fertility at young age 
showed a later end of reproductive capacity. This finding is in line with the theory of 
ovarian aging. 
2. Are fertility chances after 12 months unsuccessful trying to conceive small, as 
implied by the current standard of calling a couple infertile after 12 months? 
After 12 months of primary infertility in patients under 35 years of age, and 12-24 
months of secondary infertility irrespective of age, prospects are on average still good, 
since 30% or more of patients will become pregnant within the next year. For young 
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women (age< 30) with secondary infertility prospects are still good even after 3 years 
of infertility. 
IMPLICATIONS FOR CLINICAL REPRODUCTIVE MEDICINE 
The studies described in this part of the thesis give an indication of how many women 
are still able to have a live birth at the relatively late ages at which women nowadays 
start their reproductive career. Clinicians and policy makers are concerned about the 
impact on health care resources of further postponement of first childbirths by women 
in the Netherlands and elsewhere. Individual women are concerned about how long 
they can wait before their chances of becoming pregnant and have a live birth, 
deteriorate. 
The results in chapter 2 tell us something about the probability that a woman who 
starts trying to get children at a certain age will not succeed to do so by natural means. 
These results are mainly interesting for individual couples. The results in chapter 3 
show the age- and duration-dependence of the chance to conceive a pregnancy leading 
to a live birth. In women under 35, after one year of primary infertility or 1-2 years of 
secondary infertility, prospects are good. If diagnostics are started at 1-2 years 
duration of infertility (earlier only on indication) and nothing is found, prognosis is 
better than the population average at that duration of infertility, and therapy could be 
withheld for the next 1 or 2 years. 
These results may be combined with the present pattern of the age at which women 
start to get children in the Netherlands to predict the demand for clinical fertility 
services. This may be done for the usual defmition of infertility, i.e. after one year of 
80% 
70% D Netherlands 2002 
60% ffil Saguenay 1850-1899 
50% 
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Age at first childbirth 
Figure 1: Distribution of the woman's age at the time of first child15irth in the Netherlands in 2002 
compared to that of the women in the study population. 
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unsuccessful attempts to become pregnant, but also when a shorter or longer period is 
used to defme infertility as a clinical problem. In Figure 1, the distribution of the 
woman's age at the time of first childbirth in the Netherlands in 2002 (Netherlands 
Central Bureau of Statistics, www.cbs.nl) is compared to that of the women in the 
study population. It is evident that women in the Netherlands nowadays have their first 
child at a much higher age than the women born between 1844 and 1899 in the SLSJ 
regwn. 
In Table 1, the estimates from the analysis in Chapter 3 are used to predict the 
percentages of women who are not pregnant of their first child after three different 
durations that could be used to defme infertility: the usual duration of 12 months, a 
shorter duration of 9 months and a longer duration of 18 months. 
Table 1: Percentages of women who are not pregnant of their first child at 9, 12 or 18 months after 
marriage. Women born between 1844 and 1899 in the SLSJ region 
%of women not pregnant at 
Age at marriage 9 months 12 months 18 months 
20-24 18% 14% 10% 
25-29 26% 21% 16% 
30-34 31% 28% 20% 
35-39 48% 46% 32% 
These results are combined with the distribution of age at first childbirth in Figure 1 to 
predict the number of women who would not yet be pregnant of their first child in the 
Netherlands in 2002. 
Table 2: Number of women who would not yet be pregnant in the Netherlands 2002, according to their 
distribution of age at first childbirth (Figure I) and the predicted percentages per age category from Table I. 
Number of women (x 1,000) not pregnant at 
Age at marriage 9 months 12 months 18 months 
20-24 2.4 1.8 1.3 
25-29 8.0 6.3 5.0 
30-34 10.8 9.7 6.9 
35-39 4.8 4.6 3.2 
Total 26.0 22.4 16.4 
The total number of women not pregnant of their first child at 9 or at 18 months 
represent an increase of 16% or a decrease with 27% compared to the numbers not 
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Figure 2: The proportion childlessness according to age at marriage. Seven historical populations (Menken 
eta!., 1986), compared to the women from the SLSJ, born between 1844 and 1899. Data on complete 
marriages. 
pregnant at 12 months. This would also be the change in demand for fertility services 
when the standard period of 12 months to defme infertility is changed to 9 or 18 
months respectively. Note that we used only the data on first childbirths, therefore this 
calculation only applies to primary infertility. The same exercise could be performed 
for secondary infertility. 
ASPECTS OF NATURAL FERTILITY IN THE STUDY POPULATION 
Comparison with other natural fertility populations 
The number of children per women in the SLSJ population was high in comparison 
with other historical populations. There are several explanations for this: The age at 
marriage was young compared to historical European populations, and there was a 
tradition of breastfeeding children for a relatively short period. Therefore, married 
women had both a long time available to produce children and did so at a relatively 
high rate. 
The proportion of women that remained childless in the SLSJ population was 7.4% 
in the whole population and 6.2% in the group of women who married between ages 
Chapter 12: Discussion and conclusions Part I 139 
20 and 24 (see chapter 3). When comparing these figures with other demographic 
data, care must be taken that this comparison is not disturbed by differences between 
the populations in mortality: Women or men who died early, without having children 
at that moment, would not necessarily have remained childless, when they had lived 
longer. In chapter 3, we dealt with this by considering these couples as censored at the 
time of death in the Kaplan-Meier method. In demography, a different approach is 
taken by selecting complete families (i.e. unions still existing at age 50). With this 
approach, we find that the proportion childlessness in our population is 7.6% and 5.5% 
in the age group 20-24. Demographers have reported values as high as 8 to 10% for 
this age-group (Vincent, 1950) (Henry, 1965) (Trussell and Wilson, 1985) (Barrett, 
1986) (Menken et al., 1986). In Figure 2, the proportion childlessness-according to 
age at marriage- in our population is compared to the data on 7 populations from the 
18th and 19th century, mostly from Europe (Menken eta!., 1986). It is seen that our 
population is in the lower end of the rather large variation. However, a few other 
populations have lower proportions of women remaining childless. Data on women 
from the Hutterite sect, analysed by Tietze (Tietze, 1957) showed 2.4% childlessness 
in women married before the age of 25. In a sub-selection of the data collected by 
Henry (Henry, 1965), from historical France (Kindly made available by prof. Henri 
Leridon), 3.7% of the women married before their 25th birthday remained childless. 
This subgroup consisted of women married between 1670 and 1790. 
In chapter 3, the proportion childlessness was estimated by the Kaplan-Meier 
method on all marriages (censoring for early ending marriages). The estimates were 
6.2% and 7.7% in the age-at-marriage categories 20-24 and 25-29 respectively. These 
estimates should be equal to the proportion estimated in the completed families -where 
we fmd 5.5% and 6.6%- unless there is selection in the latter on fertility 
(corresponding to informative censoring in the Kaplan-Meier analysis). Since the 
Kaplan-Meier estimates are 0.7% and 1.1% higher than the estimates on complete 
families, informative censoring cannot be excluded. 
Comparison with modern times 
We established above that the proportion childlessness in the study 
population falls within the range that was found in other natural populations. However, 
the aim of our studies was to learn lessons from the past for Reproductive Medicine, 
not to compare fertility in one historical population to that found in others. We 
therefore have to answer the question: Is infertility in a modem western society 
comparable to that in a 19th century rural society? In chapter 3 we assumed that the 
proportion childlessness in a modem society is about half the proportion observed in 
this population (7.4%). This assumption is based on the literature: In 1990, Greenhall 
and Vessey published a review of the literature together with data from their own 
study on the prevalence of subfertility (Greenhall and Vessey, 1990). Studies using 
interviews or postal questionnaires gave rates for unresolved primary subfertility of 
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between 2.4% and 5.9%. Below we will discuss possible reasons for the relatively 
high proportion of childlessness in historical populations. 
Possible reasons for the high incidence of childlessness 
There is an intriguing disparity between two aspects of fertility in the study 
population: a relatively high incidence of childlessness compared to modem times, 
together with a very high number of children per woman. We discuss several possible 
reasons for the high incidence of childlessness, some of which are particular for our 
population, while others apply to all historical populations. 
High incidence of genetic disorders? 
This population is known to have a high incidence for several genetic disorders, 
probably due to a founder effect (De Braekeleer and Gauthier, 1996). None of the 
studies done so far revealed a difference in fertility between affected and non-affected 
men and women (Roy eta!., 1989) (Veillette et al., 1989) (De Braekeleer et al., 1990) 
(Dao eta!., 1992) (De Braekeleer, 1993). Further, there doesn't seem to be a biological 
explanation for fertility being linked to any of these diseases. 
Emigration? 
Because we needed information about the end of marriage, we only used the data of 
women who died in the region, i.e. women who did not emigrate. We stated in chapter 
1 that emigration may pose a problem: if women who had children were more likely to 
emigrate than women without children, the women who did not emigrate are not 
representative of the total group of married women: they will have a higher proportion 
of childlessness. In chapter 1 we found -for women who had a child- that there was no 
difference in time to first pregnancy between emigrating women and women who 
stayed in the region. However, this does not exclude the possibility that women 
without children are over-represented in the group that did not emigrate. 
Voluntary childlessness?" 
Finally, we cannot exclude that a substantial part of the high proportion childlessness 
is voluntary, i.e. through the use of contraceptive measures. Then it would also be 
likely that there were couples that used contraceptives to limit their family size. 
However, in order to achieve the very high average number of children that we 
observe, a part of the population must have had a very high fertility. It would be 
interesting to look at the distribution of births in completed families and compare it 
with other populations. It is unlikely that this factor can explain why in almost all 
historical populations the infertility (measured by the proportion childlessness) was 
higher than it is today. 
Chapterl2: Discussion and conclusions Part I 141 
Causes of infertility 
Another issue is whether the causes of infertility in our study population are the same 
as in modem times. There are speculations that infertility is higher nowadays than it 
used to be, because of two trends. Tubal disease may have become more frequent 
during the twentieth century, as a consequence of the increased incidence of Pelvic 
Inflammatory Disease (PID). The primary cause of PID is sexually transmitted 
diseases (STD's) such as gonorrhea and chlamydia (Jones et al., 1982) (Kane et al., 
1984). Indeed the incidence of STD's increased in the USA between 1965 and 1975, 
but remained constant thereafter (Curran, 1980). The growing awareness of the risks 
of STD's has stopped the increase in incidence and a downward trend has been 
observed in later years. Although we don't have data for our study population on 
STD's, their incidence appears to be low in most natural fertility settings (Wood, 
1994). Next to tubal disease, speculations concern a possible increase of male 
infertility due to environmental factors. However, the literature on this subject is 
conflicting. Some studies have found a systematic decline in semen quality (Carlsen et 
al., 1992) (Auger et al., 1995) (Van Waeleghem et al., 1996) (Irvine et al., 1996), 
where others found no such decline (Bujan et al., 1996) (Vierula et al., 1996) 
(Wittmaack and Shapiro, 1992) (Fisch et al., 1996) (Paulsen et al., 1996). Two recent 
studies (Akre et al., 1999) (Joffe, 2000) that have investigated time trends in overall 
infertility found that infertility decreased in the second half of the 20th century and 
they came to the same conclusion: if a decline in male fertility is present, it has been 
more than compensated for by others factors (see also: chapter 4). 
Finally, couples nowadays probably have more knowledge than in earlier times on 
the fertile period of the woman and know better how to make maximal use of it, in 
order to become pregnant. In historical times this knowledge -if at all present- might 
have been used by women to achieve the opposite: avoid pregnancy. A recent study 
showed that indeed high pregnancy rates may be achieved by having well-timed 
intercourse (Gnoth et al., 2003). 
In summary, we conclude that childlessness observed in historical 'so-called' natural 
fertility populations is more frequent than involuntary childlessness in modem times. 
Most likely, the reasons for this may be a combination of a true decrease in infertility 
over time, voluntary childlessness in historical populations and selective emigration. 
Two estimates for the age-dependency of sterility 
We obtained estimates of the age-specific probability of being effectively infertile in 
two different ways. In chapter 2 Figure I, it was derived from the woman's age at last 
childbirth, while in chapter 3 Figure 2, it was based on the woman's age at marriage, 
using Cox-regression for the chance to remain childless after marriage. The two curves 
are shown together in Figure 3. The results of the two methods agree for ages until30. 
However, the shape of the curves is different: the curve based on age at marriage 
(chapter 3) remains 'flat' until older ages than the curve based on age at last childbirth 
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Figure 3: Two estimates (with 95% Confidence Interval) of the age-specific chance to be effectively 
infertile.(!) Kaplan-Meier curve for the age at last live birth (thin line with shaded area) and (2) using Cox-
regression on the time between marriage and birth of the first child (thick line). 
(chapter 2), while from about age 35 onwards it becomes more steep. Care should be 
taken not to over-interpret this difference: the uncertainty in the estimates based on the 
age at marriage (chapter 3, Figure 2) is huge for ages above 30, due to the fact that 
there were only few women who married at these ages (see also chapter 1, Figure 1). 
In contrast, the results based on age at last childbirth from chapter 2 have many 
women contributing to the estimates at these ages, as is reflected in the narrow 95% 
confidence band around the curve. 
Despite the small statistical uncertainty, some reflection is in place with 
respect to the results based on age at last childbirth (chapter 2). Breastfeeding causes 
postpartum amenorrhoea, which made the women practically infertile for at least a few 
months after the birth of the last child. Without breastfeeding, some women might 
have been able to conceive yet another child, so that the actual age at which they were 
still able to have a child would be later than their observed age at last childbirth. On 
the other hand, some woman might already have been effectively infertile while 
carrying the last child, i.e. before the age at last childbirth. Although these two effects 
will (at least partly) cancel out, there clearly is extra uncertainty in the curve that is 
difficult to assess. 
Demographers have recognized these problems long ago (Barrett, 1971) (Leridon, 
1977). Attempts have been made to obtain the 'true' curve of age at'sterility by using 
computer simulations of the whole process of becoming pregnant and having a live 
birth. This process is assumed to consist of the age-dependent chance to be definitely 
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sterile, temporal infertility due to postpartum amenorrhoea, the age-dependent monthly 
chance to conceive and the age-dependent chance of pregnancy loss (due to intra-
uterine death of the foetus) (Trussell and Wilson, 1985). Age at defmitive sterility in 
their analysis is therefore the age at which the woman is no longer able to become 
pregnant, where in our analysis only pregnancies leading to live birth are considered. 
While the demographic analysis is probably more precise and may be of value in a 
theoretical respect, we consider our analysis more meaningful for modem reproductive 
medicine: it is now widely agreed upon that patients are interested in having a 
(healthy) child and not just in becoming pregnant. 
HISTORJCAL DEMOGRAPHIC DATABASES AS A RESEARCH OBJECT FOR 
CLINICAL REPRODUCTIVE MEDICINE: OPPORTUNITIES AND 
LIMITATIONS 
Observations on natural fertility: a unique opportunity for reproductive medicine 
Women in a natural population express two unique aspects of fertility that are not 
observable in a modem population: 1) the absence of contraception and treatment for 
infertility gives an undisturbed observation of time to pregnancy leading to live birth 
and 2) the age at last childbirth marks the end of fertility for a woman. Both aspects 
are of interest for reproductive medicine, but there are limitations. Biology and 
behavior are indistinguishable in historical data, and we assume that women were fully 
expressing their biological capacity. There is good evidence for this: The demographic 
transition in Quebec did not occur until 1930 and the only method of intentional birth 
control that may have been practiced was prolonged breastfeeding of children. In this 
respect, this population is special since it had a tradition of short lactation periods 
(Lalou, 1990). However, for more detailed analyses of the process of getting children, 
it data on aspects of fertility such as the frequency of miscarriage, coital frequency and 
cycle regularity of women would have been of value, but is not available from church 
registers. 
Statistical aspects of analysis on demographic data 
One of the consequences of the high fertility of this population is that there were large 
families. Many women in our selection of subjects had therefore sisters who were also 
selected, or brothers who were married to other selected women. Therefore, the 
women in our sample may not be regarded as completely independent, there is 
clustering within a family. We dealt with this by performing additional analyses, 
particularly multilevel modeling, in which the level of daughters is nested within the 
level of mothers. 
As mentioned in the introduction (chapter 1), the nature of church registers is such 
that there are inevitably missing data, due to couples moving away (emigration), 
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missing birth dates of women and missing birth dates of children. For the former two 
we assumed that they were not related to fertility, while for the latter we had to correct 
our analysis, to avoid bias in the estimates of childlessness by age. 
Topics for further research 
The material at hand is well suited for further research on questions from reproductive 
medicine. Several topics have been suggested during the present research. 
1) The role of breastfeeding in the relationship between fertility at young age and 
age at last childbirth (chapter 2) might be investigated further, by using the data of 
subsequent birth intervals from the same woman. For this aim we might use frailty 
models, along the way set out by previous work of Vaupel and Larsen (Vaupel, 1988) 
(Larsen and Vaupel, 1993) (Larsen and Yan, 2000) 
2) The fact that we have data on the birth cohorts from 1844 to 1899 implies that 
several generations are present. The women in our dataset may also have their mother 
or their daughters in the data. This offers an opportunity to study heritability of 
parameters of fertility. Technically, multilevel modeling may be used to decompose 
the variability in fertility of women in several generations. 
3) There are several other research questions from reproductive medicine that could 
be analysed on these data. We mention two of these here. 
• Is maternal age related to the fertility of the male offspring? Theories on 
mitochondrial inheritance predict that sons born of older mother would be less 
fertile. 
• Is paternal age related to the sex-ratio of offspring? (Jacobsen et al., 1999). 
Further, questions of a more methodological nature may be further pursued. 
4) The observation of the high maternal mortality (chapter 2) raises the question of 
selection of healthy women in the group that stayed married (thus also alive) at least 
until age 50. Although we concluded in chapter 2 that the selection was probably not 
working on fertility, further research is required, e.g. on the parity dependence of 
maternal mortality. 
5) Informative censoring: in chapter 3 we used the Kaplan-Meier method on time to 
first childbirths, to estimate the chance of remaining childless by age at marriage. 
Women whose marriage ended before they had their fust child (mainly through death) 
were considered censored in that analysis. In this chapter we showed that these 
estimates are higher than simple counts of childlessness in the subgroup of women 
who remained alive (and married) until age 50. Apparently the censoring of the 
women who died before age 50 in Kaplan-Meier was informative. Further 
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investigation in the reasons why women died before age 50 may reveal to what extent 
the Kaplan-Meier estimates are statistically valid. 
CONCLUSIONS AND RECOMMENDATIONS 
• The end of female fertility shows huge variation: The chance that a woman is 
no longer able to conceive a pregnancy leading to live birth at ages 20, 25, 
30, 35 and 40 is 5%, 7%, 10%, 17% and 40% respectively. 
• Fertility at young age and the age at which fertility ends are positively 
related, supporting the concept of ovarian aging. 
• After 12-24 months of infertility, under 35 years of age, prospects to conceive 
naturally are on average still good. If diagnostics are started at these durations 
of infertility (earlier only on indication) and nothing is found, prognosis is 
better than the population average at that duration of infertility, and therapy 
could be withheld for the next 1 or 2 years. 
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Discussion and conclusions part II 
Part II of this thesis addresses research questions related to the development of an 
individualized treatment protocol in patients with WHO II anovulatory infertility. In 
this chapter, we summarize the answers to these questions and discuss the implications 
for the treatment protocol. 
ANSWERS TO THE RESEARCH QUESTIONS 
1. Which patient characteristics are predictive of pregnancy chances following 
ovulation induction with Clomiphene Citrate (CC)? What is -in this respect-
the relation between the intermediate endpoint 'ovulation' and the final 
endpoint pregnancy? 
Three analyses were performed: 1) prediction of the chance to remain anovulatory (i.e. 
to be CRA 2) prediction of pregnancy, given that the patient was not CRA and 3) 
integration of 1) and 2). 
For the prediction of the chance to be CRA (1), a mu1tivariab1e logistic regression 
model was built, including the Free Androgen Index (F AI), Body Mass Index (BMI), 
cycle history, and mean ovarian volume as predictors. Patients whose ovaries are less 
likely to respond to stimulation by FSH due to CC treatment had elevated F AI, higher 
BMI, amenorrhea instead of oligomenorrhea and large mean ovarian volume. The 
prediction model for the pregnancy chances in patients who were not CRA (2) was a 
Cox regression model and contained two predictors: patients who became pregnant 
presented more frequently with lower age and amenorrhea upon initial screening. The 
two models (1) and (2) were combined in a graphical tool (3) to facilitate the 
calculation of the probability of pregnancy leading to live birth with CC treatment. 
The opposite effects of amenorrhea versus oligomenorrhea (a negative effect in (1), a 
positive effect in (2)) more or less cancelled out. 
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2. Which patient characteristics are predictive of pregnancy chances of classical 
ovulation induction with Clomiphene Citrate (CC) followed by 
Gonadotrophin ovulation induction (GOI)? 
A Cox regression model was built containing the woman's age, the insulin/glucose 
ratio and the duration of infertility as predictors of pregnancy leading to singleton live 
birth. The effects of factors that were important in predicting the outcome of CC 
treatment alone, such as F AI and BMI, apparently disappear with the use of GOI after 
CC. 
3. What is the optimal treatment sequence for WHO II patients based on their 
individual characteristics and on the response in previous treatment steps? 
A cost-effectiveness analysis was performed comparing several alternative treatment 
strategies with the reference strategy CC+GOI+NF, for 16 different patient groups. 
The alternative strategies were GOI + NF (i.e. skip CC), CC + NF (i.e. skip GOI), 
CC (i.e. stop after unsuccessful CC), CC + GOI (stop after unsuccessful GOI) and 
fmally no treatment at alL In the latter three strategies it was assumed that patients 
would try to become pregnant spontaneously. The maximal acceptable threshold for 
the extra costs per extra ongoing pregnancy was assumed to be € 10.000. 
For most patients, the reference strategy CC+GOI+NF is cost-effective. An 
exception may be made for women over 30 years of age who have elevated androgen 
levels. For them, the treatment strategy CC + NF (i.e. skip GOI) is indicated, as the 
addition of GOI produces only few extra pregnancies against costs of over 90,000 
Euro per pregnancy. The reference strategy is therefore not acceptable for this patient 
group, which comprises about 14% of the group of patients that is not pregnant after 
CC and who would start GOI treatment. The strong association between outcome of 
treatment and obesity (for CC from our own analysis, for gonadotrophins mainly from 
literature) implies that chances could be improved by reducing overweight. This 
concerns 30-40% of the WHO II group. 
METHODOLOGICAL CONSIDERATIONS 
A few remarks should be made in retrospect with regards to methodological issues. 
They concern both the general aspects of prognostic model validation, as well as the 
more specific issue of the role of the intermediate outcome CRA in the analysis of 
time to pregnancy. 
Prognostic model validation 
In chapter 6 we formulated recommendations for the development of prognostic 
models, including internal validation and shrinkage of regression coefficients as a fmal 
step. We followed these recommendations in chapter 7, when we developed the 
prediction model for CRA. However, we did not perform an internal validation of the 
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Cox-regression model for pregnancy chances in non-CRA patients in chapter 8. At the 
time of development of that model, no standard statistical package was accessible to 
perform these procedures for Cox-models. Only later on, when the model was used in 
chapter 9 to be combined with the CRA-model from chapter 7, we established a 
shrinkage factor by performing a bootstrap procedure. The details were omitted from 
chapter 9 and will be given here. The model was built using backward stepwise 
selection of variables starting with 7 candidate predictors. In the final model only 2 of 
these were retained, age and type of cycle disturbance (oligo- or amenorrhea). The 
bootstrap procedure (with 200 replications) revealed that the shrinkage factor, 
necessary to produce well-calibrated predictions in future patients, was 0.84. Further, 
the apparent discriminative ability of the model, measured by a c-statistic of 0.68, was 
corrected for optimism by the bootstrap procedure to a value of 0.65. The shrinkage 
factor was applied in the development of the nomogram in chapter 9, as well as in the 
cost-effectiveness analysis in chapter 11. 
So far, none of the prediction models in this thesis has been externally validated. 
Nevertheless, we used the models in a cost-effectiveness analysis to formulate 
recommendations for the treatment protocol of WHO II anovulatory infertile patients 
(chapter 11). Because only internal validity has been assessed we may only rely on the 
results of this cost-effectiveness analysis for patients that are similar and from a 
similar setting. Future studies should be designed to perform external validation of the 
prediction models in independent patient groups. 
Analysis of time to pregnancy 
As stated in chapter 6, the analysis for research question 1 -the prediction of time to 
pregnancy following CC treatment- was split into three separate analyses: one for the 
probability to be CRA (chapter 7), one for time to pregnancy given that the patient is 
not CRA (chapter 8), and finally the integration of these two (chapter 97). If we had 
performed a Cox regression analysis for time to pregnancy on the whole group of CC 
patients, the CRA patients would become censored from the moment they are 
identified as such. The reason for this is that CRA is an intermediate outcome that 
leads to stopping CC-treatment, because a patient who is CRA has no chance of 
pregnancy with this medication. However, this implies that the censoring would be 
informative, violating a basic assumption of Cox regression. Cox regression assumes 
that patients who are censored at a certain follow-up time have the same chance to get 
the event of interest (become pregnant) after that time, as do the patients who are not 
censored. The result of such an analysis would be that the cumulative probability to be 
pregnant would be overestimated. 
In chapter 10, we used Cox regression to predict the chance of pregnancy from the 
start of CC treatment onwards and continuing until the treatment with GOI was 
stopped. In contrast to the analysis for the prediction of pregnancy with CC, which 
was done in two steps, we did this analysis in one step. Patients who after three 
unsuccessful cycles of CC-treatment are identified as CRA, from that moment on do 
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not have a zero chance to become pregnant, since they will start treatment with GOI, 
which is included in this analysis. Therefore, informative censoring is not an issue for 
CRA patients in this analysis. One could argue that the group at risk in the Cox 
regression from the moment of identifying patients who are CRA (i.e. after 3 cycles of 
CC treatment) will consist of two groups of patients: patients who are non-CRA and 
still continuing CC, together with the CRA patients who have started GOI treatment: 
their pregnancy chances may be different. However, this non-homogeneity in chances 
is different from informative censoring: No assumption of the analysis is violated here 
and the estimate will give a proper account of the experience of the group of patients 
that started treatment. 
CONCLUSIONS AND RECOMMENDATIONS 
• For most patients, the current standard treatment protocol -start with CC and 
proceed with GOI followed by NF, in case no pregnancy has been achieved-
is cost effective. 
• An exception may be made for women above 30 years of age with elevated 
androgen levels, for whom the treatment with gonadotrophins could be 
skipped: performing GOI in these women gives only a small increase in 
pregnancy chances against costs of over 90,000 Euro per extra pregnancy. 
• The strong association between outcome of treatment and obesity (for CC 
from our own analysis, for gonadotrophins mainly from literature) implies 
that chances could be improved by reducing overweight. This concerns 30-
40% of the WHO II group. 
Summary 
This thesis is devoted to chances in fertility. It treats two subjects that are of interest to 
clinical reproductive medicine: fertility chances in a historical population and chances 
of success of treatment in one particular group of patients: those with anovulatory 
infertility. 
Part I of the thesis describes studies in a 19th century natural fertility population on 
variation between individuals in fertility chances. Two research questions are 
investigated with the aim to learn something from the past: one concerns the variation 
in the age at which female fertility comes to an end, and seeks evidence whether this 
variation is consistent with the concept of an underlying biological process of ovarian 
ageing. The second question concerns the pregnancy chances after a period of 
unsuccessful trying. This is of interest to clinicians who have to decide to start 
treatment for a given patient. 
Chapter 1 introduces the 19th century population of the Saguenay Lac St.-Jean 
region in Quebec Canada. The historical and social/religious (Roman-Catholic) 
context of this region are briefly reviewed, the concept of natural fertility is explained 
and a demographic analysis of the data is presented that shows that the study 
population may be considered a natural fertility population. We selected 4,125 married 
women from this population, who were born in the region between 1844 and 1900, 
and who did not emigrate. 
In Chapter 2, the first research question is analyzed: variability in female 
reproductive life span is evaluated and the association between the reproductive life 
span and fertility at young age is studied. To be able to assess the reproductive life 
span, a woman should be followed at least until an age at which it is certain that she 
will not have any more children. We therefore selected the 2,488 women whose 
marriage lasted at least until age 50. The chance that a woman no longer bares a child 
was 10% at age 29 years. It increased to 25%, 40%, 50%, 60% and 75% at ages 37, 
39, 40.5, 41 and 42.5 respectively, and was already 90% at age 44 years. There was a 
significant correlation (r = 0.15, P < 0.001) between fertility at young age and age at 
last childbirth: the more children a woman had before her 30th birthday, the longer she 
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was able to go on having children after age 30. This finding is consistent with the 
theory of ovarian ageing. 
The subject of Chapter 3 is inspired by the clinical question of when to start 
treatment in a couple with primary or secondary infertility. To answer this question, a 
reliable estimate of the spontaneous pregnancy chances is needed, taking into account 
the woman's age, the duration of infertility and parity. To obtain these estimates, we 
followed the women in our study population from marriage onwards. Women who had 
not conceived their first child within 1 to 4 years after marriage or their second child 
within 1 to 4 years after the first childbirth were then labeled as primary or secondary 
infertile. Of the women with 'primary' infertility of one year duration, 44% were 
found to conceive a child within the next year in the age group 20-24, and 39%, 32% 
and 22% respectively in the age groups 25-29, 30-34 and 35-39. At 2 years durations 
the age specific predictions were 26%, 21%, 17% and 12%. Predictions for 
'secondary' infertility at one year duration were 63%, 56%, 48% and 36%, and at 2 
years duration 38%, 33%, 28% and 19% respectively in the age groups 20-24, 25-29, 
30-34 and 35-39. We concluded that in women under 35, after one year of primary 
infertility and 1-2 years of secondary infertility, prospects are on average fairly good. 
Translated to modem times, we could say that if the diagnostic work-up ofthe couple 
does not point to adverse factors influencing pregnancy chances, their prognosis may 
be better than the average estimate that we found here, and therapy could be withheld 
for the next 1 or 2 years. 
The final chapter of Part I, Chapter 4, contains a short expose on the concept of 
time to pregnancy and how this concept relates to monthly pregnancy chances. Based 
on studies using the concept of time to pregnancy, the conclusion is drawn that the 
near panic sometimes expressed in the lay press about the effects of environmental 
pollution on sperm quality and male fertility is not justified. 
The subject of Part II is the prediction of pregnancy chances after treatment of 
patients who have fertility problems due to cycle disturbances (normogonadotropic 
anovulatory infertility, classified as WHO group 2). The current treatment protocol for 
these patients consists in the first line of ovulation induction with Clomiphene Citrate 
(CC), a simple and cheap medicine. When the patient doesn't become pregnant with 
this medication, the second line treatment, gonadotrophin ovulation induction (GOI) is 
started. This treatment is more burdensome, and also more costly than CC. The fmal 
treatment is In Vitro Fertilization (IVF). Patients differ in their response to each of 
these treatment modalities. The aim here is to construct tools that may be used to 
predict -for individual patients- the pregnancy chances with the standard treatment 
protocol. These prediction tools are then used in an analysis in which the efficiency of 
the current treatment protocol is investigated and compared to several alternatives. The 
background and aims ofthis part of the thesis are briefly introduced in Chapter 5. All 
subsequent chapters are based on the prospectively collected data of a consecutive 
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series of these patients in ErasmusMC Rotterdam, included between 1992 and 1999, 
with ongoing follow-up. 
Chapter 6 presents a tutorial on the methodology of prognostic modeling in 
fertility. Prognostic evidence is summarized in a statistical model that relates 
individual characteristics with the possible outcomes. Such a model will provide 
estimates of prognosis for individualized patient profiles, allowing new patients to 
profit from the experience of the cohort of previous patients used to build the modeL 
We present and discuss characteristics of good prognostic evidence for clinical use, 
focusing on study design, statistical analysis, evaluation, and presentation of results. 
As an example, this chapter discusses the prediction of time to pregnancy following 
induction of ovulation with CC. This prediction was broken down in two steps for 
methodological reasons, leading to two separate prognostic models. The first model 
predicts an intermediate outcome, the chance that the patient will have Clomiphene 
Resistant Anovulation (CRA), i.e., no ovulation in response to CC medication; the 
second model predicts the final outcome (time until pregnancy) in women who do 
ovulate. 
The next three chapters are the elaboration of the ideas expressed in Chapter 6, and 
concern the prediction of outcome after ovulation induction with Clomiphene Citrate 
(CC), based on patient characteristics assessed during standardized initial screening. 
To begin with, in Chapter 7, a prediction model of the chance that a patient will 
remain anovulatory during CC treatment (CRA) is developed. This study used the data 
of 201 patients presenting with oligomenorrhea or amenorrhea and infertility. After a 
complete follow-up (in the case of a no response, at least 3 treatment cycles with daily 
CC doses up to 150 mg), 156 patients (78%) ovulated. Patients whose ovaries are less 
likely to respond to CC treatment can be predicted on the basis of initial screening 
characteristics, such as Free Androgens Index (F AI: testosterone : 'sex hormone-
binding globulin' ratio), the body mass index (BMl), cycle history (oligomenorrhea or 
amenorrhea), and mean ovarian volume. The multivariable prediction model based on 
these four factors had an 'area under the receiver operating characteristics curve' of 
0.82. 
Next, in Chapter 8, the prediction of the step from ovulation to pregnancy was 
undertaken. A multivariable prediction model was built on the data of 160 women who 
reached ovulation after Clomiphene Citrate (CC) medication. This was a slight 
extension of the group of patients who reached ovulation during CC treatment in 
Chapter 7. A cumulative conception rate of 73% was reached within 9 CC-induced 
ovulatory cycles. Age and cycle history (oligomenorrhea vs. amenorrhea) were 
identified as the most important parameters for prediction of conception. Once they 
ovulate, there is more to be gained from CC ovulation induction by younger women 
presenting with amenorrhea. We see here that having amenorrhea has a positive effect 
on pregnancy chances in ovulatory women, whereas we have seen in Chapter 7 that 
amenorrhea is a negative risk factor to reach ovulation. 
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The objective of the last chapter in this trilogy on outcome after CC, Chapter 9, is 
to establish whether initial screening characteristics predict live birth after Clomiphene 
Citrate (CC) induction of ovulation. To this end, the prediction model for the chance to 
be CRA from Chapter 7 was combined with an adapted version of the prediction 
model for pregnancy chances in ovulatory women from Chapter 8. Based on this 
integrated analysis, the cumulative live birth rate within 12 months was 42% for the 
total study population. The combined prediction model contains four variables: free 
androgen index (testosterone sex hormone-binding globulin ratio), body mass index, 
cycle history (oligomenorrhea versus amenorrhea) and woman's age. For convenient 
use of the model in practice, it was represented in the form of a nomogram. Applying 
this nomogram in the clinic may be a step forward in optimizing the decision-making 
process in the treatment of normogonadotropic anovulatory infertility. Alternative first 
line treatment options could be considered for some women with limited chances for 
success. 
The first two steps of the current protocol may be called classical ovulation 
induction. Because the overall chances of success following classical ovulation 
induction are not well established, a shift in first line therapy can be observed towards 
alternative treatments. In Chapter 10, our aim was to (1) reliably assess the 
probability of singleton live birth following classical induction of ovulation and (2) 
construct a prediction model, based on individual patient characteristics assessed upon 
standardized initial screening, to help identify patients with poor chances of success 
with classical ovulation induction. The cumulative singleton pregnancy rate (leading to 
live birth) after 12 and 24 months of follow-up was 50% and 71%, respectively. A 
multivariable Cox regression model was constructed, containing the woman's age, the 
insulin/glucose ratio and the duration of infertility. With a cut-off value of 30% for 
low chance, the model predicted probabilities at 12 months lower than this cut-off for 
25 out of 240 (10%) patients. We conclude that classical ovulation induction gives 
very good results in normogonadotrophic anovulatory infertility. Alternative treatment 
options are not indicated as first line therapy in these patients, except for subgroups 
with poor prognosis. These women can be identified by older age, longer duration of 
infertility and higher insulin/glucose ratio. 
The standard treatment algorithm in normogonadotrophic anovulatory infertility 
consists of Clomiphene citrate (CC) as least burdensome and cheapest first line, 
exogenous gonadotrophin ovulation induction (GOI) as second line and In Vitro 
Fertilization (IVF) as the most costly and most burdensome last resort. Response to 
these treatment modalities is highly variable, but may be predicted on the basis of 
individual patient characteristics, as we have seen in our studies. In Chapter 11, our 
aim was to devise a patient-tailored and cost-effective treatment algorithm, based on 
individual patient characteristics. Sixteen different patient subgroups are defined, 
according to the presence or absence of the following 4 risk factors: age > 30, 
amenorrhea, elevated androgens and obesity. For each subgroup, the chances of 
response with each of the three treatments, and their costs, were calculated using the 
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previously developed prediction models. The costs per pregnancy of the reference 
strategy CC+GOI+IVF were compared with three alternative strategies: one in which 
the CC step is skipped (i.e. start with GOI and after that go to IVF), one without the 
GOI-step (i.e. start with CC and after that go directly to IVF), and the final one in 
which no treatment is started. For most patients, the current standard treatment 
protocol is cost-effective, at a threshold-value for the cost-effectiveness ratio of € 
10.000 per extra ongoing pregnancy. An exception should be made for women above 
30 years of age with elevated androgen levels, for whom the treatment with 
gonadotrophins could be skipped. Performing GOI in these women gives only a small 
increase in pregnancy chances against costs of over 90,000 Euro per extra pregnancy. 
Finally, the strong association between outcome of treatment and obesity (for CC from 
our own analysis, for gonadotrophins mainly from literature) implies that chances 
could be improved by reducing overweight. This concerns 30-40% of the WHO 2 
group. 
In conclusion we have demonstrated in Part I that the end of female fertility is very 
variable and that fertility at young age and the age at which fertility ends are positively 
related, consistent with the concept of ovarian ageing. Next, we have found that for 
women under 35 years of age, after 12-24 months of infertility, prospects to conceive 
naturally are on average still good. This could give support to a conservative attitude 
towards early treatment. 
In Part II we have seen that for most patients, the current standard treatment 
protocol -start with CC and proceed with GOI followed by IVF, in case no pregnancy 
has been achieved- is cost effective. An exception may be made for women above 30 
years of age with elevated androgen levels, for whom the treatment with 
gonadotrophins could be skipped. The results are critically discussed in Chapter 12 
and recommendations for further research are given there. 

Samenvatting 
Dit proefschrift gaat over kansen op het gebied van vruchtbaarheid. Er worden twee 
onderwerpen behandeld die van belang zijn voor de klinische praktijk van de 
voortplantingsgeneeskunde: vruchtbaarheidskansen in een historische populatie en 
kansen op succes van behandeling bij een bepaalde groep van infertiliteitspatienten, 
namelijk die met ovulatiestoornissen. 
Deel I van het proefschrift beschrijft studies in een 19-de eeuwse natuurlijke 
popu1atie over vruchtbaarheidskansen en de variatie daarin tussen individuen. Er 
worden twee onderzoekvragen uitgewerkt, met als doel een les uit het verleden te 
leren: de eerste vraag gaat over de variatie in de leeftijd waarop de vruchtbaarheid van 
de vrouw eindigt en zoekt naar een mogelijke verklaring van die variatie die verband 
houdt met het biologisch proces van ovariele veroudering. De tweede vraag gaat over 
de zwangerschapskansen na een bepaalde periode van onvervulde kinderwens. Deze 
vraag is van belang voor klinici die moeten beslissen of zij al dan niet gaan behandelen 
bij een gegeven patient. 
In Hoofdstuk 1 wordt de 19-de eeuwse populatie uit het Saguenay Lac St. Jean 
gebied in Quebec, Canada gemtroduceerd. We bespreken de historische en sociaal-
religieuze (Rooms-Katholieke) achtergrond van dit gebied, geven een defmitie van wat 
het concept natuurlijke vruchtbaarheid inhoudt en presenteren de resultaten van een 
demografische analyse die laat zien dat deze populatie als een natuurlijke 
vruchtbaarheidspopulatie mag worden beschouwd. V oor ons onderzoek werden uit 
deze populatie 4.125 getrouwde vrouwen geselecteerd, die in het gebied zelf waren 
geboren tussen 1844 and 1900, en die niet emigreerden. 
In Hoofdstuk 2 wordt de eerste onderzoeksvraag behandeld. De variatie in 
'reproductieve levensduur' van de vrouw is onderzocht en de samenhang met de 
vruchtbaarheid op jonge leeftijd werd bestudeerd. Met 'reproductieve levensduur' 
wordt bedoeld tot op welke leeftijd een vrouw nog in staat is om kinderen te krijgen. 
Om dit goed te kunnen vaststellen dienen de vrouwen lang genoeg in leven, en 
getrouwd te blijven. Daarom werd de selectie uit de populatie beperkt tot de 2.488 
vrouwen die nog in leven en nog getrouwd waren op hun 50-ste veijaardag. Zo'n 10% 
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van de vrouwen kreeg geen kinderen meer na haar 29-ste. Dit percentage lag op 25%, 
50% en 75% op de leeftijden 37, 40,5 en 42,5 respectievelijk, en was al 90% voor 
vrouwen van 44. De leeftijd waarop de vrouwen hun laatste kind kregen hing samen 
met een maat voor hun vruchtbaarheid op jonge leeftijd (r = 0.15, P < 0.001): hoe 
meer kinderen een vrouw voor haar 30-ste kreeg, hoe langer ze na haar 30-ste door 
kon gaan met kinderen krijgen. Deze bevinding is consistent met de theorie van 
ovariele veroudering. 
Hoofdstuk 3 heeft als doel vast te stellen hoe hoog de spontane 
zwangerschapskansen zijn van paren met onvruchtbaarheid, en hoe deze kansen 
samenhangen met de leeftijd van de vrouw, de duur van de onvruchtbaarheid en ofhet 
paar al dan niet kinderen heeft. Hiertoe werden de vrouwen gevolgd vanaf het 
huwelijk. Vrouwen die binnen 1 tot 4 jaren na het huwelijk nog niet zwanger waren 
van hun eerste kind, danwel van hun tweede kind binnen 1 tot 4 jaren na de geboorte 
van hun eerste kind, werden als primair respectievelijk secundair infertiel beschouwd, 
volgens de klinische defmitie die tegenwoordig wordt gehanteerd. In de leeftijdsgroep 
20 tot 24 jaar bleek 44% van de vrouwen met primaire infertiliteit met een duur van 1 
jaar in het daarop volgende jaar zwanger te worden. Dit percentage lag op 39%, 32% 
en 22% respectievelijk in de leeftijdgroepen 25-29, 30-34 en 35-39. Bij een 
infertiliteitsduur van 2 jaar waren de leeftijds-specifieke percentages 26%, 21%, 17% 
en 12%. De kansen voor vrouwen met secundaire infertiliteit lagen een stuk hoger: na 
1 jaar secundaire infertiliteit was 63%, 56%, 48% en 36% zwanger in het volgende 
jaar, en bij een infertiliteitsduur van 2 jaar was dit 38%, 33%, 28% en 19% 
respectievelijk in de genoemde leeftijdsklassen. Onze conclusie is dat voor vrouwen 
onder de 35 jaar, bij een infertiliteitsduur van een jaar, en 1-2 jaar bij secundaire 
infertiliteit, de vooruitzichten gerniddeld genomen nog redelijk goed zijn. V ertaald 
naar de modeme tijd betekent dit dat als er bij een gegeven paar niets wordt gevonden 
dat wijst op een slechte prognose, de kansen waarschijnlijk beter zijn dan hier 
gegeven, en dat overwogen kan worden om behandeling nog 1 tot 2 jaar uit te stellen. 
In het laatste hoofdstuk van Deel I, Hoofdstuk 4, wordt een kort expose gegeven 
over het belangrijke concept van tijd tot aan zwangerschap ('time to pregnancy') en 
hoe dit concept is gerelateerd aan de maandelijkse kans om zwanger te worden. Op 
basis van gepubliceerde studies die dit concept hebben gehanteerd, wordt 
geconcludeerd dat de vruchtbaarheid in de algemene bevolking de laatste decennia 
eerder is toegenomen dan afgenomen. De paniek die soms wordt geuit in de 
'lekenpers' over de effecten van rnilieuvervuiling op de kwaliteit van het sperma en de 
mannelijke vruchtbaarheid, lijkt dan ook niet terecht. 
Het onderwerp van Deel U van dit proefschrift is predictie van zwangerschaps-
kansen na behandeling van patienten met een vruchtbaarheidsprobleem ten gevolge 
van cyclusstoornissen (normogonadofe anovulatoire infertiliteit, WHO groep 2). Het 
huidige behandelprotocol voor deze patienten bestaat uit een sequentie van drie 
behandelstappen. De eerstelijnsbehandeling is ovulatie-inductie met Clornipheen 
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Citraat (CC), een weinig belastend en goedkoop medicijn. Als de patient hiermee niet 
zwanger wordt binnen een bepaald aantal maanden, begint men doorgaans met de 
tweedelijnsbehandeling, Gonadotrofinen Ovulatie Inductie (GOI). Deze behandeling is 
aanmerkelijk belastender en ook duurder dan CC. De laatste behandelingsoptie is In 
Vitro Fertilisatie (IVF). De patienten verschillen nogal in hun respons op elk van deze 
behandelingen. Het doel is hier om materiaal aan te dragen dat kan helpen om voor 
individuele patienten de zwangerschapskansen met dit behandelprotocol in te schatten. 
Deze predictie-tools worden vervolgens gebruikt in een analyse waarin de efficientie 
van het huidige behandelprotocol wordt vergeleken met verschillende altematieve 
protocollen. De achtergrond en doelstelling van dit deel vormen het onderwerp van 
Hoofdstuk 5. Alle verdere hoofdstukken in dit deel zijn gebaseerd op de prospectief 
verzamelde data van een consecutieve reeks patienten in ErasmusMC Rotterdam. De 
inclusie liep van 1992 tot en met 1999, met doorgaande follow-up daama. 
Hoofdstuk 6 is een tutorial over de methodologie van prognostisch modelleren in de 
fertiliteit. In het algemeen wordt prognostische evidentie samengevat in de vorm van 
een statistisch model dat de relatie beschrijft tussen individuele patientkarakteristieken 
en de mogelijke uitkomsten. Zo'n model geeft dan schattingen van de prognose voor 
individuele patientprofielen, waarmee nieuwe patienten kunnen profiteren van de 
ervaring van de groep patienten die is gebruikt bij het bouwen van het model. We 
geven en bediscussieren kenmerken van goede prognostische evidentie, met name 
geschikte studie-designs, statistische analyse, evaluatie, en presentatie van de 
resultaten. Als illustratief voorbeeld wordt de predictie van zwangerschapskansen na 
ovulatie-inductie met CC gebruikt. Dit predictie-probleem werd opgesplitst in 2 
stappen, omwille van methodologische redenen, wat leidde tot twee predictiemodellen. 
Het eerste model voorspelt een tussengelegen uitkomst, de kans dat de patient niet zal 
reageren met een ovulatie ( eisprong) op het medicijn ( wat Clomiphene Resistant 
Anovulation (CRA) wordt genoemd); het tweede model voorspelt de uiteindelijke 
uitkomst (zwangerschap) voor de vrouwen die wel ovuleren met CC. Tot slot worden 
deze twee modellen gefutegreerd in een predictiemodel. 
De volgende drie hoofdstukken bevatten de concrete uitwerking van de ideeen die in 
Hoofdstuk 6 zijn neergezet met betrekking tot de predictie van de uitkomst van 
ovulatie-inductie met Clomipheen Citraat (CC). Om te beginnen wordt in Hoofdstuk 
7 een predictie-model besproken voor de kans dat een patient geen ovulatie bereikt 
tijdens de behandeling met CC (i.e. de patient is CRA). Deze studie gebruikte de 
gegevens van 201 patienten met oligomenorroe ( cylcusduur > 35 dagen) of amenorroe 
(geen cyclus, of cyclusduur > 6 maanden) en infertiliteit. Na een volledige follow-up 
(wanneer er geen ovulatie optreedt: tenminste 3 behandelcycli met dagelijkse CC-
dosis oplopend tot 150 mg/dag) waren 156 patienten (78%) ovulatoir. Patienten 
hadden een lagere kans op ovulatie met CC naarmate ze hogere waarden hadden van 
de factoren vrije androgeen-index (F AI: testosteron : 'sex hormone-binding globulin' 
ratio), de body mass index (BMI) en gemiddeld volume van de ovaria, en wanneer ze 
160 
amenorroe m plaats van oligomenorroe hadden. Het predictiemodel met deze 4 
factoren had een 'area under the receiver operating characteristics curve' van 0.82. 
V ervolgens werd m Hoofdstuk 8 een predictiemodel gebouwd voor 
zwangerschapskansen na ovulatie, op de data van 160 vrouwen die een ovulatie 
hadden bereikt met CC. Dit was een kleine uitbreiding van de data van de patienten 
die ovulatie bereikten met CC uit Hoofdstuk 7. De 'cumulative conception rate' na 9 
CC-induceerde ovulatoire cycli was 73%. De leeftijd en oligomenorrhea versus 
amenorrhea waren de belangrijkste voorspellende parameters voor de kans op 
conceptie. Het bleek dat -als ze eenmaal ovuleerden met CC- jongere vrouwen en 
vrouwen met amenorroe de hoogste kans op zwangerschap hadden. We zien hier dat 
het hebben van amenorroe in plaats van oligomenorroe een positief effect heeft op 
zwangerschapskansen in vrouwen die ovuleren met CC, terwijl in Hoofdstuk 7 bleek 
dat het hebben van amenorroe juist een negatieve factor is voor het bereiken van 
ovulatie. 
Het doel van het laatste hoofdstuk in deze trilogie over de uitkomst van CC-
behandeling, Hoofdstuk 9, is om een predictiemodel op basis van initiele 
patientkarakteristieken te ontwerpen voor de zwangerschapskansen met CC ovulatie-
inductie. Het predictiemodel voor de kans om CRA te zijn, uit Hoofdstuk 7, werd 
gecombineerd met een aangepaste versie van het predictiemodel voor 
zwangerschapskansen in ovulatoire vrouwen uit Hoofdstuk 8. Op basis van deze 
gefutegreerde analyse was de cumulatieve kans op het bereiken van een zwangerschap 
leidend tot een levendgeboren kind 42% voor de hele groep van patienten in de studie. 
Het gecombineerde predictiemodel bevat vier variabelen: F AI, BMI, oligomenorroe 
versus amenorroe en de leeftijd van de vrouw. Om het model toegankelijk te maken 
voor gebruik in de praktijk is er een nomogram van gemaakt. Toepassing van dit 
nomogram zou een stap voorwaarts kunnen zijn tot het optimaliseren van de 
behandeling van patienten met WHO 2 anovulatoire infertiliteit. 
De eerste twee stappen uit het huidige behandelprotocol vormen samen de klassieke 
methode van ovulatie-inductie. Omdat nooit goed is vastgesteld wat hiervan de kans 
op succes is, lijkt er een verschuiving op te treden in eerstelijnstherapie naar andere 
behandelmethodes. In Hoofdstuk 10 stellen we ons ten doel om (1) een betrouwbare 
schatting te verkrijgen van de kans op een eenling zwangerschap (leidend tot een 
levendgeboren kind) met klassieke ovulatie-inductie en (2) een predictiemodel te 
maken op basis van individuele patientkarakteristieken, om patienten met een lage 
kans op succes met deze behandelingen te helpen identificeren. De cumulatieve kans 
op een eenlingzwangerschap (leidend tot levendgeboren kind) bedroeg 50% en 71%, 
na 12, respectievelijk 24 maanden follow-up. De statistische analyse leverde een 
predictiemodel op met als voorspellende factoren de leeftijd van de vrouw, de uit 
bloed-serum bepaalde insuline/glucose ratio en de duur van de infertiliteit. Wanneer 
we de kans op zwangerschap met deze behandelingen als laag defmieren wanneer die 
onder de 30% komt, voorspelt het modellage kansen na 12 maanden voor 25 van de 
240 (10%) patienten. Samengevat concluderen we dat klassieke ovulatie-inductie zeer 
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goede resultaten geeft in normogonadotrope anovulatoire infertiliteit. Andere 
hehandelingsopties zijn niet geindiceerd voor deze groep patienten, hehalve rnisschien 
voor suh-groepen met een slechte prognose. Deze vrouwen kunnen worden 
gekenschetst door een hogere leeftijd, langere duur van de infertiliteit en een hogere 
insuline/glucose ratio. 
In Hoofdstuk 11 komen we toe aan het uitwerken van de doelstelling dat met 
hehulp van predictiemodellen de keuze en volgorde van de drie hehandelingen 
misschien efficienter kan worden gemaakt. De predictiemodellen in de voorgaande 
hoofdstukken vormen hiervoor de basis. We hehben 16 verschillende prognostische 
suh-groepen gevormd door het combineren van de 4 belangrijkste voorspellende 
factoren uit de voorgaande analyses en uit de literatuur, te weten: leeftijd > 30, 
amenorroe, verhoogde mannelijke-hormoonspiegels en overgewicht. De kansen op 
zwangerschap met elk van de drie hehandelingen en de kosten van behandeling 
werden berekend voor alle 16 patient-profielen. De kosten per doorgaande 
zwangerschap van de referentie-strategie CC+GOI+IVF zijn vervolgens vergeleken 
met drie altematieve strategieen: een waarin de CC-stap wordt overgeslagen, een met 
overslaan van de GOI-stap en een waarin wordt afgezien van (verdere) behandeling. 
V oor de meeste patienten is het standaard protocol kosten-effectief, wanneer een 
grenswaarde wordt gehanteerd van € 10.000 per extra doorgaande zwangerschap. Er 
kan wellicht een uitzondering worden gemaakt voor vrouwen hoven de 30 jaar met 
verhoogde mannelijke-hormoonspiegels, voor wie de GOI-behandeling overgeslagen 
zou kunnen worden. Tot slot suggereert de sterk negatieve rol die overgewicht speelt 
in het hepalen van de kans op succes (voor CC in onze eigen analyses, voor GOI 
vooral in de literatuur) dat gewichtsreductie een relatief goedkope en effectieve 
methode kan zijn om de kansen op succes van behandeling te vergroten. Dit betreft 
zo'n 30-40% van de WHO 2 groep. 
Concluderend kunnen we stellen dat Deel I van dit proefschrift laat zien dat in een 
natuurlijke vruchtbaarheidspopulatie, de leeftijd waarop de vruchtbaarheid van een 
vrouw eindigt grote variatie vertoont en dat deze leeftijd hoger is naarmate de vrouw 
op jongere leeftijd een hogere vruchtbaarheid had. Deze bevinding is consistent met 
het concept van 'ovariele veroudering'. Daamaast vonden we dat vrouwen jonger dan 
35 jaar, die 12 tot 24 maanden zonder succes hebben gepoogd zwanger te worden, nog 
steeds heel redelijke kansen hebben. Deze bevinding geeft steun aan een terughoudend 
beleid m.h.t. vroegtijdige hehandeling. 
In Deel II hebben we gezien dat voor de meeste patienten met WHO 2 anovulatoire 
infertiliteit, het huidige standaard hehandelprotocol -heginnen met Clornifeen Citraat, 
doorgaan met Gonadotrofme Ovulatie-Inductie (GOI), en tenslotte In Virto Fertilisatie 
(IVF)- kosten-effectief is. Een uitzondering kan worden gemaakt voor vrouwen van 
hoven de 30 met verhoogde mannelijke-hormoonspiegels. Bij hen zou de GOI 
hehandeling kunnen worden overgeslagen. De resultaten worden kritisch 
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bediscussieerd in Hoofdstuk 12 en daar worden ook aanbevelingen voor nader 
onderzoek gegeven. 
Dankwoord 
Mijn promotie tot doctor beschouw ik als een late roeping. Na lange tijd met veel 
plezier aan verschillende projecten te hebben gewerkt op de afdeling Maatschappelijke 
Gezondheidszorg, zonder doelgericht naar een promotie te streven, heeft het op een of 
andere manier toch zover moeten komen. Ik geloof meer in de samenloop der dingen 
dan in voorbestemdheid. Toch waren hier naar rnijn idee enkele sturende krachten in 
het spel, die ik nu zeer erkentelijk ben voor hun bijdrage. 
Allereerst en bovenal was dat Dik Habbema, die met veel geduld dit langdurige proces 
heeft begeleid: als het aan jou had gelegen zou ik waarschijnlijk al drie keer zijn 
gepromoveerd. Dik, ik waardeer je steun, je scherpzinnigheid en je bereidheid in de 
laatste fase zo veel tijd voor rnij vrij te maken, zelfs in de avonduren. Ik wil daarbij 
ook Annelies betrekken: dank voor de goede zorgen. 
Daamaast hebben rnijn twee andere promoteren, Egbert te Velde en Bart Fauser, een 
groot aandeel gehad. Egbert, door jou heb ik de fertiliteit leren kennen. Met je 
originele ideeen en je gedrevenheid voor onderzoek aan natuurlijke fertiliteit ben je 
een blijvende inspiratie voor mij. Bart, jij bent een stimulans voor me om door te gaan 
in dit vak. Jouw creativiteit, daadkracht en voortvarendheid zijn fenomenaal en zie ik 
als een groot voorbeeld voor mij. Ik dank jullie heiden voor jullie inzet en geduld. 
De co-auteurs van al dan niet doorgezette artikelen dank ik voor hun constructieve 
commentaar. Met name Luc Smits, via wie ik heb kennisgemaakt met de database uit 
Quebec en Peter Pearson voor de goede discussies. Henri Leridon, I thank you for 
your participation in the paper that led to Chapter 3, and for your valuable comments 
on some of my ideas. I hope we will have the opportunity to work closer together in 
the future. 
De meeste van de vrouwen die in het Canadese databestand voorkomen zijn 
inrniddels overleden. De grote aantallen kinderen die zij hebben gekregen maakten 
deze populatie geschikt voor het onderzoek in Deel I van het proefschrift. Zonder het 
te weten en zich schikkend naar het keurslijfvan de religieus-sociale omgeving waarin 
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zij leefden, zijn zij belangrijk geworden voor de wetenschap. De grootsheid van hun 
prestatie is niet in woorden te vatten. J e restreints mes mots de grace -ne signifiant 
aucunement avec moins d'appreciation- aux employees de l'Institut Interuniversitair 
de Recherches sur les Populations (IREP) a Chicoutirni, Quebec Canada pour avoir 
rnis a la disposition des donnees. Specialement je remercies le directeur Gerard 
Bouchard, 'Super' Mario, et Michele Jomphe pour ses e-mails toujours serviables et 
affectueux (sur des femmes qui peuvent appartenir a trois generations en meme temps: 
'God this is hard to explain in English and moreover by email!'). 
Het tweede en tevens grootste deel van dit proefschrift zou er nooit zijn gekomen 
zonder twee mensen: Babek Imani en Annemarie Mulders. Babek, de unieke database 
die er nu ligt is zowel in opzet als in inhoud grotendeels jouw werk geweest. Ik dankje 
voor de prettige samenwerking en voor je vriendschap. Annemarie, jij bent uniek in je 
hartelijkheid en warmte, en daamaast een enorme volhouder. W aardering, en dank 
voor het werk dat je voor mij hebt gedaan. Daamaast wil ik zeker noemen, de andere 
leden van de Rotterdamse fertiliteitsgroep, met wie ik al zovele jaren samen optrek en 
van wie ik steeds weer nieuwe dingen leer. Met name Joop Laven en Nick Macklon, 
meer recent Evert van Santbrink, de 'follicle girls en boys': Fernke, Mark, Nicole, 
Christien, en eerder Diederick, Elena en Esther van het lab, ik maak met jullie allemaal 
steeds genoeglijke en tegelijkertijd leerzame momenten mee. En wie ik zeker ook wil 
noemen zijn Marita op het secretariaat en Lizka die zoveel weet te coordineren. Dank 
dat ik met jullie mag werken, en voor de hartelijkheid waarmee dat altijd gaat. 
Claudine, ik bewonder je vasthoudendheid en je instelling om overal het positieve 
van in te zien. Het leek vanzelfsprekend dat ik eerder zou promoveren dan jij, hoewel 
ik daar zelflang aan heb getwijfeld. Nu is het dan toch zover. In rnijn eindsprint heb ik 
soms te weinig tijd en aandacht gehad voor jouw voortgang, terwijl dat juist zo hard 
nodig is in de taaie materie waar jij mee worstelt, rnijn excuses daarvoor. Ik hoop het 
tijdens jouw eindsprint te kunnen goedmaken; gaan weer voor? 
De vele samenwerkingen op fertiliteitsgebied nu en in het verleden, die mij stuk 
voor stuk hebben verrijkt, en waarvan de weerslag ongetwijfeld ook in dit proefschrift 
terug te vinden is. Ik noem allereerst Jan-Willem en Pietemel. Wat een fijne mensen 
zijn jullie allebei, en wat een prestatie dat het OFO-project gaat lukken: mooie 
promoties gaan dat worden. Ik betrek hierin meteen ook de rest van de OFO-project-
groep, Fulco van der Veen, Peter Hompes en Patrick Bossuyt, maar bovenal Ben-
Willem Mol: over drijvende kracht gesproken ... BW, ik hoop dat we elkaar nog vaak 
zullen vinden in het fertiliteitsveld. Jij bent iemand om wie je moeilijk heen kunt ('niet 
te passeren, die man ... '). Niet minder belangrijk voor rnij is het 'minimal stimulation' 
project. Esther, met name door jouw vele talenten enje grote inzet is het een heel goed 
lopende studie geworden. Ook Cora en Suzanne hebben daar zeker hun aandeel in. Ik 
ben ontzettend benieuwd hoe dit verder zallopen. Didi ('voordat we beginnen met de 
vergadering: Rene, hoe gaat het met je boekje?'), Bea met wie ik inrniddels stad en 
land heb afgereisd, en Rianne, Clazien en Leona: ook het project 'indicaties voor IVF' 
gaat iets heel groots worden. Ik prijs me gelukkig met jullie allen te mogen werken. 
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De collega's van MGZ. Allereerst wil ik Ewout Steyerberg noemen. Ewout, WlJ 
werken al zo lang samen, tegenwoordig minder dan voorheen als de siamese tweeling 
waar we soms voor werden aangezien. Ik heb ongelooflijk veel van j e geleerd, en veel 
daarvan is in dit proefschrift terechtgekomen, dank, dank, dank. 
Vanje kamergenoten moetje het hebben. Pieta, met wie ik wel bijna getrouwd lijk, 
zo lang samen en zo vertrouwd: ik kon altijd m'n verhaal even kwijt, al ging het dan 
ook nergens over (whuu!) en Cecile: je hebt me in korte tijd meer gegeven danje zelf 
voor mogelijk had gehouden. Ret was niet minder gezellig met de oud-kamergenoten. 
Judith (lief en leed delen ... ), daar voor Margriet, en wie ik nooit zal vergeten: Veerle. 
Allen bedankt voor de nooit aflatende interesse en de gezelligheid en wat al niet. 
De ondersteunende diensten van het instituut. Jullie zijn onmisbaar, maar worden 
niet altijd op waarde geschat. Met wie ik te maken heb gehad en nog steeds heb: Ton, 
Kees en Peter-altijd-bereid-een-brandje-te-blussen, bedankt. Op het secretariaat met 
name de secretaresses van Dik: Mirela, en daar voor Edith ('say no more . .', zie 
hieronder) en weer daar voor Tineke. En daar ergens tussendoor en af-en-toe of juist 
heel vaak: Sonja. Mona voor de literatuur en voor nog zoveel meer, lieve 
Mona ... bedankt! Tenslotte: Barry, Iolande en Selma. Ret was en is voor jullie niet 
makkelijk met rnijn lappendeken aan subsidies ('welk project is dit nou? lets met 
fertility . .'). Jo, ik ben zo blij dat ook voor jou de zon weer schijnt. 
Mijn paranimfen Jan en Edith (zie hierboven). Jan, het voelt weldadig te weten dat 
rnijn beste vriend straks naast me zal staan. Toch het samen fietsen maar weer 
oppakken, lijkt me? En Edith, ik leerde je kennen in de tijd van het gouden trio Mona, 
Sonja, Edith. Onvergetelijk. Ik ben blij dat we zo close zijn gebleven, ook na die tijd. 
De vrienden uit Delft waren en zijn belangrijk: Ellen, Renk, Jaap, Wim, Aijo, Nico 
en Nicole. Bedankt voor de steun, de belangstelling en voor het gevoel een tweede 
farnilie te hebben. En dat jullie me serieus zijn blijven nemen, ook toen ik tussen 'die 
medici' ging werken. 
Tot slot enkele woorden aan de mensen die mij het meest na staan. Mijn ouders, zus en 
broer. Ret leek altijd zo ongrijpbaar wat ik aan het doen was. Nu zien jullie het 
resultaat. Papa en mama, ik ben nog een heel eind gekomen, wat nooit zou zijn 
gebeurd zonder jullie steun. 
Laatst en liefst, Litanja. Door een toeval kwam jij in mijn leven, hoewel ik niet uitsluit 
dat ook hier een sturende kracht heeft meegespeeld. Wij hebben het zo goed samen, 
laten we samen verder gaan ... 
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